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Abstract: 
The purpose of the studies described in this thesis was to study the purported metabolic effects of 
two dietary agents, L-Histidine and Epigallocatechingallate (EGCG). Supplementation of both L-
Histidine and pure EGCG in animal models has previously shown effects on components of energy 
balance and blood glucose regulation. Studies of their supplementation among humans are none (in 
case of L-Histidine) or very limited (in case of EGCG supplementation). The studies presented 
herein are novel as there have been no previous studies conducted to measure their effects on 
thermogenesis in humans and the present studies are the first to do. Three studies were performed 
to investigate metabolic effects of L-Histidine and two studies were performed to investigate 
metabolic effects of EGCG among healthy men. Duration of supplementation and varying doses 
were considered in different studies which led to the variation in study designs and protocols.   
Effects of L-Histidine: The metabolic effects of the essential amino acid L-Histidine (25 mg/kg) on 
healthy and overweight men were investigated in a series of studies. A pilot study was conducted to 
develop a protocol for measurement of resting metabolic rate (RMR), mean skin (MST), core 
temperature (CT) simultaneously. The protocol implemented was successful and was applied in all 
further studies. This study also examined the effect of L-Histidine supplementation (25 mg/kg) on 
RMR, MST, CT over a short period (3.25 hours). No conclusive results were obtained from this 
study. A single blind, placebo controlled cross-over study was then conducted to examine the 
effects of 10-day supplementation of L-Histidine on RMR, MST, CT and fasting blood glucose 
(FBG) in healthy male subjects (n = 9).  Following L-Histidine ingestion, mean body weight (p = 
0.008) and FBG (p = 0.04) were significantly reduced compared to baseline measurements. A 
randomised, parallel, single blinded and placebo controlled study was conducted following on from 
this to examine the effects of long-term (8 week, 25 mg/kg/day) intake of L-Histidine on RMR, 
MST, CT, lipid profile, FBG, insulin, leptin, non-esterified fatty acid (NEFA) and body fat 
composition in overweight and obese but otherwise healthy men (n = 18 (9 participants each in 
placebo and L-Histidine group)). Results of this study showed significantly decreased weight after 
8 weeks (p = 0.007) compared to baseline, irrespective of the type of supplementation. Oral 
supplementation of L-Histidine improved FBG concentrations and reduced body weight after 10 
days’ ingestion, however, no effects of long-term supplementation was established.  
Effects of EGCG: The second part of this thesis presents studies performed to investigate metabolic 
effects of pure EGCG. The first study was randomised, cross-over, placebo controlled and single-
blinded in design. the effects of an oral intake of 150 mg pure EGCG over an acute period (2.5 
hours), on key metabolic parameters and following an oral glucose challenge was measured (n = 8, 
healthy men). Results of this study were inconclusive on RMR, MST, CT plasma insulin, leptin 
and NEFA concentrations and appetite regulation. The second study tested the effects of varying 
doses (75, 150 and 300 mg/day) of pure EGCG on afore mentioned key metabolic parameters when 
supplemented over a period of 7 days each (n = 8, male). No significant changes in measured 
parameters were found. The results of these two studies indicate the need for further studies to 
investigate effects of EGCG on weight loss / weight maintenance possibly in combination with 
caffeine and/or other green tea flavanols.  
Both L-Histidine and EGCG supplmentations have previously shown to influence regulators of 
energy balance, blood glucose and cardiovascular risk factors via activation of the sympathetic 
nervous system in animal models. The present studies however did not provide any definitive 
conclusions following EGCG ingestion in healthy humans. L-Histidine supplementation brought 
about significant decrease in FBG and body weight after 10 days’ ingestion but its effect after 3.25 
hours and 8 weeks was inconclusive. The effects following supplementation of both L-Histidine 
and EGCG ingestion needs to be further studied to clarify any potential metabolic consequences in 
humans. 
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Introduction 
- 1 - 
1 Introduction 
Human health and well-being is dependent upon multiple factors including those heritable 
traits that may affect health, environmental influences, diet and lifestyle and psychological 
profile. Amongst these, there is considerable plasticity within the area of diet and lifestyle 
and the present text is focused in this arena. It is understood that a lack of control of energy 
balance and frequently associated problems with blood glucose regulation, represent a 
significant component of risk as understood at both an epidemiological and 
physiochemical level. The broad aim of the research presented herein is to examine the 
application of naturally occurring compounds with the aim of positively impacting on 
human energy balance and blood glucose control. Particular emphasis will be placed on 
those physiological and biochemical systems upon which the potentially bioactive agents 
may impact. The thesis will first outline the nature and general mechanistic control of the 
relevant parameters and will then describe novel interventions with non-pharmacologic 
agents.  
 
Energy balance regulation is an extremely complex process encompassing multiple 
interacting homeostatic and behavioural pathways aimed at maintaining constant energy 
stores (Niswender and Beech, 2008). Body weight control is achieved through integrated 
interactions between nutrient selection, organoleptic influences and endocrine responses to 
diet, in addition to being influenced by genetic and environmental factors (Berthoud, 
2006). The brain plays a critical role in maintaining whole body energy balance by 
regulating energy intake and energy expenditure (Schwartz et al., 2000). From an 
evolutionary stance, humans eat to satisfy their immediate caloric and nutritional 
requirements from meal to meal, but also to allow energy and nutrients to be stored in 
anticipation of high energy demands or food shortages. Thus, control of food intake 
involves the integration of external environmental triggers with multiple internal 
physiological signals as well as external social elements and reward factors (Zheng and 
Berthoud, 2007).  
 
Similarly, blood glucose regulation is also dynamically controlled in the body principally 
by two pancreatic hormones – insulin and glucagon. Together, these hormones co-ordinate 
the metabolic fate of endogenous glucose, free fatty acids, amino acids and other substrates 
to ensure that energy needs are met in the basal state and during activity (Costanzo, 
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2006a). Optimum regulation of blood glucose is imperative in order to maintain nutrient 
(glucose) homeostasis, therefore preventing chronic metabolic disorders i.e retinopathy, 
nephropathy etc (UKPDS, 1998).  
 
In broad terms there appears to be an emerging global problem of factors capable of 
overriding homeostatic control of energy balance. Discourse in academic and medical 
literature frequently describes an obesogenic environment and even obesogenic economies 
driving the problem (Burgoine et al., 2009; Horst et al., 2007). It is possible that given the 
teleological imperative of calorie acquisition and retention, that the modern era represents a 
special challenge to metabolism in which ‘hardwired’ responses to food (drive to eat 
underpinned via powerful reward systems) are more potent than homeostatic controls of 
energy balance. Perspectives in behavioural science and neurochemistry do seem to 
support this possibility (Berthoud, 2006; (Davis et al., 2004). In addition it can be argued 
that there is little evolutionary adaptation to either hyperalimentation or diseases or 
syndromes of middle to later life ((beyond peak reproductive age) (Bellisari, 2008)). 
 
Investigations into the so called ‘obesity epidemic’ have revealed an interesting and 
sometimes counter-intuitive picture of possible drivers of the problem. While much data 
does show that there is greater availability and affordability of high calorie food (Bellisari, 
2008), there is also much evidence that total calories consumed per person in the UK at 
least, may not have increased significantly (ONS, 2006). In this case the logical 
assumption is that energy expenditure must have decreased (Hoare et al., 2004). In this 
connection studies of changing levels of physical activity are of interest and many do 
suggest that levels of physical activity and hence energy expenditure have been falling 
steadily for 20 years (BNF, 2007). Increased use of motor vehicles, increasing automation 
in the workplace and an increase in television watching and other sedentary leisure 
activities are all implicated in total reductions in average energy expenditure (ONS, 2006). 
 
While public health initiatives have increased general awareness of diet/lifestyle factors in 
terms of weight and health (Hillsdon et al., 2004), the numbers of overweight and obese 
have continued to rise (Foresight, 2007). Pharmacological solutions to the problem are 
expensive and to date, not without side-effects (Rucker et al., 2007). Interest is therefore 
ongoing in effective interventions with high compliance rates and low incidences of 
unwanted effects, to unbalance the energy balance equation in favour of weight 
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loss/control (Hill, 2009; Swinburn et al., 2004). In this connection the manipulation of diet 
through changing levels of naturally occurring compounds is an attractive option for 
researchers in the field of human nutrition. The present text is an example of such an 
initiative.  
1.1 Energy balance 
1.1.1 Energy intake 
Regulation of food intake is controlled by various external and internal stimuli. External 
stimuli include taste, smell, and sight of food and possibly even time of the day. Eating is 
also influenced by age, sex and behavioural influences such as and physical activity levels, 
social, cultural, emotional and psychological needs. Increased buying power, increased 
availability of ‘fast foods’, access to energy-dense foods all influence food intake (Dulloo 
and Schutz, 2005c). Internal stimuli for modulation of feeding are more complex and 
involve neuroendocrine and gastrointestinal signals (Figure 1.1, Table 1.1). The central 
neuroendocrine pathways include regulatory mechanisms from various parts of the 
hypothalamus. The peripheral signals for the maintenance of energy intake are controlled 
by the gut hormones (these include cholecystokinin (CCK), ghrelin, amylin and the 
glucagon-like peptides (GLP-1 and GLP-2)) (Williams et al., 2000). Adipose tissue also is 
a major contributor to energy homeostasis. Fat cells secrete several adipokines including 
leptin, which influence either the storage or mobilisation of fuel along with combustion 
and energy homeostasis. The central and peripheral regulation of energy intake is 
extensively reviewed to date by various researchers (Bloom, 2007; Bloom et al., 2005; 
Chaudhri et al., 2006; Rolls, 2007; Wynne et al., 2004; Wynne et al., 2005).   
 
Figure 1.1 - Sequence of events in food intake control  
Reference: (Dulloo and SChutz, 2005a) 
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Table 1.1 - Neurotransmitter, hormones, peptides implicated in food intake control  
Orexigenic Anorexigenic 
Agouti-related protein (AgRP) Alpha melanocyte stimulating hormone (α 
MSH) 
Cortisol  Cholecystokinin 
Dopamine Corticotrophin-releasing hormone (CRH) 
Endocannabinoids Glucagon 
Glucocorticoids Glucagon-like peptide 1 and 2 (GLP-1, GLP-2) 
Ghrelin Histamine 
Melanin-concentrating hormone (MCH) Insulin 
Neuropeptide Y(NPY) Leptin  
Opiod peptides Noradrenaline 
Orexins Peptide YY (PYY) 
 Serotonin 
 Thyrotropin-releasing hormone (TRH) 
 Tumor necrosis factor – α 
 
Control of food intake also occurs in a short phase (glucostatic or glycogenostatic), 
medium term (day-to-day) and over longer terms (lipostatic or adipostatic) (Figure 1.1). 
The glucostatic theory proposes that the chemoreceptors in the hypothalamic satiety centre 
are sensitive to the availability and utilisation of glucose (Mayer, 1952). This theory is the 
basis for the proposition that the control of food intake via the prevention of 
hypoglycaemia and maintenance of adequate glycogen levels, maintain carbohydrate 
balance (Flatt, 1995). Long-term control of food intake can been explained by the lipostatic 
theory (Kennedy, 1950) which proposes that body fat is maintained at a set value and 
deviations from this value are detected by the hypothalamus via a circulating  molecule 
which is produced in proportion to adipose mass. It is suggested that the hypothalamus 
then elicits changes in energy intake (and expenditure) to restore the level of body fat 
stores to its putative set-point. While clearly it is possible to observe both the underweight, 
and increasingly overweight state in a given population, it is true that for many individuals, 
long term maintenance of stable weight can be observed in the absence of any conscious 
effort to maintain such (Schoeller, 1998; Sherwood, 2005).  
 
1.1.2 Energy expenditure 
Energy expenditure (EE) consists of different components: namely, basal metabolic rate 
(BMR), the energy cost of physical activity, the thermic effect of food (post-prandial 
thermogenesis), and thermoregulation. The role of adipose tissue in thermoregulation is 
well documented (Frühbeck, 2008). Uncoupling proteins present in the mitochondrial 
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membrane release energy as heat and thus may play an important role in energy balance (a 
brief summary of the energy dissipating function of uncoupling proteins is given in the 
following section). The factors affecting and effecting EE have been extensively reviewed 
to date (Leibel, 2008; Speakman, 2004; Vermorel et al., 2005; Westerterp, 2008).  
 
A constant expenditure of energy occurs over each 24-hour period in humans. Most of this 
EE represents the energy required to maintain vital functions (maintaining electrolyte 
equilibrium across cell membranes, nerve impulse conduction, cellular metabolic processes 
and respiratory and cardiovascular function). This component of total EE accounts for 60-
75% of daily EE and is known as BMR (Frayn, 2003a). BMR is beyond voluntary control 
and is influenced by are body size (those with greater surface area have higher metabolic 
rate) (Rolfes et al., 2008) body composition (those with higher fat free mass have higher 
metabolic rate (compared to weight matched individuals with lower fat free mass, higher 
fat mass); age (the loss of fat free mass with aging leads to a decline in BMR (Nielsen et 
al., 2000) ; sex (differences in BMR between men and women is due to difference in body 
size and composition (Geer and Shen, 2009); hormonal factors (those with endocrine 
problems i.e hypothyroidism (decreased BMR) and hyperthyroidism (increased BMR), 
BMR in women fluctuates with the menstrual cycle and is increased in the final stages of 
pregnancy) (Frary and Johnson, 2004). EE resulting from physical activity can be 
controlled voluntarily and depends on the type and intensity of physical activity and time 
spent in different activities (Dulloo and Schutz, 2005). 
 
The human body maintains an average body temperature within the range of 35.5 – 37.7 
°C through thermogenesis (Silverthorn, 1998a). EE in response to various thermogenic 
stimuli has been described as isometric thermogenesis (due to increased muscle tension 
when no physical work is done), dynamic thermogenesis (heat production of stretched 
muscle, without any work done), psychological thermogenesis (some psychological states 
such as anxiety and stress, stimulate adrenaline secretion leading to increased heat 
production), cold-induced thermogenesis (increased heat production for thermal 
regulation), diet-induced thermogenesis (heat production following consumption of a meal) 
and drug-induced thermogenesis (consumption of caffeine, nicotine and alcohol among 
many others stimulate thermogenesis) (Miller, 1982). Regulation of thermogenesis in the 
human body can be both voluntary (decreased food intake or decreased physical activity 
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leads to decreased heat production) and involuntary (increased heat production due to 
shivering).  
 
1.1.3 Energy regulation and adipocytes 
Research presented in later sections will outline interventions with compounds that have 
possible effects on adipocyte metabolism; therefore the following section is a brief review 
of the role of adipocytes in the energy balance equation.  
 
Thermogenesis is an important component of EE and is mediated by the sympathetic 
nervous system (SNS). Thermoregulation can occur by two mechanisms. Cold-induced 
thermoregulation or shivering thermogenesis occurs during periods of cold exposure. 
During this process, heat loss is prevented by vasoconstriction of the cutaneous vasculature 
and the body uses shivering to generate heat. Non shivering thermogenesis on the other 
hand is the metabolic production of heat and has been shown as principally occurring in 
the brown adipose tissue ((BAT) (Himms-Hagen, 1984)). 
 
BAT express uncoupling proteins (UCPs; UCP1 and UCP2) and they function in the 
generation of heat. The thermogenic effect of BAT is controlled by the SNS and begins 
with release of noradrenaline from the terminal endings of the sympathetic neurones. 
Noradrenaline binds with β3 adrenoceptor and as a consequence fatty acids are mobilised 
from triglyceride stores and further oxidised following their entry into the mitochondria. 
The oxidative phosphorylation of fatty acids is then ‘uncoupled’ (ie ATP is not 
synthesised) by the UCPs present in BAT mitochondrial membrane and the resultant 
metabolic end product is heat (Trayhurn, 1989). BAT is present abundantly in hibernating 
animals and to a lesser extent in non-hibernators especially adult humans. Many 
morphological studies have shown BAT to be present in the perirenal region in humans 
(Ito et al., 1991). Recent studies have demonstrated the presence of functional BAT in 
healthy adults in the region extending from the anterior neck to the thorax (Virtanen et al., 
2009), which are UCP1-immunopositive (Cypess et al., 2009) and are also activated during 
cold exposure (Lichtenbelt et al., 2009).  
 
Fat stores in adults are predominantly made up of white adipose tissue (WAT). It is 
estimated that there is one brown adipocyte for every 200 white adipocytes in humans 
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(Kozak, 2000). A recent study quantified BAT present in the cervical, supraclavicular 
depots with combined positron-emission tomography and computed tomography (PET-CT) 
scanning to be 10g or more in men and women (Cypess et al., 2009). It is of interest 
however that adipocytes can transdifferentate from white to brown cell type in response to 
for example cold ambient temperatures, suggesting that thermic effects at the level of the 
whole organism may be attainable via BAT (Cancello et al., 1998; Cinti, 2009; Himms-
Hagen et al., 2000; Murano et al., 2005). The main distinguishing feature between WAT 
and BAT are their different metabolic functions. WAT primarily serves as an energy store, 
whereas BAT’s main function is to oxidise substrates to produce heat (Trayhurn, 1989) and 
this is clearly reflected by the differences in their histological appearances. WAT has one 
large fat droplet (unilocular structure) and BAT has multiple fat droplets (multilocular 
structure; Figure 1.2).  
 
Figure 1.2 - Morphology of brown and white adipose cell  
Reference : (Plowman and Smith, 2008) 
 
Further research into the role of BAT and WAT in thermoregulation has led to greater 
attention towards investigating the role of UCPs in thermogenesis present also in other 
tissues such as skeletal muscles (Rolfe and Brand, 1996), as they make up 40% of body 
weight and have been advocated as a major site for adaptive thermogenesis in large 
mammals, for any expression of UCPs.  
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Reproduced with permission from Dulloo AG and Samec S. Uncoupling proteins: Do they have a role in body weight 
regulation?  Obesity Matters, 1999, 2(1),  5-8, (Mediscript, London, UK) (Dulloo and Samec, 2000). 
Rolfe and others showed that mitochondrial proton leaks exist in tissues other than BAT 
and contribute as much as 30% of skeletal muscle heat production at rest (Rolfe and Brand, 
1996). This led to the discovery of several new members of the UCP family (UCP1, UCP2, 
UCP3, UCP4, UCP5 and brain mitochondrial carrier protein 1 (BMCP1)) (Ricquier and 
Bouillaud, 2000). UCP1 is expressed exclusively in BAT and is responsible for 
thermogenesis in hibernating mammals and mammal neonates. UCP2 is expressed in all 
tissues so far examined and UCP3 is highly expressed in skeletal muscles and BAT whilst 
UCP4-5 and BMCP1 are expressed only in the brain (Erlanson-Albertsson, 2003).  
 
Following these breakthrough discoveries, UCP2 and UCP3 have been successfully cloned 
(Dulloo and Samec 2000, (Ricquier and Bouillaud, 2000). Transgenic mice generated with 
skeletal muscle over-expression of UCP were found to have enhanced insulin action and 
were resistant to weight gain and insulin resistance induced by a high fat diet (Li et al., 
2000). It is possible that uncoupling in skeletal muscle by stimulating expression of UCP2 
and UCP3 will result in an increase in EE which could be a potential target to treat obesity 
its complications. Figure 1.3 shows the action of UCPs to release heat. The reader is 
guided to review articles for further reading about the metabolic actions of UCPs (Costford 
et al., 2007a; Costford et al., 2007b; Fukuda et al., 2007; Gambert and Ricquier, 2007). 
  
Figure 1.3 - Action of Uncoupling proteins 
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Considering the potential to ‘dissipate’ heat via uncoupling, it is therefore of interest to 
know if the rate or magnitude of such dissipation can be increased without deleterious 
effects upon the organism. To this end, research to investigate a specific approach to 
achieving increased heat production through the induction of uncoupling is detailed later in 
this thesis.  
 
1.2 Physiological control of blood glucose regulation 
Blood glucose is an important fuel and is utilised by muscle, liver, kidney (cortex, 
medulla), WAT, large intestine, red blood cells and lymphocytes (Dulloo and Schutz, 
2005b). It is transported around the body in the blood circulation. The normal levels are 
maintained between 4 – 7 mmol/l (WHO, 1999), this represent only 3 – 5 g of glucose in 
circulation at any one time (Benardot, 2006). High levels of circulating blood glucose are 
damaging as it results in catabolism of muscle proteins and ketosis during acute periods of 
hyperglycaemia and hyperglycaemia-induced tissue damage, hypertension, dyslipidemia 
and cardiovascular disease (CVD) over a chronic hyperglycaemic state (Jellinger, 2007). 
Equally low blood glucose is detrimental because it causes sweating, trembling, anxiety, 
inability to concentrate, confusion, tiredness, behavioural changes, incoordination, 
weakness, and drowsiness acutely and if prolonged may lead to seizures, coma and sudden 
death (Frier, 2002). Therefore the accurate control of the ‘euglycaemic’ state is a 
physiological set-point which is vigorously defended. Glucose is available from 
carbohydrates in the diet (post-absorptively) and as glucose released from hepatic glycogen 
stores. The actual circulating levels reflect a balance between cellular utilisation of 
glucose, release from the liver and the appearance of glucose in the blood stream following 
the ingestion of carbohydrates. The hormonal control of the release and uptake of glucose 
is outlined in the following paragraphs. 
1.2.1 Insulin  
Blood glucose control is chiefly by the opposing actions of insulin and glucagon. Insulin 
decreases blood glucose concentrations by increasing glucose transportation into target 
cells such as muscle and fat tissue via GLUT4 (insulin regulated glucose transporters) into 
the cell membranes. This pancreatic hormone is synthesised and secreted by the β cells of 
the islets of Langerhans and has been one of the main adiposity signals to be studied to 
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date (Schwartz et al., 1992). Factors which influence the secretion of insulin are many and 
are listed in Table 1.2. 
 
Table 1.2 - Factors influencing the secretion of insulin 
 
Insulin affects the liver, muscles and adipose tissue by several mechanisms. It inhibits 
glycogenolysis and thus promotes formation of glycogen in the liver and muscles. Insulin 
also inhibits gluconeogenesis (Costanzo, 2006). Additionally, insulin decreases fatty acid 
and ketoacid concentrations in the blood by inhibiting the mobilisation and oxidation of 
fatty acids in blood and concurrently increasing the storage of fatty acids in adipose tissue. 
As insulin inhibits lipolysis, decreased fatty acid degradation will result in reduced 
availability of acetyl-CoA for formation of ketoacids and therefore reducing ketogenesis. 
Finally, insulin decreases blood amino acid concentrations by stimulating protein uptake 
into muscle, increasing protein synthesis and inhibiting protein degeneration (Costanzo, 
2006). 
 
Insulin also plays an important role in energy balance along with control of blood glucose 
concentrations. Plasma insulin concentrations are dependent on peripheral insulin 
sensitivity, which in turn is related to body fat stores and fat distribution with visceral fat 
being the main determinant (Porte et al., 2002). There is a substantial amount of evidence 
that insulin acts as an anorectic factor within the central nervous system (CNS) (McGowan 
et al., 1990; VanderWeele, 1994; Woods et al., 1984). Intracerebroventricular (ICV) 
administration of insulin and insulin mimetics in rats altered the expression of 
Stimulatory factors   Inhibitory factors  
Cortisol  Adrenergic agonists 
Glucagon  Decreased glucose concentrations 
Glucagon-like peptide 1 Exercise 
Increased amino acid concentrations Fasting  
Increased fatty acid and ketoacid concentrations Leptin 
Increased glucose concentrations   
Obesity  
Potassium  
Sulfonylurea drugs  
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hypothalamic genes (POMC and NPY) known to regulate food intake and resulted in a 
dose dependant reduction in food intake and body weight (Air et al., 2002). Acute 
injections of insulin antibodies into the ventromedial hypothalamus (VMH) of rats 
increased food intake suggesting that endogenous insulin normally suppresses food intake 
(Strubbe and Mein, 1977). Therefore, optimal control of insulin regulation ensuing in 
blood glucose and energy balance and metabolism are interrelated and essential for 
longterm well – being. 
 
1.2.2 Glucagon 
Glucagon is synthesised and secreted by the α cells of the islets of Langerhans and its 
actions are in contrast to insulin as it promotes mobilisation and utilisation of metabolic 
fuels. The actions of glucagon are coordinated to increase and maintain blood glucose 
concentration. Other main actions of glucagon are increased glycogenolysis, 
gluconeogenesis, lipolysis and ketoacid formation (McArdle et al., 2007a). Factors which 
affect glucagon secretion are given in Table 1.3. 
 
Table 1.3 - Factors affecting glucagon secretion 
Stimulatory factors Inhibitory factors 
Acetylcholine  Insulin 
β-adrenergic agonists  Increased fatty acid and ketoacid 
concentration 
Cholecystokinin (CCK) Somatostatin 
Decreased glucose concentration  
Exercise  
Fasting  
Increased amino acid concentration (especially 
arginine) 
 
 
The main actions of glucagon are on the liver. The mechanism of its action on target cells 
begins with glucagon binding to the cell membrane receptor; following which cyclic 
adenosine monophosphate (cAMP) activate protein kinases that phosphorylated various 
enzymes, which then mediate the physiologic actions of glucagon.  
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Other neurohormonal factors influencing blood glucose concentrations include growth 
hormone, thyroxine, cortisol, adrenaline, somatostatin and ACTH, all of which increases 
blood glucose concentrations. They are less dominant and marginally less important for 
glycaemic regulation when compared with insulin and glucagon actions. These hormones 
facilitate increase in glucose production and limit glucose utilisation, suppress insulin 
realease and may act over a prolonged period of time to both directly and indirectly to 
regulate blood glucose (Costanzo, 2006). 
 
1.3 Exogenous factors influencing energy balance and blood glucose levels 
Positive energy balance leads to the development of overweight and obesity and these if 
uncontrolled, can lead to elevation in blood glucose concentrations due to development of 
insulin resistance and subsequently other metabolic disturbances such as hyperlipidaemia 
and hypertension.  
 
Obesity and related diseases are a major contributor to the cost (NAO, 2001) of healthcare 
and the overall cost is estimated to be £50 billion per annum by the year 2050 if similar 
trends persist (Foresight, 2007). Public health initiatives such as ‘Change4life’ (January 
2009) (DOH, 2008), ‘Small change big difference’ (since 2007) (DOH, 2007), Foresight 
project (since 2007) (Foresight, 2007) and ‘5 a day’ (since 2005) (DOH, 2004), (BNF, 
1999, 2003; DOH, 2001) are currently directed at extending life and also to ensure that 
increased years are spent free of chronic diseases such as obesity, diabetes mellitus, CVD 
and metabolic syndrome (syndrome of a cluster of metabolic abnormalities, which 
comprise of obesity, insulin resistance, hyperlipidaemia and high blood pressure (Grundy 
et al., 2004)). Below is a brief discussion of factors which influence energy balance and 
blood glucose regulation.  
 
1.3.1 Diet composition 
Diet composition affecting energy balance: 
The composition of dietary intake has been suggested to play an important role in 
regulation of energy balance. A low carbohydrate and high protein diet may cause 
anorectic effects but may have negative effects on cardiovascular risk factors (increased 
lipids), despite the weight loss (Astrup, 2005). The amount of water and fibre intake along 
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with other macronutrients affects satiety (Slavin, 2005). Increased protein intake has been 
shown to increase satiation and bring about greater weight loss than variation among other 
macronutrients (Soenen and Westerterp-Plantenga, 2008). Individual amino acids have 
been suggested as particularly important in this respect, for example, phenylalanine as a 
dietary precursor of the satiety hormone, cholecystokinin (Pohle-Krauza et al., 2008). High 
fat intake appears to have a weak satiating effect and high fat diets which are low in 
carbohydrates, may promote quick weight loss by inducing ketosis, and if this imbalance 
between macronutrients continues ketosis will lead to muscle breakdown and may result in 
certain minerals and vitamins deficiencies (Astrup et al., 2004). In obese individuals, it has 
been shown that macronutrient composition of the diet has little effect on the rate or 
magnitude of weight loss unless nutrient composition influences caloric intake (Rolls, 
2009; Sacks et al., 2009). 
  
Diet composition affecting blood glucose regulation: 
Dietary changes are aimed towards optimisation of blood glucose control in persons with 
blood glucose dysregulation. Dietary fibre has been shown to modulate the glycaemic 
response to carbohydrate intake (Ulmius et al., 2009). As glycaemic response to 
carbohydrate rich foods can be influenced by other factors such as physical state of foods 
and type of starch present, the in-vivo response to varying glycaemic index of foods has 
been extensively investigated. It has been shown that a diet consisting of low glycaemic 
index foods results in a reduction in post prandial hyperglycaemia (Fontvieille et al., 1992; 
Rovner et al., 2009). Recent studies have shown that variation in the type of monomeric 
and polymeric sugars may affect postprandial metabolism. Intake of a meal consisting of 
rapidly digestible starch causes significantly more rapid, greater changes in postprandial 
plasma glucose, NEFA and serum insulin concentrations in comparison with a meal 
composed of slowly digestible starch (Ells et al., 2005). Dietary fructose seems to  produce 
a smaller postprandial rise in plasma glucose and serum insulin than other common 
carbohydrates (Bantle, 2009). Variation in macronutrient composition for glycaemic 
control has also been extensively studied. A low carbohydrate diet (40% carbohydrate) 
intake may be beneficial over a short period of time to improve insulin sensitivity and 
blood glucose levels, but dietary adherence to such a dietary change has been found to be 
poor (Boden et al., 2005; Brinkworth et al., 2004). Low energy, high protein dietary (30% 
proteins) intake although may facilitate weight reduction and therefore reduction in 
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circulating glucose concentration, does not affect on blood glucose and insulin 
concentrations over prolonged periods of time (Nuttall et al., 2003; Sargrad et al., 2005).  
 
1.3.2 Medical and pharmacological influences on energy balance 
As compliance with lifestyle modifications of increased physical activity and low 
fat/calorie eating habits tend to decline over time (Castellani et al., 2003; Shay, 2008), 
various other means to help minimise the incidence of obesity are being explored. These 
measures include invasive surgical techniques designed to alter the size of elements 
(usually the stomach) of the GI tract, or its mechanism of action. These surgical options 
usually involve either a gastric bypass or gastric banding and are not without potentially 
serious adverse effects (Pories, 2008; Woodward, 2003). Non-invasive interventions 
include pharmacological means to help reduce energy intake and reduce nutrient uptake. 
This is achieved either via suppression of appetite or the induction of malabsorption of 
nutrients, especially fats. Drug treatments for alleviating obesity (as outlined in Table 1.4) 
are costly and not without side effects (Rucker et al., 2007; Zieba, 2007).  
 
Table 1.4 - Summary of anti-obesity drugs† currently used in healthcare in the UK 
Brand name Active 
ingredient 
Mechanism of 
action 
Side-effects  Dose 
Xenical* Orlistat Reduces absorption 
of dietary fat 
Oily leakage from 
rectum, faecal urgency, 
liquid or oily stools, 
abdominal distension 
(gastrointestinal effects 
minimised by reduced fat 
intake) 
120 mg 
tds with 
meals  
 Reductil ** Sibutramine 
hydrochloride 
monohydrate 
Inhibits re-uptake of 
noradrenaline and 
serotonin 
Constipation, dry mouth, 
hypertension, taste 
disturbances, depression, 
anxiety 
10 mg 
od 
† These drugs are available on prescription only and careful observation of their side-effects are always 
indicated; * Acts on the gastrointestinal tract; ** Centrally acting appetite suppressant; tds - three times 
daily; od – once a day; Reference: British National Formulary (BNF, 2008) 
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1.3.3 Nutritional interventions to control energy balance and blood glucose 
regulation 
Along with public health policies promoting changes in lifestyle, the effectiveness of non-
pharmacological measures to address causes and consequences of energy imbalance and 
associated co-morbidities are being explored (Kumanyika et al., 2008). A breakthrough in 
identifying such an approach might prove more economical along with conservative 
methods of treatment in the longer run. There is therefore ongoing interest in developing 
non-pharmacologic dietary interventions (Norris et al., 2004; Norris et al., 2005) which 
may have the potential to regulate parameters of energy balance and blood glucose levels, 
which additionally may have low associated costs to healthcare providers.  
 
Dietary agents may facilitate weight loss by increasing BMR or reducing food intake. 
Over-the-counter (purported) weight loss supplements (Appendix 1) are widely available 
and include chromium, guar gum, ephedra, caffeine, chitosan, conjugated linoleic acid, 
ginseng, glucomannan, green tea, hydroxycitric acid, L-carnitine, psyllium and pyruvate 
(Lenz and Hamilton, 2004; Saper et al., 2004). The purported mechanism of action of these 
dietary supplements are suggested to include: increasing EE, modulation of carbohydrate 
metabolism, increased satiety, increased fat oxidation or reduced fat synthesis, blocking 
dietary fat absorption, increased water elimination or enhanced mood (DeBusk, 2001). 
Common dietary and herbal supplements promoted for weight loss frequently lack 
sufficient supporting efficacy and safety data. More research with larger and better-
controlled trials is needed to draw firmer conclusions regarding their effects on energy 
balance. Table 1.5 gives a brief summary of dietary agents used to regulate energy intake 
and/or energy expenditure.  
 
Table 1.5 - Dietary agents purported to regulate energy intake and/or energy 
expenditure  
Dietary agent Purported metabolic 
effects 
Mechanism of action Adverse effects 
Caffeine Increase energy 
expenditure 
Inhibit 
phosphodiesterase, 
resulting in increased 
cAMP concentrations 
in cells and prolonged 
noradrenaline release 
(Dulloo et al., 2000; 
Westerterp-Plantenga 
et al., 2006). 
↑ Blood pressure, heart 
rate and cortisol 
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Dietary agent Purported metabolic 
effects 
Mechanism of action Adverse effects 
Chitosan Reduction of body 
weight 
Prevents fat absorption 
by binding negatively 
charged fat molecules 
within the intestinal 
lumen (Kanauchi et al., 
1995). 
Gastrointestinal 
symptoms such as 
constipation and 
flatulence (Mhurchu et 
al., 2005). 
 
 
Chromium 
 
 
Reduction of body 
weight and increased 
insulin sensitivity 
 
 
Considered to play a 
role in carbohydrate 
and lipid metabolism 
thereby possibly 
influencing body 
composition and weight 
(Anderson, 1998) 
 
 
Short-term intervention 
trials have not shown 
any adverse effects 
(Anderson et al., 1997) 
but long-term intake of 
chromium has been 
shown to cause free 
radical damage as 
assessed from cell 
culture and in vivo rat 
studies (Vincent, 2003) 
Conjugated linoleic acids Reduction in body fat 
and body weight 
Increased fat oxidation 
and decreased 
triglyceride uptake in 
the adipose tissue 
(DeLany et al., 1999) 
CLA isomer trans-10, 
cis-12 may produce 
liver hypertrophy and 
insulin resistance 
(Larsen et al., 2003) 
Ephedra Thermogenic, lipolytic 
and anorectic effects 
Sympathetic activation 
of the CNS (Astrup et 
al., 1992) 
Strokes, hypertension, 
palpitations and 
tachycardia (Haller et 
al., 2000), and may 
also predispose people 
to ischemic and 
hemorrhagic strokes 
(Chen et al., 2004) 
Glucomannan Reduction of body 
weight, blood lipids 
and blood  glucose 
Absorbs water within 
the gut, causing 
increased satiety and 
lower caloric intake 
None reported 
Green tea Increased 
thermogenesis and 
reduction in body 
weight 
Inhibit catechol o- 
methyl transferase 
(COMT), thereby 
increasing 
noradrenaline effects 
on thermogenesis 
(Dulloo et al., 1999) 
None reported 
Guar gum Reduction in weight 
loss 
Soluble fibre in guar 
gum absorbs water 
within the gut, causing 
increased satiety and 
lower caloric intake 
(Saper et al., 2004). 
abdominal pain, 
flatulence, diarrhoea 
and cramps 
Hydroxycitric acid  
 
Increase fat oxidation 
or reduce fat synthesis 
Inhibiting 
mitochondrial 
citratelyase thereby 
leading to decreased 
acetyl coA production 
and decreased fatty 
acid synthesis 
(Lowenstein, 1971) 
None reported 
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Similarly, numerous dietary agents are being investigated for their role in blood glucose 
regulation. These include ivy gourd (coccinia indica), ginseng species, garlic (Allium 
sativum), fenugreek (Trigonella foenum graecum), fig leaf (Ficus carica), nopal (opuntia 
streptacantha), gymnema sylvestre, bitter melon (Momordica charantia), aloe vera, 
chromium, magnesium, vitamin E, L-carnitine, vanadium, alpha lipoic acid. Their 
purported mechanisms of hypoglycaemic action are suggested to be facilitation of 
peripheral glucose uptake, decreased rate of carbohydrate absorption and so on (Table 1.6 
shows summary of dietary agents along with their purported mechanism). Further evidence 
is needed from controlled trials using these supplements as current supportive evidence is 
few and long-term effects of these supplements need to be further examined (Yeh et al., 
2003). 
 
Table 1.6 - Dietary agents purported to regulate blood glucose 
Dietary agent Purported metabolic 
effects 
Mechanism of action Adverse 
effects 
Alpha lipoic acid Increased glucose uptake, 
improve insulin sensitivity 
Enhanced glucose uptake in muscle and 
prevents glucose-induced protein 
modifications (Jacob et al., 1999; 
Konrad et al., 1999) 
None 
reported 
Aloe vera Decrease FBG Aloe gel contains glucomannan, fibre 
which accounts for hypoglycaemic 
effects (Kim et al., 2009) 
None 
reported 
Bitter melon 
(Momordica 
charantia 
Decrease FBG, PPG Increased insulin secretion, tissue 
glucose uptake, liver muscle glycogen 
synthesis, glucose oxidation (Akhtar, 
1982; Singh et al., 2008) 
None 
reported 
Chromium Decrease FBG, PPG Increase number of insulin receptore to 
enhance receptor binding and to 
potentiate insulin action (Althuis et al., 
2002; Anderson et al., 1997) 
None 
reported 
Fenugreek 
(Trigonella 
foenum graecum) 
Decrease FBG, PPG, urine 
glucose 
Delayed gastric emptying, slow CHO 
absorption, inhibition of glucose 
transport from the fibre content, 
modulation of peripheral glucose 
utilisation (Sharma et al., 1990; 
Vijayakumar and Bhat, 2008) 
None 
reported 
Fig leaf (Ficus 
carica) 
Decrease PPG Facilitation of glucose uptake 
peripherally (Frati et al., 1990; 
Serraclara et al., 1998) 
None 
reported 
Garlic (Allium 
sativum) 
Decrease FBG Increased secretion or slowed 
degradation of insulin, increased 
glutathione peroxidase activity and 
improved liver glycogen storage (Bailey 
and Day, 1989; Shane-McWhorter, 
2001) 
None 
reported 
Introduction 
- 18 - 
Dietary agent Purported metabolic 
effects 
Mechanism of action Adverse 
effects 
Ginseng species Decrease FBG, HbA1C Decreased rate of CHO absorption into 
the partal hepatic circulation, increased 
glucose transport and uptake mediated 
by nitric oxide, increased glycogen 
storage and modulation of insulin 
secretion (Vuksan et al., 2001; Vuksan 
et al., 2000; Vuksan et al., 2008) 
None 
reported 
Gymnema 
sylvestre 
Decrease FBG, HbA1C Increase in glucose uptake and 
utilisation, increase in insulin release 
through cell permeability and 
stimulation of β cell function (Liu et al., 
2009; Persaud et al., 1999) 
None 
reported 
Ivy gourd 
(coccinia indica) 
Decrease FBG and PPG Due to insulin-mimetic properties 
(Kamble et al., 1996; Kamble et al., 
1998; Kuriyan et al., 2008) 
None 
reported 
L-Carnitine Increase glucose uptake, 
glucose storage, glucose 
oxidation 
Possibly effect insulin sensitivity and 
enhance glucose uptake and storage 
(Giancaterini et al., 2000; Mingrone et 
al., 1999) 
None 
reported 
Magnesium Decrease FBG, improve 
insulin sensitivity 
A cofactor in various enzyme pathways 
involved in glucose oxidation, it 
modulates glucose transport across cell 
membranes, may increase insulin 
secretion and/or improve insulin 
sensitivity and peripheral glucose 
uptake (Paolisso et al., 1992; Rumawas 
et al., 2006) 
None 
reported 
Nopal (opuntia 
streptacantha) 
Decrease FBG, insulin Contains high soluble fibre and pectin 
content, which may affect intestinal 
glucose uptake (Shapiro and Wong, 
2002) 
None 
reported 
Vanadium Decrease FBG, increase 
insulin sensitivity 
Enhanced glucose oxidation and 
synthesis, modulate glucose output 
(Cusi et al., 2001; Goldwaser et al., 
2000) 
Transient 
gastrointestin
al discomfort 
Vitamin E Decrease FBG, PPG Attributed to its lipophilic anti-oxidant 
activity, with possible influences on 
protein glycation, lipid oxidation, 
insulin sensitivity and secretion 
(Mooradian et al., 1994; O'Connell, 
2001) 
None 
reported 
FBG- Fasting blood glucose; PPG- Post prandial glucose, HbA1C- Glycosylated haemoglobin, CHO- 
carbohydrate 
 
1.4 Choice of two natural substances with potential to affect energy 
expenditure and blood glucose control 
The remit for the present research was to evaluate, via a review of the literature, likely 
candidates for novel nutritional interventions affecting key metabolic parameters. Within 
this the broad intention was to investigate possible mechanisms for increasing EE and 
stabilising/reducing blood glucose. This is in accord with a generic interest in nutritional 
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science which seeks to find qualitative perspectives by which health benefits may be 
elicited from the diet. The concept of functionality of food components is well established 
and has proved highly efficacious (eg iodisation of salt (UNICEF, 2008), fortification of 
commonly eaten foodstuffs with vitamins (FAO, 1996), use of plant esters to sequester 
cholesterol from bile (Plat and Mensink, 2005) etc). In keeping with the search for 
functional benefit derived from specific manipulation of dietary components, the amino 
acid L-Histidine and the tea-derived catechin, Epigallocatechingallate (EGCG) were 
identified as novel agents for testing. The criteria by which they were deemed suitable 
were that there should be sufficient data and mechanistic information regarding mode of 
action in the extant literature to suggest that appropriate research could demonstrate a 
beneficial effect of these compounds. The review of the literature (described in the 
following study introductions) revealed much interest and relevant preliminary work with 
L-Histidine and EGCG with respect to energy balance and blood glucose regulation. The 
dimension of efficacy in free living humans was however found to be incompletely 
represented for both compounds, suggesting the need for further investigation via 
controlled interventions. 
 
1.5 Overarching hypothesis for the thesis 
Supplementation with L-Histidine or EGCG in healthy subjects (age range: 18 – 55 years) 
will increase resting metabolic rate, decrease fasting blood glucose and lipid concentrations 
and affect other parameters of energy balance (reduction in dietary intake and increased 
lipolysis).  
 
1.6 Aim of the research 
The aim of this research was to investigate in humans, the potential exergonic and other 
metabolic properties of two dietary supplements: an essential amino acid, L-Histidine, and 
the main catechin present in green tea, EGCG. A review of literature of human trials 
investigating the metabolic effects of both these dietary agents shows a lack of evidence 
with very few controlled human studies having been conducted to date. However, many 
intervention studies have been conducted in animal models to examine the effects of L-
Histidine and EGCG and the results from these studies show positive effects of these 
interventions with respect to increased EE, reductions in body fat, plasma glucose 
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concentrations and circulating lipids. There is a need therefore to examine these effects in 
humans and further explore the practicalities of oral ingestion, such as dose and period of 
supplementation, with respect to potential positive changes in body composition and 
energy balance.  
 
The metabolic effects of L-Histidine and EGCG were analysed by measurement of RMR, 
body composition, mean skin and core temperatures, fasting blood glucose and lipids, 
insulin, leptin and changes in dietary intake. 
 
The aims will be addressed by the following objectives: 
• To conduct a pilot study in normal weight volunteers into the effect of L-Histidine 
supplementation (over 3.25 hours) on parameters of energy balance.  
• Investigate the effect of 10 days L-Histidine supplementation on parameters of 
energy balance and metabolism in normal weight volunteers.  
• Investigate the effect of L-Histidine supplementation among overweight and obese 
subjects on parameters of energy balance and metabolism over an 8 week period. 
• Examine the effects on healthy men of acute (2.5 hours) EGCG supplementation on 
energy balance and metabolism.  
• Examine the effect of varying doses of EGCG supplementation on healthy men 
over a period of 7 days on energy balance metabolism.  
 
1.7 Structure of thesis 
The general methods employed to measure outcomes in all studies are detailed in Chapter 
2. Chapter 3 is divided into five sections beginning with the review of literature (section 
3.1) of metabolic effects of L-Histidine/histamine and sections 3.2, 3.3 and 3.4 serially 
describing the outcomes of L-Histidine ingestion over an acute, 10-day and 8 weeks period 
of supplementation respectively. Findings from these studies and further directions for 
future studies investigating L-Histidine ingestion are discussed in Section 3.5. Chapter 4 
describes the studies conducted with EGCG, beginning with the review of literature of 
EGCG’s metabolic effects (section 4.1). Sections 4.2 and 4.3 explore the effects of EGCG 
ingestion following acute and chronic periods of supplementation among healthy men 
respectively. Findings from these studies and further directions for forthcoming studies are 
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discussed in section 4.4. Chapter 5 provides a final conclusion, to allow a clearer 
understanding of the implications of the studies’ results.  
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2 General Methodology 
 
In the following section, the methods employed for collection of data and the justification 
for the selection of these methods will be described in detail. In the subsequent chapters of 
this thesis the reader will be referred to this chapter to find details of methods. Table 2.1 
provides a concise summary of the measures performed in each individual study. 
2.1 Ethical approval and informed consent: 
Experimental plans were prepared for the proposed studies to test the effects of L-Histidine 
and EGCG ingestion in healthy humans. These proposed plans were used to apply for 
ethical approval. All studies were approved by the University of Westminster Ethics 
Committee (Application numbers 04/05-62, 06/07/27; Appendices 2 and 8, respectively). 
At the time of the initial ethics application, investigations on the rate of lipid oxidation 
following varying durations of resistance exercise and changes in lipid oxidation following 
alterations in fat intake in response to ingestion of cordeceps sinesis supplementation in 
humans was envisaged. Following further review of literature, the experiments on the topic 
of lipid oxidation following resistance exercises were not conducted as the author chose to 
investigate effects of dietary agents only, without any changes in physical activity. 
Continual review of literature on the effects of Cordeceps sinesis on EE and blood glucose 
concentrations revealed a lack of in vitro data to support the proposed in vivo mechanisms 
of its actions among animal models. Therefore, due to the paucity of data regarding effects 
of cordeceps sinesis among humans the author decided to further study the literature for 
other dietary agents capable of influencing neurochemical activity in vivo and therefore 
bring about changes in EE and blood glucose concentrations. EGCG has been studied 
extensively in the recent years and considerably more data regarding its in vivo and in vitro 
activities among animals and humans are emerging in the literature. This dietary agent was 
therefore chosen to be studied and a further ethics application detailing the proposed 
studies supplementing EGCG among humans was submitted to the University of 
Westminster Ethics Committee (Appendix 8). 
 
Prior to the commencement of the first test session, participants were provided with a 
written research study information sheet which detailed the test protocol, safety measures 
taken and any potential risks associated with the tests (Appendices 5 – 7 and 10 - 11). 
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Informed consent (Appendices 3 and 9) was obtained from all participants at the start of 
the study.  
2.2 Sample recruitment: 
Participants for all studies were recruited by advertising around central London campuses 
of the University of Westminster, London, England, by means of fliers and posters as well 
as advertising in local newspapers (Metro and Evening Standard). Lean, healthy men and 
women along with overweight and obese male participants were recruited according to the 
following criteria- 
 
Inclusion criteria: Male, (females only for the pilot study Chapter 3.2), BMI < 35, healthy, 
between the age group of 18 - 55 years, not diagnosed with any chronic medical condition 
such as cardiac problems, hypertension or diabetes mellitus, not following any stringent 
training schedule and not supplementing their diets with dietary agents (any amino-acid or 
green tea ingestion) were included into the studies. 
 
Exclusion criteria: Participants were screened for any health related issues which made 
them unsuitable as test subjects (including chest pains, respiratory difficulties, heart 
disease, thyroid disease and orthopaedic problems). Participants were excluded if they 
were on medications expected to alter the results of the study; including medications that 
affect metabolism or weight loss; (such as, psychiatric medications, appetite suppressants 
(Sibutramine), fat absorption inhibitors (Orlistat) and thyroid medications) or suffering 
from hay fever (taking anti-histamines). Furthermore, subjects who were obese due to a 
confounding diagnosed disease (for example, Cushing’s syndrome) were not recruited.  
 
Apart from the pilot study (Chapter 3.2) which involved investigating the acute effects of 
oral ingestion of L-Histidine, all other studies were conducted on male participants only as 
the variations in body temperature during different stages of the menstrual cycle in women 
would interfere with the mean skin and core body temperature measurements (Kuhl, 2002). 
All participants recruited for the studies were Caucasians (white). This selection was 
unintentional as only Caucasian (white) male responded to the adverts.   
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Table 2.1 - Summary of methods used in studies conducted 
Parameter measured 
Chapter 
3.2 
(Pilot 
study) 
Chapter 
3.3  
(30 day 
cross-
over L-
Histidine 
study) 
Chapter 
3.4  
(8 week 
parallel 
L-
Histidine 
study) 
Chapter 
4.2 
(Acute 
EGCG 
study) 
Chapter 
4.3 
(Chronic 
EGCG 
study) 
Height 9 9 9 9 9
Weight 9 9 9 9 9
Skinfold measurements  9 9  9
BMR 9 9 9 9 9
RER 9 9 9 9 9
Skin temperature 9 9 9 9 9
Core temperature 9 9 9 9 9
Fasting blood 
glucose 
concentrations
Accutrend GC  9 9   
HemoCue    9 9
Fasting total 
cholesterol 
concentrations
Accutrend GC  9    
Miniphotometer 
LP20 
  9  9
HDL    9  9
LDL    9  9
Heart rate    9 9
Blood pressure   9 9 9
Dietary analysis  9 9 9 9
VAS    9  
Plasma NEFA concentrations   9 9 9
Plasma insulin concentrations   9 9 9
Plasma leptin concentrations   9 9 9
 
2.3 Participant handling at test sessions: 
The handling of all participants prior to the start and during the test session was 
standardised as follows: 
• All participants were instructed to consume their last meal prior to the test session 
by 8 pm or earlier, allowing an overnight fasting period of 12 hours prior to the test 
session.  
• In order to keep the physical activity to a minimum in the morning of the test 
session, participants came to the laboratory by public transport.  
• On the test day, participants arrived at the laboratory between 7 am – 10:30 pm. 
The arrival time was kept constant for each participant.  
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• The participants changed into light indoor clothes, voided urine and were asked to 
rest for 10 minutes. At the first test session, this time was used to discuss the study 
information sheet and procedures to be carried out, and informed consent was 
obtained. At following test sessions, participants used this time to settle in and 
relax. 
• Anthropometric measurements (height, weight) and skinfold measurements were 
then recorded (details in 2.5 and 2.6). Participants inserted the rectal probe in 
privacy and further measurements according to each individual study were carried 
out. These are outlined below.  
• Resting metabolic rate (RMR); each test period was 45 minutes. For this period, 
participants lay on the bed in a comfortable position. Noise was kept to a minimum 
to avoid arousal stimuli and participants were instructed to remain awake and 
motionless. Participants listened to meditation music (Sleep, Nukarma) (details in 
2.7).  
• At the same time, mean skin and core temperatures were recorded continuously as 
participants were connected to the Squirrel Data Logger with thermistors firmly 
attached at four sites (described in detail in 2.9) along with having previously 
inserted the rectal probe.  
• At the end of RMR monitoring, participant’s blood pressure was measured thrice. 
The skin thermistors were detached from the participants and the rectal probe 
removed by the participants in privacy.  
• Finger prick blood samples for measurement of fasting blood glucose and total 
cholesterol were obtained. For later studies (Chapters 3.4, 4.2, 4.3), whole blood 
samples by venepuncture were obtained following the finger prick blood sample.  
• At the end of each session, completed food diaries were collected. Following the 
test session, subjects were told to continue with the relevant next phase of the study 
(wash out period or taking capsules and maintaining food diaries). 
 
2.4 Dose of supplementation: 
L-Histidine: 
Excess L-Histidine ingestion (from a 5% increase in diet to up to 50 g/kg of diet) in 
rodents causes hypercholesterolemia, hepatomegaly, lipid dysregulation, copper and zinc 
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loss (Hitomi-Ohmura et al., 1992; Ohmura et al., 1986; Aoyama et al., 1999; Harvey et al., 
1981; Soloman and Geison, 1978). Investigations researching the effect of excess dietary 
histidine in humans are few. Single oral administration of 64.8 g/day in men caused 
anorexia, taste and smell dysfunction and cerebellar dysfunction with significant decreases 
in serum zinc concentrations and significant increases in urinary zinc excretion (Henkin et 
al., 1975). Conversely, 4 g/day oral ingestion of L-Histidine in gelatine capsules among 8 
volunteers for a period of 2 weeks, found no significant changes in appetite, taste and smell 
perceptions (Schechter and Prakash, 1979). The recommended daily requirement of L-
Histidine is 12 mg/kg/day (840 mg/day for a 70 kg adult) (FNB, 2002). Reviewing the 
above literature regarding dose responses to histidine and taking into consideration the 
WHO/FAO (Kriengsinyos et al., 2002) guidelines on estimated daily requirement of 
histidine in adults, the test dosage was doubled and chosen to be 25 mg L-Histidine per 
kilogram body weight to supply a supraphysiological dose in order to bring about 
metabolic changes. Calculating this dose with mean pre-treatment body weight of study 
participants results in an average dose of 2.1 g of L-Histidine (1.8 – 3.5 g/day), which was 
much lower than previously studied doses and was considered safe and non-toxic. Analysis 
of dietary intake pre-treatment for the L-Histidine supplementation studies showed that the 
average histidine intake for all study subjects (n = 27) was 2.15 g/day. The orally 
supplemented L-Histidine was an additional 98% (average) (84 – 163%) over and above 
the dietary intake and it was therefore presumed to result in metabolic changes.  
 
EGCG: 
The United States Department of Agriculture (USDA) database for flavonoid content of 
foods specify the mean content of EGCG in 100 ml of brewed green tea as 26.00 - 82.89 
mg depending on the addition of caffeine or other flavours (USDA, 2003b). There is no 
statistical data on consumption of green tea among population in the UK; hence for the 
purpose of the study, the EGCG dose was chosen to be based on an intake of 2 cups/day 
(250 ml/cup) of green tea. The lower range of EGCG content in brewed green tea (USDA, 
2003b) was used to calculate the single oral dose of EGCG to be used in the acute 
ingestion study (EGCG for 100 ml = 26 mg; for 1 cup (250 ml) = 65 mg; for 2 cups = 130 
mg). This dose was rounded up to 150 mg and was used to investigate a single oral dose 
over a period of 2.5 hours (Chapter 4.2).  
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Single oral doses of purified EGCG ranging from 50 mg to 1600 mg have been well 
tolerated among healthy humans (Ullmann et al., 2003). In the chronic ingestion of EGCG 
study (Chapter 4.3), oral doses of up to 300 mg/day (3 doses, 75, 150 and 300 mg/ day) (as 
this represents an approximate intake of 1 – 4.5 cups (1 cup measuring 250 ml) of green 
tea/day) have been used which is much lower than the doses administered in the safety 
studies, therefore no adverse effect of EGCG administration was envisaged.  
 
2.5 Measurement of height and weight: 
The full standing height of all subjects was measured using a wall mounted stadiometer 
(Holtain Ltd, Britain) at the beginning of the first test session. The subjects were standing 
straight, looking ahead with their feet flat and heels almost together. They had their arms at 
the sides with shoulder blades, buttocks and heels touching the stadiometer (Gibson, 2005). 
Body weight was measured at the start of each test session, with subjects wearing light 
indoor clothes and no shoes on a digital balance (Salter 461, UK) and recorded to the 
nearest 100 g. 
 
2.6 Measurement of body fat percentage by skin-fold measurements: 
Estimation of body fat was by measurement of skinfold thickness in all studies presented in 
this thesis. This method was chosen over the use of BODPOD system (version 4.1, Body 
Composition System; Life Measurement Instruments, Concord, CA) which measures body 
volume by using air displacement plethysmography as it was unavailable to use due to 
technical malfunction at the beginning of the project. Skinfold thickness measurements 
provide an estimate of the size of subcutaneous fat depots, which in turn, provides an 
estimate of body fat. In a previous study conducted in the Department of Human and 
Health Sciences, University of Westminster, to measure bias, if any, in the different 
methods of measuring percentage body fat, it was found that both BODPOD and skinfold 
measurements by the use of Harpenden callipers can be used interchangeably as the results 
obtained from both techniques were similar and reliable (CV of 3.5%) (Stiegler et al., 
2005). There were no statistically significant differences when comparing the BODPOD 
and skinfold measurement by analysis of variance. A Bland-Altman plot (Figure 2.1) for 
body fat determined by the two techniques revealed a wide scatter of data points without 
an apparent trend (r = -0.16, not-significant). The limits of agreement of the difference 
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between the two techniques indicate that 95% of the results for percentage body fat 
determined by skinfold measures were between 6.9% higher and 9.1% lower than results 
from the BODPOD measurement (Figure 2.1). 
 
Figure 2.1- Agreement between BODPOD and skinfold measurements, showing bias 
(-1.1%) and limits of agreements (-9.1%, +6.9%) 
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For the purpose of studies presented herein, skinfold measurements were employed to 
measure body fat composition as this method has been shown to detect changes in body fat 
reliably and accurately over time (Demura and Sato, 2007; Orphanidou et al., 1994). Care 
was taken to perform these measurements by a single, trained anthropometrist so as to 
avoid interrater differences and maintain accuracy (Jebb and Elia, 1993; Kispert and 
Merrifield, 1987) (investigator is a trained level one anthropometrist, International Society 
for the Advancement of Kinanthropometry). 
 
Skinfolds were measured by the use of Harpenden callipers (British Indicators, England) 
and a Harpenden anthropometer (Holtain, UK), all on the right side of the body and at four 
sites: namely, subscapular, biceps, triceps and supraspinale (ISAK, 2001) (see Appendix 
23 for sites). Skin folds were measured three times at each site to the nearest 0.1 mm and 
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the mean of the closest two measurements was used for the calculation of percentage body 
fat. The percentage body fat was calculated first by determining body density: 
 
BD (Body Density) = C-[M (log 10 of all four skin folds)]  
where, C and M are constants according to gender and age (Durnin and Womersley, 1974). 
 
The result from the calculation of BD is substituted into the Siri equation to estimate 
percentage body fat (Siri, 1993). 
% BF (Body Fat) = ([4.95 ÷ BD] – 4.5) × 100 
 
2.7 Measurement of resting metabolic rate (RMR): 
Many energy releasing actions in the body depend on oxygen use. Measuring a person’s 
oxygen consumption either during rest or physical activity, provides an indirect and highly 
accurate estimate of EE (McArdle et al., 2007b).  
 
RMR for all studies was measured with the use of Deltatrac II (Datex-Ohmeda, Finland) 
which employs indirect calorimetry using a continuous, open circuit, ventilated canopy 
system. Numerous studies have been conducted to validate and test the reliability of Datex 
Deltatrac to accurately measure gas exchange. The measurements of VO2 and VCO2 has 
been found to be accurate under a variety of simulated clinical conditions and when 
compared with other models (Makita et al., 1990; Phang et al., 1990; Takala et al., 1989; 
Weissman et al., 1990).  
 
In the following studies described in this thesis, the measurement unit was adjusted for 
ambient pressure and calibrated using a reference gas mixture of 95% oxygen and 5% 
carbon dioxide before the beginning of each test session. Participants were required to lie 
on the bed for 45 minutes with a perspex hood over their head. They were encouraged to 
be in a complete state of rest but not asleep. To help them achieve this, they were supplied 
with a set of headphones with calming music playing (Sleep, Nukarma), to block out any 
distractions. For calculation of RMR, the initial 15 minutes’ data were not used as this time 
was given for acclimatisation under the hood. 
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Oxygen consumption (VO2) and carbon dioxide production (VCO2) were calculated from 
continuous measurements of oxygen and CO2 concentrations in inspired and expired air.  
The estimate of RMR was calculated using the formula: 
RMR (kilocalorie) = (3.9 * litres O2 used) + (1.11 * litres CO2 produced) (Weir, 1949). 
 
2.8 Measurement of respiratory exchange ratio (RER): 
RER reflects the pulmonary exchange of carbon dioxide and oxygen under differing 
physiological and metabolic conditions (McArdle et al., 2007b). This measurement is an 
indicator of relative percentages of carbohydrate and fat utilisation by the whole body. It 
was calculated by using the formula: 
 
RER = VCO2 (litres/minute) ÷ VO2 (litres/minute) 
where VCO2 and VO2 data were obtained from Deltatrac during RMR measurement.  
 
2.9 Measurement of skin and core temperature: 
Mean skin (MST) and core temperatures (CT) were measured in all studies presented in 
this thesis to examine the effects of L-Histidine and EGCG supplementations on 
thermogenesis. This interest in the measurement of possible changes in MST and CT was 
to observe variation in adaptive thermogenesis, thereby contributing to an increase in 
overall EE. Both L-Histidine and EGCG supplementations have been shown to increase 
expressions of UCP 1 and 2 in BAT and UCP 3 in WAT among animal studies (Kao et al., 
2006; Masaki et al., 2004; Takahashi et al., 2002) and UCPs produce heat instead of ATP. 
Therefore MST and CT were measured to detect any increase in body temperature, and as 
a consequence, increase in EE. 
 
The measurements of skin and core temperatures were taken using a Squirrel data logger 
(Grant Instruments Ltd, 2020 series, Cambridge, UK). Measurements of skin temperature 
involved placing thermistors on four different skin sites on the body (namely the sternum, 
forearm, calf and thigh) and securing them with hypoallergenic tape (TransporeTM, 3M, 
USA). Core temperature was measured by a rectal probe inserted to a depth of 8cm beyond 
the external anal sphincter (Reilly and Waterhouse, 2005). The participants inserted the 
probe themselves, in privacy, under sterile conditions. The probe and skin thermistors were 
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left in position for 45 minutes (period of time when participants were under the perspex 
hood during the measurement of RMR). There are different methods (invasive and non-
invasive) for the measurement of CT; such as, measuring temperature orally, in the axilla 
or the tympanic membrane. Invasive measurement techniques include measurements taken 
in the oesophagus, pulmonary artery or the urinary bladder or the use of a radio-sensitive 
pill. The use of these measurement sites have been found to be complicated and rectal 
temperature is considered the gold standard for CT measurement (Moran and Mendal, 
2002; Reilly and Waterhouse, 2005). The Squirrel data logger was calibrated to record data 
every minute. The 45 minute data thus obtained were averaged and used to calculate the 
final skin and core temperatures. 
 
Mean skin temperature (MST) was calculated by using the equation: 
MST (°C) = 0.3* t chest + 0.3 * t arm + 0.2 * t thigh+ 0.2 * t leg  (Ramanathan, 1963) 
where t chest, t arm, t thigh and t leg are the temperatures recorded by the chest, arm, thigh and 
leg thermistors, respectively. 
 
2.10 Blood metabolites: 
Blood glucose and lipid concentrations reflect the individual’s well-being. Reduction in 
any elevated concentrations reveals positive changes towards health. Measurement of their 
markers such as fasting blood glucose, high density lipoprotein, and total cholesterol 
indicate any predisposition to diabetes or hypercholesterolemia. Hormones such as insulin 
and leptin are implicated in various metabolic processes such as blood glucose regulation, 
lipolysis, amino acid uptake, glycogen synthesis (McArdle et al., 2007a, c) and appetite 
regulation. Fatty acids are delivered to the tissues in the form of non-esterified fatty acid 
(NEFA). NEFA is released by lipolysis of adipose tissue triacylglycerol (Yaqoob et al., 
2005). Measurement of NEFA therefore gives an indication towards rate of lipolysis and 
overall indication of metabolic changes. These blood metabolites are measured in the 
following studies to assess the metabolic pathways of action of the two supplements. 
 
2.11 Measurement of fasting blood glucose: 
An Accutrend GC monitor (Roche, Germany) was used to measure fasting blood glucose 
(FBG) for all L-Histidine studies. The process involved obtaining a drop of capillary blood 
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sample with the use of an Accuchek soft clix pro lancet device (Roche, Germany) and 
placing the drop of blood on a BM-Accutest test strip (Roche, Germany). A reading (in 
mmol/l) from the glucometer was obtained after 30 seconds. The technique used during 
measurement was as instructed by the manufacturer. A reliability study previosusly 
conducted to assess the Accutrend meter showed good correlation coefficients (r = 0.988) 
with those obtained by the laboratory method (Devreese and Leroux-Roels, 1993).  
 
The system automatically performs a control check before each measurement by reading 
the bar code on the test strip and by comparing the code-strip data stored before the blood 
sample is applied. In addition, the control solution Accutrend® Control G (glucose) was 
used for performance checks. The intra-assay co-efficient of variation (CV) performed for 
studies described in Chapters 3.3 and 3.4 was 5.5% at 3.7 mmol/l (the hypoglycaemic 
range) and 4.8% at 9.6 mmol/l (the hyperglycaemic range). 
 
For all the EGCG studies, a HemoCue® Glucose 201 analyser (HemoCue AB, Sweden) 
was used for measurement of FBG. This change in apparatus was due to availability of 
more funds and thus procurement of HemoCue® Glucose 201 analyser for all further 
studies in the Department of Human and Health Sciences, University of Westminster, 
London. The method involved obtaining a capillary blood sample using the Accuchek soft 
clix pro lancet device (Roche, Germany). By capillary action 5µL of blood were drawn 
into the cavity of a HemoCue® Glucose 201 microcuvette which was then placed into the 
analyser for measurement. All techniques used in the measurements were as per 
manufacturer’s instructions. The accuracy and precision of HemoCue® has been found 
previously to be comparable to other laboratory diagnostic methods (Fogh-Anderson, 
2004). The HemoCue® Glucose 201 analyser has an internal electronic self-test system. It 
automatically verifies the performance of the optronic unit of the analyser every time it is 
switched on. This self-test is also performed at regular intervals if the analyser is on for a 
period of time. The intra-assay CVs (n = 10 for each) using Eurotrol GlucoTrol-NG control 
solution, by the current investigator during the EGCG studies, were 1.63% at 6 mmol/l and 
1.15% at 10 mmol/l. 
 
The accuracy of the type of blood sample used (capillary blood samples) for glucose 
monitoring have been studied during various conditions such as measurement during 
gestational diabetes and among patients undergoing haemodialysis, and has been found to 
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be comparable and highly correlated with plasma blood glucose levels investigated in the 
laboratory (Bosch and Hyneck, 1984; Meriggi et al., 1988). Correlation of results obtained 
from capillary blood samples to laboratory assay technique ranged from 0.74 - 0.99 in 
hospitalised patients with diabetes (Bustamante et al., 1994), during resuscitation (mean 
difference of 0.01 mmol/l between the capillary sample and lab result) (Kumar et al., 2004) 
and in general intensive care patients (the mean difference (bias) was 0.12 mmol/l and 
precision 0.77 mmol/l) (Kulkarni et al., 2005). Capillary blood glucose measurements have 
been found to be significantly different when compared with venous blood sample (Boyd 
et al., 2005) and in healthy volunteers (correlation coefficient with venous blood sample 
was 0.24) (Funk et al., 2001). In all of the studies, all subjects were euglycaemic and only 
capillary blood samples have been employed for measurement of FBG. Hence consistency 
has been maintained and accuracy was expected to be high as shown with the CVs. 
 
2.12 Measurement of total cholesterol: 
The measurement of total cholesterol for the first L-Histidine study (Chapter 3.3) was done 
using an Accutrend GC monitor (Roche, Germany) and an Accu-chek soft clix pro lancet 
device (Roche, Germany) to obtain a capillary blood sample, which was then dropped onto 
an Accutrend Cholesterol test strip (Roche, Germany). The test strip was completely 
covered by the blood sample and a result was obtained after 120 seconds when the 
cholesterol value (in mmol/l) was read on the monitor. Measurement technique was carried 
out according to manufacturer’s instructions. The accuracy and precision of Accutrend GC 
monitors to measure cholesterol concentrations has been found to be high in previous 
studies (correlation co-efficient = 0.96 against enzymatic laboratory method and CV of 
0.07% and differences of +2.5% to -3.2% with the laboratory technique for total 
cholesterol assay (Cañizo et al., 1996; Gottschling et al., 1995) respectively.  
 
The system automatically performs a control check before each measurement by reading 
the bar code on the test strip and by comparing the code-strip data stored before blood is 
applied. The control solution Accutrend® Control CH1 (cholesterol) was used for 
performance checks. The intra-assay CV (n = 10) performed by the current investigator 
was 3.61% at 4.5 mmol/l.  
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2.13 Blood procurement for plasma and serum samples: 
Venous blood samples (8 ml) were obtained by a trained phlebotomist. Following mild 
occlusion of the upper arm using a tourniquet, a suitable antecubital vein was located, and 
the skin sterilised using a cotton wool ball containing Hydrex Denaturated Ethanol B 96% 
(Adams Healthcare, Leeds, UK). The needle (21-guage blood collection set, Becton, 
Dickinson and Company, Plymouth, UK) was inserted, the tourniquet was released, and 
blood was collected in heparinised Vacutainer® tubes (Becton, Dickinson and Company, 
Plymouth, UK). Then the needle was removed and sufficient pressure was applied until 
bleeding had stopped. The blood was immediately centrifuged for 11 minutes at 3000 rpm 
in room temperature (Centaur 2, MSE, Centaur, Leicester, UK). Supernatant plasma was 
aliquoted into conical tubes (Eppendorf, Hamburg, Germany) and stored at -80°C 
(Ultralow Freezer, Revco Technologies, Asherville NC, USA) until analysis. To obtain 
serum samples, blood was collected in serum separator tubes with clot activators (9.5 ml) 
and stored at room temperature for 1 hour to allow for full coagulation, centrifuged and 
immediately analysed.  
 
2.14 Measurement of total cholesterol (TC), High density lipoprotein (HDL) 
and Low density lipoprotein (LDL) by Miniphotometer LP20: 
Due to additional University investment during the course of the study, analyses of TC and 
further components of lipid profile (HDL and LDL) were performed using a spectro-
photometrical method (miniphotometer LP20, Dr Lange, Germany) for the studies 
described in Chapters 3.4 and 4.3.  
 
Venepuncture was used to collect 9.5 ml of whole blood using the vacutainer system 
(Becton and Dickinson, USA) and drawn into a serum separator tube (Becton and 
Dickinson, USA). This was thoroughly mixed and left standing at room temperature for 1 
hour, before being centrifuged for 12 minutes at 3500 rpm. This resulted in the separation 
of the blood components and accumulation of serum at the top of the tube. This serum was 
collected and used to measure total cholesterol, LDL and HDL with the use of 
miniphotometer LP20 and reagents from Dr. Lange, Germany. The procedures employed 
for measurements were in accordance with the manufacturer’s instructions. The 
repeatability measure for the miniphotometer was measured by measuring the same serum 
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sample, 5 times, by the current investigator and using the same procedures. The standard 
deviation (0.02) was small and well within the probability of 95%.  
 
Measurement of total cholesterol – Serum (20 µl) was pipetted into a cuvette containing 
pre-pipetted cholesterol buffer solution as following manufacturer’s instructions. The 
starter reagent (in start caps) was added, mixed and left to stand at room temperature for 5-
8 minutes. A blank cuvette (containing no blood) was used to calibrate the miniphotometer 
before measuring the sample cuvette. The results were read at 546 nm. The intra-assay CV 
(n = 5) for total cholesterol performed by the current investigator was 4.0% at 7.05 mmol/l. 
 
Measurement of LDL – LDL precipitant (100 µl) was added to 200 µl serum and left to 
stand at room temperature for 15 minutes before being centrifuged at 1500 rpm for 15 
minutes. Clear supernatant (50 µl) obtained after centrifugation, was pipetted into a cuvette 
containing pre-pipetted cholesterol buffer solution and mixed thoroughly with the starter 
reagent (in start caps). This was then left standing at room temperature for 5-8 minutes. A 
blank cuvette (containing no blood) was used to calibrate the miniphotometer before 
measuring the sample cuvette. The results were read at 546 nm. The intra-assay CV (n = 5) 
for LDL cholesterol was 7.01% at 5.16 mmol/l. 
 
Measurement of HDL – HDL precipitant (50 µl) was added to 500 µl serum and left to 
stand at room temperature for 10 minutes before being centrifuged at 3000 rpm for 5 
minutes. Clear supernatant (50 µl) obtained after centrifugation, was pipetted into a cuvette 
containing pre-pipetted cholesterol buffer solution and mixed thoroughly with the starter 
reagent (in start caps). This was then left standing at room temperature for 5-8 minutes. A 
blank cuvette (containing no blood) was used to zero the miniphotometer before measuring 
the sample cuvette. The results were read at 546 nm. The intra-assay CV (n = 5) for HDL 
cholesterol was 1.54% at 1.30 mmol/l. 
 
2.15 Measurement of plasma NEFA: 
Plasma NEFA concentrations were measured on an ILAB 600 clinical chemistry analyser 
at the Hugh Sinclair Nutrition Research Group laboratory at the University of Reading. A 
WAKO NEFA-C kit (Wako Chemicals, Germany) was used in the enzymatic quantitative 
colorimetric test. The samples, after treatment with reagents according to manufacturer’s 
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instructions (see Appendix 21 for detailed instructions), were measured at a wavelength of 
560 nm. Quality control was done with the use of 3 control sera (control serum I, II and I + 
II) with the assay. The values of all control sera were within the expected values for the 
assay. The measuring range of the assay kit is up to 2mmol/l. The lowest detectable level 
on the ILAB is 10 μmol/L and the range of the assay on the machine is 10-4000 μmol/L. A 
single point calibration was used for the test; the concentration of the calibrator was 1000 
μmol/L. The intra-assay CV (n = 20) was found to be 1.2%.  
 
2.16 Measurement of plasma insulin: 
To measure insulin concentrations in plasma, an Enzyme-Linked ImmunoSorbent Assay 
(ELISA) technique was employed. The kit was manufactured by Mercodia AB, Sweden. 
The procedure involved using 25 µl of unknown plasma along with standard solutions with 
a range of 0 – 200 mU/l. The assay was performed as specified by the manufacturer (see 
Appendix 19 for details and standard curve) the results were read at 450 nm. The R2 value 
of calculated values from the assay was 0.9998. The intra-assay CV for 6 replicates of 4 
samples was found to be between 2.8% and 4.0% (data obtained from pack insert). 
 
2.17 Measurement of plasma leptin: 
An ELISA technique was employed to measure leptin concentrations in plasma samples. 
The ELISA kit was obtained from DRG Instruments GmbH, Germany. The leptin ELISA 
test kit required 15 µl of standard (the range of concentration was 0 – 100 ng/ml), control 
and unknown plasma. Following the manufacturer’s instructions (see Appendix 20 for 
details and standard curve) the results were read at 450 nm. The R2 value of calculated 
values from the assay was 1. The intra-assay variation of 10 replicates of 2 samples was 
5.95% and 6.91% (data obtained from pack insert). 
 
2.18 Measurement of heart rate: 
Heart rates were measured in all subjects participating in the EGCG studies as analysis of 
heart rate variability is an useful tool to assess cardiovascular function and stress 
(Omerbegovic, 2009). Heart rates were measured using a Polar heart rate monitor S610i 
(Polar Electro, Kempele, Finland). A Polar T61 transmitter belt was firmly attached onto 
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the participant’s chest during the measurement of RMR (45 minutes) in each test session. 
The belt detected the electrocardiogram (ECG) and sent an electromagnetic signal to the 
Polar S610i wrist receiver which was worn by the participant at all times during the test 
session. This recorded the ECG and the recording was downloaded by using Polar IR 
Interface™, onto a computer for ease of analysis. The Polar IR Interface™ communicates 
between the Polar heart rate monitor and Polar software. The data thus obtained were used 
to calculate the mean heart rate for each test session and used for further analyses. The 
precision and accuracy of portable heart rate monitors have been well documented for 
subjects both at rest and during different types and intensities of exercise (Durant et al., 
1993; Gamelin et al., 2006; Seaward et al., 1990).  
 
2.19 Measurement of blood pressure: 
A boso-medicus sphygmomanometer (Bosch + Sohn GmbH, Germany) was used to 
measure participants’ blood pressure. The measurement of blood pressure was performed 
as per the manufacturer’s instructions. Participants were supine and rested during the 
measurements. All three measurements were recorded after the measurement of RMR, 
while the participants lay on the bed. The participants were rested and comfortable, and all 
the measurements were performed at the same point during each test session. An average 
of 3 recordings was calculated and used for analysis.  
 
2.20 Dietary assessment and analysis: 
All participants kept 3-day food diaries during varying periods of the studies. Diet diaries 
recorded pre-treatment were used as baseline data and those recorded during the course of 
the study were used to detect changes from baseline intake.  
 
2.20.1 Formulation of diet diary and a guide to keeping the diet diary to record food 
intake: 
In view of the data available regarding the validity and reliability of 3-day dietary recalls, a 
three-day prospective diet diary was designed for the analysis of food intake during the 
study (Appendix 15). This was the chosen method as it provides a direct measure of the 
current diet (Bates et al., 2005). The 3-day dietary intake record has been validated for use 
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among all age groups and when compared with other methods of dietary intake assessment 
(Crawford et al., 1994; Lührmann et al., 1999; Schröder et al., 2001 ). The food diary was 
prepared based on a model used nationwide by the European Prospective Investigation of 
Cancer and Nutrition (EPIC) (Frobisher and Maxwell, 2003). Participants were asked to 
record their dietary intake on 2 weekdays and 1 day of the weekend, before and after the 
supplementation. 
 
A photographic guide to aid in the keeping of the food diary was prepared based on the 
‘photographic atlas of food portion sizes’ and ‘food portion sizes: a user’s guide to the 
photographic atlas’ formulated by the Food Standards Agency (Nelson et al., 2002). This 
involves the use of colour pictures of everyday foods in varying quantities where each 
quantity was assigned a code, to be entered into the food diary (Appendix 16). This was 
used as a visual aid to assist with quantification of portion sizes and also aid to minimise 
coding errors. This was further used to input quantities of food intake during analysis. 
2.20.2 Analysis of food intake: 
Quantification of dietary intakes was carried out using the prospective 3-day diet diary and 
photographic atlas as described above. The food diaries were coded and data entered into 
the dietary analysis software, Dietplan 6 (Forestfield Software Ltd, West Sussex, UK). 
This allowed the calculation of nutrient intakes. The Dietplan 6 database is pre-installed 
with the full set of UK food tables (from the 5th and 6th Editions of McCance and 
Widdowson’s The Composition of foods plus all the published supplements, including 
Fatty acids and the Composition of Foods Integrated Data Set), Dietary Reference Values 
(COMA, 1991), Food Portion Sizes (MAFF 2nd Edition, 1993), Food Labelling Data (EC 
Directive, 1990). A small number of foods were not defined in Dietplan 6, which were then 
defined individually by the author by inputting each ingredient separately to make up the 
reported food product. The food database and results are produced in pdf format, with 
clearly labelled graphs and tabulated list of foods. The guidelines for selecting a dietary 
analysis system specify choosing the software based on characteristics such as validity of 
the database, clear and complete documentation, an easy-to-read computer output (Frank 
and Pelican, 1986; Stumbo, 2008). Dietplan 6 met all of these characteristics as its 
database was based on National standard food tables and the search and analysis process is 
efficient with clearly produced reports and was therefore chosen to be used for dietary 
analyses for all studies presented in this thesis. Averages of all the 3-day diaries were used 
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during statistical analyses for dietary intakes of all macronutrients (pre and post 
treatments).  
 
Histidine quantification of reported dietary intakes was performed by using the 
INTERMAP (International Collaborative Study of Macronutrients, Micronutrients and 
Blood Pressure) database to control for dietary histidine intake in the analyses following a 
personal communication (discussion followed by email on 16/6/09) with Dr Claire 
Robertson, UK Country Nutritionist (Schakel et al., 2003) (permission to use the data from 
the principal authors was sought via email, their response is awaited). The database 
constituted of 1448 commonly consumed foods in UK and histidine content expressed as 
mg/100 g.  
  
To assess the validity of the reported dietary intakes, the Goldberg cut-off method was 
used on all diet diaries. This was performed to quality control the reported dietary intakes 
as underreporting of dietary intakes might occur in all dietary assessment methods and 
among all age groups and in both males and females (Livingstone and Black, 2003). The 
Golberg cut-off method is based on the principle that an individual of a given sex, age and 
body weight needs a minimum energy intake and intakes below this level are considered to 
be unacceptable representation of habitual intake (Goldberg et al., 1991). This method 
compares the daily mean reported energy intake (EIrep) to the FAO/WHO/UNU (1985) 
recommended energy intakes for a sedentary lifestyle of 1.5 × BMR. BMR estimated 
(BMRest) was calculated using the Schofield equation (Schofield, 1985). Underreporting 
for individuals can be identified by calculating the ratio EIrep: BMRest. The ratios were then 
compared with the cut-offs given in table 5 (page number: 576) of Goldberg et al (1991) 
for n = 1 and number of days of dietary assessment used to calculate the EIrep.  A ratio of 
less than 1.0 was considered as energy intake lower than the minimum intake needed and 
therefore considered as under-reported.  
 
The challenges in obtaining accurate dietary intake information are manifold (Black et al., 
1991; Cook et al., 2000; Samaras et al., 1999; Voss et al., 1998). The present series of 
studies attempted wherever possible to circumvent isssues of subject compliance and 
recording accuracy through the use of clear and consistent guidelines, and adjuncts to 
written information in the form of visual cues (shown to enhance recording accuracy) 
(Turconi et al., 2005). In this way, and based on best practice as described in the extant 
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literature, the data collection process regarding qualitative and quantitative aspects of 
intake was made as robust as possible. As mentioned above, macronutrient intake, as it 
would affect total energy intake was evaluated for validity through the use of the Goldberg 
Cut-off method. In addition, it should be noted that the designs of the studies in the present 
series were cross-over in nature with subjects acting as their own controls. Therefore, 
consistency in the explanations given to subjects regarding their role as self-recorders of 
nutrient intake was of paramount importance and prioritised by the present author.  
 
2.20.3 Assessment of appetite sensations: 
Visual analogue scales (VAS) were used to assess subjective appetite sensations during the 
first EGCG study (Chapter 4.2). The validity and reproducibility of VAS for measurements 
of appetite sensations, with and without diet standardisation prior to the test day has been 
shown previously (Flint et al., 2000). The VAS (Appendix 14) used were 100 mm in 
length with words anchored at each end, expressing the most positive and the most 
negative rating. This was used to assess hunger, satiety, fullness and prospective food 
consumption. The questionnaires were made as small booklets showing one question at a 
time. Participants marked on the scale according to their appetite sensations at the 
beginning and end of each test session. 
 
2.21 Analysis of biomarkers: 
Biomarkers of L-Histidine metabolism were not analysed in the studies described as 
existing literature indicates that oral consumption of the doses utilised (25mg/kg BW, > 2 x 
RDA) in the present studies leads to a significant increase in the levels of blood histidine. 
L-Histidine is rapidly and extensively absorbed when administered orally or intravenously 
in humans, with bioavailability of oral doses reaching 80% or higher (Wade and Tucker, 
1998). An oral dose of 100 mg/kg L-Histidine (average intake of 7 g for a reference man 
weighing 70 kg) increased mean peak plasma concentration to 8.8-fold above baseline and 
an oral dose of 50 mg/kg L-Histidine (average intake of 3.5 g for a reference man weighing 
70 kg) has shown to increase mean peak plasma concentration to 4.7-fold above baseline 
(Sitton et al., 1988). It has been suggested that the relationship of L-Histidine dose (oral or 
intravenous) and peak plasma concentration is linear up to at least 200 mg/kg (Wade and 
Tucker, 1998). These elucidations in pharmacokinetics of L-Histidine administration 
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provide evidence that the doses administered in the studies presented in this thesis (1.9 – 
3.5 g/day) will be rapidly absorbed and will increase plasma concentrations and may 
account for any changes observed in the study parameters. Following the acute phase of L-
Histidine metabolism, there is a compartmentalisation of resultant compounds and 
financial constraints upon the research dictated that it was not feasible to assay possible 
metabolites or products of further biochemical reactions induced by L-Histidine 
consumption.  
 
The pharmacokinetics of EGCG in humans is well documented and it has been shown that 
EGCG concentrations in plasma accounts for 2% of the ingested amount (Nakagawa et al., 
1997) and the plasma and urine concentrations reach undetectable levels in 24 hours 
following ingestion and it has been suggested that most of the ingested EGCG does not get 
into the bloodstream and the absorbed EGCG is preferentially excreted through the bile to 
the colon (Lee et al., 2002). With respect to EGCG, there is no normal blood level for this 
compound and it was determined from the literature that 4 cups of green tea would deliver 
~300mg EGCG. It was therefore decided that the test dose would be designed to reflect 
this level of intake as this would be of broad relevance (ie apply to a large number of tea 
drinkers) in terms of any effects measured. Following the completion of all EGCG 
supplementation studies, the analysis of urine following ingestion of EGCG over an acute 
and chronic period was performed to detect EGCG in the urine. However, the procedure 
(in collobaration with University of Reading) at the time of submission of this thesis was 
not optimised and is not presented in this thesis  
 
2.22 Statistical analyses: 
2.22.1 Sample size calculation: 
The number of subjects required for both the studies was determined by sample size 
calculations to determine the size of significant differences in EE and metabolic responses 
that may be observed after ingestion of L-Histidine and EGCG. Sample size calculations 
were performed taking into account the probability of failing to detect a real difference 
(type II error) and the significance level, that is the probability of incorrectly rejecting the 
null hypothesis (type I error) (Armitage and Berry., 1971). The sample size was calculated 
to incorporate a 5% significance level (two sided), and 80% power (1- β). The standardised 
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n > 2  
(1.96+0.842) 20
27
2
= 8.6
difference was calculated as the physiologically significant difference divided by the 
standard deviations (SD) of the measures in question: weight loss, EE and fasting blood 
glucose. 
 
L-Histidine studies: 
One of the aims of the L-Histidine studies was to detect a difference in fasting blood 
glucose concentrations following chronic ingestion of L-Histidine. Prior to commencement 
of this investigation, review of literature showed that apart from the current study, there 
were no other studies performed to test efficacy of L-Histidine supplementation in humans. 
The investigator was required to use the key metabolic parameter (blood glucose) 
measured in the below mentioned study, as a guide during sample size calculation.  
 
From a previous study (Song et al., 1998), it was identified that after ingestion of bovine 
prostrate powder (containing cyclo His-Pro, a metabolite of thyrotropin releasing hormone, 
and a cyclic form of the di-peptide L-Histidine and Proline) men with type 2 diabetes 
showed significantly reduced fasting blood glucose levels as much as 27 mg/dl. This was 
used to calculate the sample size for this study. The significance level was set at 5% (α, 
two-sided) and a power of 80% (corresponding to a 20% chance of a type II error) is 
required to detect a mean difference between the experimental and control groups. 
The following equation was used to determine the size of the sample (Armitage and Berry, 
1971):  
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Using the equation with α2z = 1.96, β2z = 0.842, σ = 20, 0δ = 27 gives 
Therefore, at least nine participants need to be included in the study to measure the effect 
of the intervention within subjects.  
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n > 2  
(1.96+0.842) 1.7
2.4
2
= 7.87
EGCG study: 
Using the same equation for sample size calculation as above, it was determined that 8 
participants were required to take part in studies investigating the efficacy of EGCG 
ingestion. 
 
According to a double-blind study conducted by Nagao et al (2005), body weight of 
healthy men were significantly lower in the group ingesting green tea extract than in the 
control group. The authors concluded that ingestion of catechins might be useful in the 
prevention and improvement of lifestyle-related diseases, mainly obesity. As this was the 
main objective to the study the weight loss data (73.9 ± 1.8 kg before ingestion of green tea 
extract and 71.5 ± 1.7 kg after 12 weeks of ingestion) was used in sample size calculation 
as below-  
 
Using the equation with α2z = 1.96, β2z = 0.842, σ = 1.7, 0δ = 2.4 gives 
 
 
 
 
2.22.2 Statistical tests employed to analyse data: 
Data are presented as mean ± standard error of mean (SEM). Raw data obtained from the 
study, were entered into the Statistical Programme for Social Sciences (SPSS 14.0 for 
windows, SPSS Inc, Illinois, USA) for analyses. To test the normal distribution of pre-
treatment data, a Kolmogorov-Smirnov test was performed on body weight, body mass 
index (BMI) and percent body fat as these measures were used to recruit participants for 
the studies. Baseline data for all studies except the pilot study were analysed for normal 
distribution. The significance value for all data sets were >0.05 (non-significant) 
confirming that the distribution of the sample was not significantly different from a normal 
distribution. 
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Table 2.2 - Tests of normality performed for body weight, BMI and body fat 
measures at baseline for subjects who completed the studies supplementing L-
Histidine and EGCG 
 Kolmogorov-Smirnov 
df Significance 
Baseline data for Chapter 3.3
Body weight 9 0.200 
Body fat % 9 0.200 
BMI 9 0.200 
Baseline data for Chapter 3.4  
1=Placebo group, 2=Histidine group
Body weight                                        1 9 0.200 
                                                             2 9 0.200 
BMI                                                     1 9 0.152 
                                                             2 9 0.200 
Body fat %                                           1 9 0.097 
                                                             2 9 0.200 
Baseline data for Chapter 4.2 
Weight 8 0.200 
BMI 8 0.200 
Baseline data for Chapter 4.3 
Weight 8 0.168 
BMI 8 0.200 
Body fat % 8 0.187 
Significance  > 0.05, therefore all data are normally distributed. 
 
Repeated measures analysis of variance (ANOVA) was performed to detect statistical 
significance among variation in data due to treatment and over time. A 0.05 level of 
significance was used so that the probability of falsely rejecting the null hypothesis (type I 
error) is only 5%. Sphericity of data (equality of variances of the differences between 
treatment levels) was examined by observing the ‘Mauchly’s test of Sphericity’ output. If 
the p value was ≤ 0.05, it was concluded that there were significant differences between the 
variances of difference and sphericity was not met. If in any instance this violation of 
sphericity was noted, the Greenhouse-Geisser correction was used. Bonferroni post- hoc 
test for pair-wise comparison was performed to observe significant difference between 
groups, as this method is the most robust, especially in terms of power and control of the 
type I error rate (Field, 2000).  
 
To detect any linear relationship between variables, Pearson’s correlation coefficient tests 
were performed. A p value of ≤ 0.05 was considered significant. Paired samples t-tests 
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were performed for the acute EGCG study as only two groups of data were available. As 
previously, a p value ≤ 0.05 was considered significant. Statistical analyses for the pilot 
study (Chapter 3.2) were performed as the sample size was small. Analyses via non-
parametric tests were not possible as more than three group means needed to be compared. 
ANOVA is used when comparing means for three or more groups of a single independent 
variable (Ritchey, 2007). As analysis of variance (ANOVA) compares each group mean to 
the grand mean (mean for all cases in the sample), it was the most appropriate method to 
test differences among three or more means and was therefore chosen for the pilot study 
(Ritchey, 2007). The variations between all data, between treatments, between subjects and 
between time periods were calculated. Following on from this data, the sum of squares and 
mean square were calculated. The results for the F test were obtained by using table of 
values according to the degrees of freedom (Table 2.3).  
 
Table 2.3 - Five percentage points of the F-Distribution 
 
 The table consulted for F value. All observed values from ANOVA were lower than the tabulated value, 
therefore indicating that there were no statistically significant variations between samples; Ref (Gravetter 
and Wallnau, 2008). 
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3 Possible histaminergic modulation of energy expenditure and blood 
glucose regulation in man  
 
This chapter presents the background information and studies conducted with L-Histidine 
as an oral dietary agent with a potential to affect various components of energy balance. 
The L-Histidine supplementation studies proposed herein are the first of their kind. The 
theoretical potential of L-Histidine to increase EE and affect blood glucose via increasing 
insulin sensitivity appear to be supported by animal studies (Masaki et al., 2001; 
Yoshimatsu et al., 2002b; Yasuda et al., 2004a; Lee et al., 2005). A review of literature 
however demonstrates a lack of knowledge regarding the effects of L-Histidine intake in 
humans. The present study was initiated with a view to examining the metabolic effects of 
L-Histidine, but also to assess the viability of implementing a complex series of metabolic 
measurements in healthy human volunteers. These measurements included whole body 
metabolic measurements alongside skin and core temperature assessments. No previous 
studies have looked at indirect calorimetric measures being taken at the same time as both 
peripheral and deep body temperature. The rationale for doing such being that should an 
intervention bring about increased EE, it may be possible to localise the area of increased 
metabolism. In the case of the present study this was of particular interest due to the 
documented effects of L-Histidine on uncoupling reactions in peripheral adipose depots.  
 
3.1 Review of Literature 
The metabolic effects of L-Histidine and consequently histamine in animals and humans 
are discussed in the following section. The literature search showed that 
histidine/histamine actions have been studied extensively among animal models, and 
evidence from human studies is few. The review of literature is divided into sections 
discussing the amino acid’s dietary quantification, its bioavailability, mechanism of action 
(in particular effects on energy balance, blood glucose and blood lipid concentrations) and 
finally data on possible toxicity are explored. 
 
L-Histidine is an essential amino acid (FAO/WHO/UNU, 1985) as a histidine free diet 
reduces haemoglobin levels (Kriengsinyos et al., 2002) and results in negative nitrogen 
balance, along with a marked decrease in both muscle and plasma histidine concentrations, 
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lower serum albumin concentrations, anaemia and clinical symptoms (such as, scaly and 
dry skin with erythema) (Kopple and Swendseid, 1975). There is little evidence that a 
metabolic pathway exists for histidine synthesis in the human body. Histidine stores in the 
human body are large as it is present in haemoglobin and carnosine (also called β-
alanylhistidine, a di-peptide present in the muscle) and the gut flora synthesises an 
unknown amount of histidine which may be absorbed and used (Visek, 1984). L-Histidine 
is a precursor of the neurotransmitter histamine which has important regulatory roles on 
lipolysis, EE, food intake and blood glucose regulation within the body (Panula, 2007).  
 
3.1.1 Histamine biosynthesis and action 
Histamine is synthesised in the brain by the enzymatic decarboxylation of L-Histidine 
catabolysed by histidine decarboxylase (HDC, a histamine synthesising hormone) (Panula, 
2007). It has been previously seen that slices of rat hypothalamus when incubated in the 
presence of 3H-L-Histidine, rapidly absorbed the amino acid and partially converted to 3H-
histamine. Inhibitors of HDC prevented this conversion and the regulation of histamine 
synthesis was independent of the addition of exogenous histamine (Verdiere et al., 1975). 
Dietary L-Histidine intake influences concentrations of tissue histamine, HDC, and 
histamine methyltransferase (HMT, a degradative enzyme) activity. Feeding rats diets 
supplying inadequate, adequate, or excess amounts of histidine for 14 days, showed that as 
the levels of dietary histidine increased, tissue concentrations of free-histidine and of 
histamine increased in all the tissues analysed (Lee et al., 1981). The increase of histamine 
was greatest in brain and stomach (5- and 4-fold, respectively), HDC activity was not 
detected in muscle, but doubled from the lowest to the highest histidine intake in brain and 
increased almost 6-fold between the lowest and the highest histidine levels in stomach. The 
increases in tissue histamine concentrations observed in the tissues analysed generally 
reflected the changes and magnitudes of enzyme activities for HMT and HDC. Similarly, 
research into the properties and localisation of HDC enzyme in adult human brain shows 
that a major portion of the enzyme is localised in a sub-cellular fraction containing nerve 
terminals and it showed an uneven regional distribution (Nowak and Zelazowska, 1987). 
Considering all of the above, it is apparent that L-Histidine metabolises histamine with the 
help of HDC. 
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Histamine transfers signals through its interaction with its receptors. Histamine receptors (a 
class of G-protein coupled receptors with histamine as their endogenous ligand), of which 
there are four known subtypes (H1, H2, H3 and H4), are widely distributed in most tissues 
such as: 
H1 smooth muscle, endothelium, adrenal medulla, heart and CNS 
H2 gastric parietal cells, vascular smooth muscles, neutrophils, CNS, heart and uterus 
H3 CNS, heart, lung, GI tract, endothelium (Homaidan et al., 2001) 
H4 various cells of the immune system, mast cells, lymphocyte T cells, dendritic cells 
and basophils (Parsons and Ganellin, 2006). 
 
The functions of histamine include its roles during allergic reactions, vasodilation, 
vasoconstriction, gastric acid secretion and neurotransmission. Of special interest to the 
current study is its action in the CNS as a neurotransmitter. Histaminergic neurons project 
from the tuberomammillary nucleus of the posterior hypothalamus to all regions of the 
brain (Mercer, 1997). The activation of the histaminergic system is responsible for a 
collection of physiologic effects; including, increased activity of the hypothalamic-
pituitary-adrenal axis, decreased blood pressure, decreased pain perception, wakefulness, 
hyperactivity, hyper secretion of corticotropin releasing hormone, hypercortisolemia, 
temperature regulation, thirst, food intake (satiety), breathing and cardiovascular function 
(Costanzo, 2006b). 
 
3.1.2 Dietary sources of histamine 
Histamine is readily available from foods such as marine products, cheeses, fermented soy 
products and other fermented foods, alcoholic beverages and vinegars. Some plant sources 
such as aubergine, spinach, and tomato also contain high levels of histamine naturally 
(Table 3.1). In addition, fish meat, eggs, food additives such as azo dyes and preservatives 
mediate the release of histamine within the body (Table 3.2) (Sellers et al., 2005). 
Recommended daily intake of histidine for adults is 12 mg/kg body weight 
(FAO/WHO/UNU, 1985).  
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Table 3.1 - Foods rich in histamine 
Food categories Histamine content 
 mg/kg mg/l 
Fish (frozen/smoked or 
salted/canned) 
  
Mackerel  ND - 1788*  
Herring  1 – 479*  
Sardine  ND – 2000*  
Tuna  ND – 402*  
Cheese    
Gouda  10 – 900  
Camembert  0 – 1000  
Cheddar  0 – 2100  
Emmental  5 – 2500  
Swiss  4 – 2500  
Parmesan  10 – 581  
Meat    
Fermented sausage ND – 650   
Salami  1 – 654  
Fermented ham  38 – 271  
Vegetables   
Sauerkraut   0 – 229  
Spinach 30 – 60  
Eggplant 26  
Tomato ketchup 22  
Red wine vinegar 4  
Alcohol   
White wine  ND – 10   
Red wine   ND – 30 
Top-fermented beer   ND – 14 
Bottom-fermented beer   ND – 17 
Champagne   670 
ND = Not detected; Reference: Adapted from (Maintz and Novak, 2007) *Original authors have collated 
data from (Beutling, 1996; Izquierdo-Pulido, 1996; Jarisch, 2004; Sarkadi, 2004).  
 
The formation histamine in foods requires the availability of free amino acids, the presence 
of decarboxylase-positive microorganisms and conditions allowing bacterial growth and 
decarboxylase activity. Changes in the presence of any of these factors account for the 
variation in histamine content in foods. Numerous bacterias and some yeast display high 
HDC activity and thus have the capacity to form histamine. Therefore, high concentrations 
of histamine are found mainly in products of microbial fermentation (aged cheese, 
sauerkraut, wine) or in microbially spoiled food (Pechanek et al., 1983). It has been 
suggested that some foods have the capacity to influence the release of histamine directly 
from tissue mast cells in the body (TNO, 1996) (Table 3.2). Histamine release following 
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ingestion of these foods is triggered in an Ig-E independent manner (by direct interaction 
of molecules with cell membrane-associated G proteins or transmembrane lipid mediators) 
and is regulated by several factors other than Ig-E, such as cytokines, prostaglandins and 
neuropeptides (Steinhoff et al., 2004b). 
   
Table 3.2 - Foods with suggested histamine releasing capacity 
Plant-derived Animal-derived Other  
Citrus fruit  Fish  Additives 
Papaya  Crustaceans Liquorice 
Strawberries Pork Spices 
Pineapple Egg white Azo dyes 
Tomatoes   
Spinach   
Nuts   
Peanuts   
Chocolate   
Reference: ((Steinhoff et al., 2004a); Sellers et al., 2005) 
 
3.1.3 Metabolic action of L-Histidine and histamine in-vivo 
There have been numerous studies conducted on animal models, demonstrating the actions 
of L-Histidine and/ or histamine on lipolysis, EE, food intake and blood glucose regulation. 
 
Effects on parameters of energy balance: Both peripheral (intraperitoneal (i.p)); 
0.35mmol/kg) and central (intraventricular; 1nmol/rat) administration of L-Histidine and 
histamine results in an elevation in plasma glycerol and free fatty (FFA) concentrations in 
rats, indicating lipolysis in progress (Yasuda et al., 2004a; Yoshimatsu et al., 2002b). This 
was due to increased activity of sympathetic nerves innervating WAT following peripheral 
administration of histidine mediated by neuronal histamine. Investigations on the effect of 
peripheral administration of L-Histidine on BAT sympathetic nerve activity as a marker for 
the central regulation of EE has shown that a bolus i.p injection of L-Histidine (0.3 
mmol/rat) induced a significant increase in nerve activity in BAT as a consequence of an 
excitatory effect of histamine on the SNS (Yasuda et al., 2004b). Histamine infusion for 7 
days (ICV; (0.05 μmol/g)) in mice reduced body fat, weight, ob gene expression and serum 
leptin concentration to a greater extent than in pair-fed controls due to increased EE via 
BAT and WAT (Masaki et al., 2001). One study (the only human study looking at changes 
in dietary intake) examining the effects of 4 g/day oral ingestion of L-Histidine in gelatine 
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capsules among 8 human volunteers for a period of 2 weeks, found no significant changes 
in appetite, taste and smell perceptions, food intake and body weight (Schechter and 
Prakash, 1979). 
 
Similar to the lipolytic effects observed following peripheral and central administration of 
L-Histidine and histamine, dietary supplementation of L-Histidine and central infusion of 
histamine have both demonstrated effects on upregulation of UCPs in BAT and WAT 
indicating influence on energy regulation. Increased dietary L-Histidine supplemention (50 
g/kg diet) in rats has shown an increase in UCP1 mRNA in BAT (Kasoaka et al., 2004) 
and ICV infusion of histamine up-regulated mRNA expression of BAT UCP1 and WAT 
UCP3 in diet induced obese and leptin resistant mice (Masaki et al., 2001). The role of 
histamine in upregulation of UCPs was further confirmed by the development of H3 
receptor knockout mice (H3-/-) which were obese and their expression of UCP1 and UCP3 
in BAT, UCP3 in WAT and in skeletal muscles was reduced, with decreased EE and 
increased body weight (Takahashi et al., 2002). Similarly, H1 receptor knockout mice 
(H1KO), gradually developes maturity-onset obesity, which is accompanied by 
hyperphagia and decreased expression of UCP1 mRNA thus suggesting that H1 receptors 
are also crucial for feeding behaviour and development of obesity (Masaki et al., 2004). 
Furthermore, targeted disruption of the HDC gene were characterised by visceral adiposity, 
increased amount of BAT, impaired glucose tolerance, hyperinsulinemia, and 
hyperleptinemia (Fulop et al., 2003). These metabolic changes are attributed to the 
impaired regulatory loop between leptin and hypothalamic histamine and the attenuated 
ability to induce UCP1 mRNA in the BAT. Impairment of either the key enzyme needed in 
the conversion of L-Histidine to histamine or the receptors through which histamine exerts 
its actions can bring about changes in parameters affecting energy balance and also 
confirms the essential role of L-Histidine and histamine in regulation of food intake and 
upregulation of UCPs in both BAT and WAT.   
 
Hypoglycaemic effect: Increased insulin sensitivity, reduction in body fat content, reduced 
leptin, insulin and glucose concentrations may bring about overall positive change in 
energy metabolism and help alleviate insulin resistance and obesity associated co-
morbidities. Evidence is emerging suggesting that activation of histamine signalling in the 
hypothalamus may have anti-diabetic actions, particularly in leptin resistant states (Masaki 
et al., 2001). It was observed that serum concentrations of glucose and insulin were 
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reduced and tests for glucose and insulin tolerance showed improved insulin sensitivity in 
those mice infused with histamine compared with pair-fed controls. Targeted disruption of 
HDC in mice resulted in impaired glucose tolerance and hyperinsulinemia (Fulop et al., 
2003). Intake of histidine and carnosine (β-alanylhistidine) (each – 1 g/l of water) 
decreased glucose and fibronectin levels (therefore decreased risk of glaucoma caused by 
high blood glucose levels) and increased insulin levels in diabetic mice (Lee et al., 2005). 
Experiments with histidine and carnosine were found to dose-dependently decrease 
triglyceride and cholesterol levels in the heart and liver. This study also showed that 
histidine and carnosine effectively protect LDL against glucose induced oxidation and 
glycation by scavenging free radicals in LDL and retarding oxidation and glycation thus 
delaying long term complications (retinopathy, neuropathy, nephropathy, heart attacks and 
strokes) of blood glucose dysregulation. The action of peripheral and central 
supplementation of L-Histidine and histamine and enzymes involved in histamine 
metabolism clearly indicates towards their role in blood glucose regulation among animal 
models but needs further investigation among humans due to lack of data in the literature. 
 
Effects on factors regulating dietary intake: Investigations on the dose-response effect of 
dietary histidine on food intake and body fat accumulation in male Wistar rats have shown 
decreased food intake with increasing concentration (0, 1, 2.5 and 5 %) of histidine in the 
diet (Kasaoka et al., 2004). The authors found a negative, significant correlation between 
dietary histidine intake and retroperitoneal fat pads after 8 days of supplementation 
indicating reduction in body fat. A similar study exploring the differences in daily food 
consumption in male Wistar rats following i.p histidine administration combined with 
either phosphate buffered solution (PBS) or α- fluromethylhistidine (FMH; a suicide 
inhibitor of HDC) found that histidine administration pre-treated with PBS decreased food 
intake to 64.2% of the baseline value compared to 88.1% of the baseline value after 
treatment with histidine pre-treated with FMH, thus demonstrating that peripheral 
administration of L-Histidine suppressed food intake and hypothalamic neuronal histamine 
suppresses food intake through H1 receptors in the VMH nucleus and the paraventricular 
Nucleus (PVN) (Yoshimatsu et al., 2002a). To study the specific areas involved in 
histamine-involved suppression in feeding, an infusion of chlorpheniramine (an H1 
antagonist) was infused into the VMH, PVN, lateral hypothalamus area (LHA), the 
dorsomedial nucleus and the preoptic anterior hypothalamus of Wistar King A rats. It was 
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observed that VMH and PVN, which are the areas with the highest distribution of H1 
receptor and hypothalamic histamine, responded to chlorpheniramine by increasing feeding 
in rats. There were no observed effects in the remaining regions. This indicates that 
neuronal histamine transmits signal for suppression of food intake through H1 receptors in 
the VMH and PVN (Sakata et al., 1997). The involvement of hypothalamic histaminergic 
activity with leptin in the central regulation of feeding behaviour has been investigated in 
animals and it is suggested that histamine is involved in leptin-induced inhibition of food 
intake (Gotoh et al., 2005; (Toftegaard et al., 2003). Infusion of leptin into the third 
cerebroventricle of mice has shown increased levels of t-MH (tele-methylhistamine, a 
major metabolite of histamine) (Yoshimatsu et al., 1999). Leptin deficient obese mice 
(ob/ob) exhibit lower histamine turnover compared to lean littermates, which has been 
shown to increase after leptin infusion (Itateyama et al., 2003). Also, leptin injection to 
wild type mice significantly reduced food intake but had no effect in H1R-KO (male 
mutant mice lacking in H1 receptors) (Morimoto et al., 1999).  
 
The above mentioned animal studies all confirm various effects of histidine or histamine 
actions in-vivo. Histidine and histamine administration increases EE, via increase in 
thermogenesis and increase in lipolysis thereby reducing body weight as increased 
sympathetic activation mediated by noradrenaline in BAT and WAT following histidine 
and histamine administration release brings about mobilisation of energy reserves, through 
the accelerated breakdown of glycogen in muscle and liver cells and the release of lipids by 
adipose tissues; altogether facilitating reduction in body weight (Martini, 2006). Histidine 
intake and histamine infusion increase UCP mRNA expression and this influence upon 
UCP function might be a pathway by which L-Histidine exerts its thermogenic influence. 
Leptin is a hormone secreted from the adipose tissue which influences energy homeostasis, 
neuroendocrine and immune function (McArdle et al., 2006). Plasma leptin concentrations 
are highly correlated to total body fat and body mass index in humans and animals (Stanley 
et al., 2005). It is considered a regulatory hormone for EE as lack of circulating leptin 
leads to hyperphagia, obesity neuroendocrine and immune disturbances which can be 
normalised by leptin administration in ob/ob mouse (Campfield et al., 1995). Histamine 
affects leptin action in the hypothalamus, thus decreasing food intake and therefore 
possibly reduce body weight.    
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3.1.4 Toxicity 
A study investigating a 5% increase in dietary histidine resulted in hypercholesterolemia 
and enlargement of the liver in rats (Hitomi-Ohmura et al., 1992). The authors suggest that 
the hypercholesterolemia caused by histidine-excess diet (50g/kg diet) appears to be due to 
the stimulation of cholesterol synthesis in the liver. They attributed this increased 
cholesterol synthesis to the significantly higher hepatic 3-hydroxy-3-methylglutaryl-
coenzyme A reductase activity in histidine-excess diet rats than in rats fed a basal diet. A 
similar study investigating the effect of 5% increase in dietary histidine for 3, 6, 14 or 30 
days on serum and liver lipids in rat models, found that it caused growth retardation, 
hepatomegaly and decreased liver lipids throughout the period of the experiment compared 
to rats fed the basal diet (Ohmura et al., 1986). This effect has been further investigated 
with rats being fed basal (no histidine + cupric carbonate 6mg copper kg diet), histidine-
excess (the addition of 50 g L-Histidine/kg diet + cupric carbonate 6mg copper kg diet) or 
copper-deficient diets (no cupric carbonate supplemented in the diet) for 0, 7, 21 and 42 
days ad libitum (Aoyama et al., 1999). It was found that liver triacylglycerol accumulated 
and the serum triacylglycerol level decreased after feeding of the histidine-excess diet for 
21 or 42 days, but not after feeding of the copper-deficient diet. Serum cholesterol level 
increased (from 5.85 ± 0.25 to 5.90 ± 0.18; 7.99 ± 0.36; 9.57 ± 0.67 μmol/g) in rats fed the 
histidine-excess diet for 7, 21 and 42 days respectively, but not in rats fed the copper-
deficient diet. Copper content in the liver and serum significantly decreased in rats fed the 
histidine-excess diet. Urinary copper and zinc increased in rats fed the histidine-excess 
diet, and decreased or showed a decreasing tendency in rats fed the copper-deficient diet. A 
previously conducted similar study fed rats histidine (50 g/kg of diet) for a period of 7 days 
and observed that dietary excess histidine lowered total liver lipids and liver phospholipids 
and serum cholesterol increased (Aoyama et al., 1990). They concluded that excess 
histidine lowers liver copper, serum copper, and ceruloplasmin (enzyme carrying 90% of 
the copper in plasma), and increased urinary output of copper, zinc, iron, and magnesium. 
Other studies have shown that excess dietary histidine induced hepatomegaly, retarded 
growth, increased plasma cholesterol and significantly reduced plasma copper and zinc and 
liver copper concentrations in rats (Harvey et al., 1981 ; Soloman and Geison, 1978).  
 
Toxicity studies for histidine ingestion in humans are very few. One study performed on 6 
patients with systemic sclerosis found that an initial daily oral administration of 8.1 g 
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histidine, increased by 8.1 g once every 3 days till a maximum dose of 64.8 g/day was 
reached, caused anorexia, taste and smell dysfunction and cerebellar dysfunction (Henkin 
et al., 1975). These changes were associated with significant decreases in serum zinc 
concentrations and significant increases in urinary zinc excretion but the research article 
fails to clarify the exact doses at which the above alterations occur. Another study 
investigating intake of L-Histidine (4g/day) in healthy men observed a significant increase 
in urine zinc excretions after supplementation for 1 week, but not after 2 weeks (Schechter 
and Prakash., 1979). The effects of oral ingestion of higher doses of L-Histidine in humans 
are ambiguous, due to fewer human investigations and needs to be studied further before 
drawing any definite conclusions.   
 
3.1.5 Rationale for L-Histidine studies 
L-Histidine consumption and histamine actions in vivo have been associated with increased 
EE, up-regulation of UCPs, therefore reduction in body weight and loss of body fat and 
glycaemic control (Costentin et al., 1973; Sakata, 1995; Sakata and Yoshimatsu, 1995). 
The majority of studies have been conducted on animal models and there is a need to 
conduct studies of oral administration of L-Histidine on humans to observe its effects on 
key metabolic functions. Thus, the following studies were designed and carried out to 
assess the influence of L-Histidine ingestion on: EE, change in mean skin and core body 
temperature, fasting blood glucose and total cholesterol concentrations, and food intake 
and substrate oxidation in lean and obese adult humans. It was hypothesised that ingestion 
of L-Histidine would increase RMR, thermogenesis, lower total body fat and increase 
lipolysis, resulting in loss of body weight and lower fasting blood glucose and total 
cholesterol concentrations, some of which may be key to alleviate risk factors for body 
weight dysregulation and development of comorbidities.  
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3.2 Experimental pilot study to evaluate effects of L-Histidine on energy 
expenditure and thermogenesis  
 
As described in the above literature review a strong association of histidine/ histamine with 
increased sympathetic nerve activation resulting in increased lipolysis and EE has been 
found (Yoshimatsu et al., 2002b; Yasuda et al., 2004a). It has also been observed that 
histidine/histamine administration increases insulin sensitivity and reduces circulating 
blood glucose concentrations (Masaki et al., 2001; Lee et al., 2005). Interestingly, 
histidine/histamine administration has been positively correlated with increasing 
expression of UCPs in BAT and WAT (Kasoaka et al., 2004; Masaki et al., 2001), which 
indicates a dissipation of heat and therefore increased EE. The metabolic effects of L-
Histidine and histamine are investigated exclusively among animal models and there is a 
need to verify the effects of oral ingestion of this essential amino acid among humans.  
Hence, the current and following studies (Chapters 3.3 and 3.4) were designed to 
investigate metabolic effects of L-Histidine over varying periods of supplementation and 
also among participants with varying body composition.  
 
The pilot study was conducted to develop an optimal technique for the real-time 
simultaneous measurement of RMR, MST and CT (and hence did not employ sample size 
calculations as the primary aim was methodological/developmental). As mentioned earlier, 
this set of measurements taken concurrently has not been previously reported in the 
literature. Due to the dearth of data regarding optimum doses of L-Histidine 
supplementation and its effects in humans, it was an opportunity to begin working with L-
Histidine as an intervention compound in a human study.  Due to the lack of previous data 
from human trials, the author was unaware of the variations to expect in measured 
parameters.  
 
3.2.1 Hypothesis 
Acute ingestion of L-Histidine will increase mean skin and core temperatures in concert 
with an increase in resting metabolic rate over the test period. 
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3.2.2 Aims 
The aims of the study were: 
1. To organise the study protocol and evaluate the practicality and feasibility of 
measurement techniques used. 
2. To study the acute effects of oral ingestion of L-Histidine on energy expenditure 
and thermogenesis in healthy men and women. 
3.2.3 Methods  
3.2.3.1 Participant recruitment and profile 
Five healthy participants (3 male and 2 female) were recruited by advertisements placed 
around the university campus (see section 2.2 for further details on recruitment). The study 
protocol was approved by the University of Westminster Ethics committee (Appendix 2) 
and informed consent (Appendix 3) was obtained at the start of the test sessions from all 
participants. The study protocol and measurements to be carried out during the test 
sessions were explained to all participants with the aid of the participant information sheet 
(Appendix 5). The mean anthropometric pre-treatment data are presented in Table 3.3. 
 
Table 3.3 - Mean anthropometric data of study participants pre-treatment 
 Mean ± SEM Range 
Age (years) 38 ± 3.2  33 - 44 
Weight (kg) 72.5 ± 4.0 57 - 79 
BMI (kg/m2) 25.5 ± 2.4 20.2 – 34.3 
n 5  
3.2.3.2 Study design 
This study was randomised and crossed-over in design. Each recruit acted as their own 
control. All participants were required to visit the laboratory on two occasions having 
fasted for a minimum of 12 hours before each visit, although they were permitted to drink 
water if desired. Participant handling was standardised as detailed in section 2.3. The 
administration of L-Histidine and placebo was single blind, randomised, with a wash out 
period of 7 days provided between each test session. A dose of 25 mg/kg L-Histidine 
(Lamberts Healthcare Ltd, Kent, UK) was used (section 2.4 for dosage calculation). The 
nitrogen content of this dose was calculated and used to calculate the placebo dose (45 
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mg/kg) and it was ensured that the placebo and L-Histidine were isonitrogenous (Casilan-
90, Complan foods Ltd, UK). The placebo and L-Histidine doses were also isocalorific 
(Casilan-90 providing 1.82 kcals and L-Histidine providing 2 kcals).  
 
There was a wash out period of 7 days between the two test sessions. This time was 
necessary because of the possibility that the intervention administered first could affect the 
outcome variable for some time even after treatment ceases. Analysis of urine for total 
radioactivity in a study performed to examine the metabolism of 3-methylhistidine (an 
amino acid, formed by the methylation of peptide-bound histidine in actin and myosin) in 
men using an intravenous infusion of radioactive 14C-3-methylhistidine showed that 75% 
of the administered dose was excreted in 24 hours and 95% in 48 hours (Long et al., 1975). 
Considering the above, a period of seven days was considered sufficient time to ascertain 
that the first administered intervention was no longer in the system. 
 
Figure 3.1 - Diagrammatical representation of study design 
 
Each recruit acted as their own control. The above timeframe is not to scale, only representative. 
 
Each test session began with participants relaxing for a period of 10 minutes during which 
time the tests to be carried out were further explained. The test supplement or placebo was 
mixed with 150 ml of tap water before being given to the subject to ingest in one acute 
dose. The participant’s RMR was measured by the use of a Deltatrac II, for a period of 
3.25 hours (section 2.7). Each test session was for 3.25 hours as there were three RMR 
sampling periods in each test session: 0 – 45, 75 – 120 and 150 - 195 minutes and between 
195 
mins 
3.25 hours
Initial 45 mins Intermediate 45mins Final 45 mins 
30mins break 30mins break 
Ingestion (placebo or 
L-Histidine) End of test 
session 
0 45 75 150 120
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them breaks of 30 minutes were given which totalled to 3.25 hours/test session (Figure 
3.1). The skin thermistors were attached (section 2.9) after insertion of the rectal probe by 
the participants and MST and CT was measured along RMR measurements for a period of 
3.25 hours. The same measurements and test protocol were repeated with the other test 
supplement following the wash out period in the second and final test session.  
 
3.2.4 Statistical analyses  
Analysis of variance was performed to analyse the variation between all data, between the 
two treatments, within subjects and between time periods. There were no significant 
differences in any of the parameters (RMR, MST, CT and RER) (Appendix 12).  
 
3.2.5 Results 
 
Table 3.4 - Mean RMR (± SEM) at 0 - 45 mins, 75 - 120 mins and 150 - 195 mins post 
placebo and L-Histidine ingestion  
 RMR 
0 - 45 mins 75 - 120 mins 150 - 195 mins 
Post placebo intake 1917.5 ± 45.8 1913.3 ± 70.2 1938.6 ± 78.0 
Post L-Histidine intake 1853.2 ± 96.8 1974.5 ± 43.9 1780.7 ± 108.9 
n = 5 
 
There appeared to be an increase in mean RMR measured between 75 – 120 minutes post 
L-Histidine ingestion and a decrease when measured between 150 - 195 minutes in 
comparison to 0 - 45 minutes post L-Histidine ingestion (Table 3.4). This variation was 
however, non-significant (f values = 0.0023 for treatment and 0.0020 for changes over 
time). Post placebo intake, mean RMR remained unchanged when measured at either 75 – 
120 or 150 – 195 minutes in comparison to RMR measured during 0 - 45 minutes. The 
average MST and CT during the 3.25 hour period post ingestion of placebo or L-Histidine 
test sessions were similar when measured at 0 - 45, 75 – 120 and 150 – 195 minutes 
(Figure 3.2). The AT was kept stable at 23.2 ± 0.5 °C throughout the test session (3.25 
hours) to avoid inducing any shivering thermogenesis. There were no differences in RER 
post placebo or L-Histidine ingestion over the 3.25 hour period (Table 3.5).  
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Figure 3.2 - Mean skin (MST; ± SEM), core temperature (CT; ± SEM) measured for 
a 3.25 hour period after ingestion of either placebo or L-Histidine  
 
n = 5; Ambient temperature (AT; ± SEM) for 0 – 45, 75 – 120 and 150 – 195 mins post placebo intake was 
23.5 ± 0. 4, 23.4 ± 0.5, 23.6 ± 0.5° C respectively; post L-Histidine ingestion 23.2 ± 0.6, 23.3 ± 0.7, 23.8 ± 
0.7° C for 0 – 45, 75 – 120 and 150 – 195 mins respectively. 
 
 
Table 3.5 - Mean respiratory exchange ratio (RER; ± SEM) at three intervals (0 - 45 
mins, 75 - 120 and 150 - 195 mins) post placebo and L-Histidine ingestion  
 RER 
0 - 45 mins 75 - 120 mins 150 - 195 mins 
Post placebo intake 0.85 ± 0.04 0.85 ± 0.02 0.83 ± 0.01 
Post L-Histidine intake 0.82 ± 0.05 0.82 ± 0.05 0.80 ± 0.03 
n = 5 
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3.2.6 Discussion 
This study was primarily conducted to determine the most practical protocols to measure 
RMR, MST and CT simultaneously. The techniques and protocols employed for measuring 
RMR, MST and CT were fully developed via this pilot study, and therefore were suitable 
for use in further studies. The second objective was to assess the acute effects of placebo 
and L-Histidine ingestion on RMR, MST, CT and RER. There was no effect of placebo on 
any of the measured parameters. There was no observed effect of L-Histidine ingestion on 
RMR, MST, CT and RER.  
 
Practicality of measuring RMR, MST and CT 
The measurement of RMR involved participants lying on a bed with a perspex hood over 
their head. They were instructed to relax and limit movement as much as possible. This 
was to minimise any increase in EE due to increased activity. Participants were unable to 
be under the hood for a continuous period of 3.25 hours. To overcome this difficulty, the 
protocol for RMR testing was designed to be measured in 45 minute intervals with 30 
minutes break between sampling periods. Participants needed a minimum of 30 minutes to 
relax; during which time they sat up to either read or use the computer and avoided any 
strenuous physical exertion. During the measurements, the initial 15 minutes’ data were 
not used for calculations of RMR, to allow for acclimatisation to being under the enclosed 
hood. The later 30 minutes data were found to be more consistent and were used for 
calculations of RMR. 
 
The ambient temperature during all test sessions was maintained at 23.2 ± 0.5 °C. A 
constant ambient temperature is essential during studies conducted to measure variations in 
body temperature as high environmental temperature results in vasodilation of cutaneous 
blood vessels, increased sweating and maximum heat loss as against low environmental 
temperature which results in vasoconstriction of cutaneous blood vessels and minimised 
heat loss (Silverthorn, 1998b). Maintaining constant ambient temperature was essential in 
all the following studies as any change in MST or CT could then be attributed as a result of 
ingestion of L-Histidine. During the study, participants experienced no discomfort during 
insertion or removal of the rectal probe, which was used for CT measurement, and were at 
ease with being attached to the skin thermistors (for MST measurement) over a prolonged 
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period of time (3.25 hours). The use of Squirrel data logger 2020 was easy and was found 
to be an uncomplicated technique for temperature measurement.  
 
Effect of L-Histidine ingestion on RMR, MST, CT and RER 
There was no effect of placebo ingestion on RMR, MST, CT and RER. There however 
seemed to be a 6.0 ± 2.7% rise in RMR measured between 75 – 120 minutes post L-
Histidine ingestion when compared to 0 – 45 minutes measurement, which gradually 
seemed to decline to 10.0 ± 1.2% below the 0 – 45minutes post L-Histidine ingestion 
measurement by the end of the test session (3.25 hours). These variations however, were 
not statistically significant. The effect of histidine in the central regulation of EE has been 
examined previously in animal models. Predominantly, the effects on lipolysis, appetite 
suppression and weight loss post histidine intake and histamine infusion have been studied 
rather than changes in RMR. One such study investigated the effect of peripheral 
administration (bolus i.p injection) of L-Histidine on BAT sympathetic nerve activity as a 
marker for the central regulation of EE (Yasuda et al., 2004a) and found significant 
increases in BAT nerve activity indicating an increase in EE. A similar study (Yoshimatsu 
et al., 2002b) examined the effect of histidine via i.p injection of histamine on rats and 
found a significant increase in WAT nerve activity, again showing possible increases in 
EE. The RMR results obtained in this study were inconclusive and if any previous 
animal/human studies had measured RMR via indirect calorimetry, further comparisons 
and conclusions might have been drawn. 
 
There were no changes in MST or CT measurements during each 3.25 hour test session, or 
between the two test conditions. The main rationale for measuring MST and CT during the 
present and proposed studies was to establish whether L-Histidine ingestion increases 
thermogenesis, thereby increasing EE and possibly upregulating expression of UCPs. The 
proposed studies on oral L-Histidine ingestion are novel and the first of their kind that we 
are aware of. These studies were designed after reviewing the literature on the expression 
of UCP mRNA in BAT and WAT and its regulation by hypothalamic neuronal histamine. 
Studies conducted using rat models have shown an increase in UCP1 mRNA in BAT with 
increases in dietary histidine (Kasaoka et al., 2004). Also, targeted disruption of the HDC 
gene has shown to down-regulate UCP1 mRNA in the BAT (Fulop et al., 2003). Several 
other studies (Masaki et al., 2001; Masaki et al., 2003; (Yasuda et al., 2004b) support these 
findings of increased expression of UCPs via neuronal histaminergic system, consequently 
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increasing thermogenesis and EE. This mechanism following L-Histidine ingestion needs 
to be further investigated among humans.  
 
There was no effect of either placebo or L-Histidine ingestion on RER over the 3.25 hour 
period. Histidine administration and histamine infusion studies performed in animal 
models have not measured RER previously as more direct measures of fuel (fat) oxidation 
such as circulating fatty acid concentrations are measured. Most studies, apart from being 
conducted on animal models and not directly measuring changes in the current study 
outcome measures, also predominantly employ infusion techniques of histidine rather than 
oral ingestion. Central or peripheral infusion of histamine and histidine although a 
possibility in humans, is not pratical to study free-living conditions and most importantly 
not an aim of the current and proposed studies. Therefore, it is important to further study 
effects of peripheral ingestion of L-Histidine, which can cross the blood-brain barrier and 
is taken up by the histaminergic neurons and converted to histamine in one step synthesis 
by decarboxylation with HDC.  
 
3.2.7 Conclusion 
The techniques and protocols employed for measuring RMR, MST, CT and RER were 
found to be simple, easy and therefore were used in all further studies. Literature regarding 
acute infusion of histidine and histamine in animals has shown promising effects on energy 
regulation. Similarly, the present experimental study did reveal a possible trend towards an 
increase in RMR in a short period of time, which then decreased below the pre-treatment 
measurement. As no other study has been performed to measure the acute effects of L-
Histidine consumption in humans, it is difficult to explain this rise and fall in RMR over a 
short period of time. It can however be reasoned that acute effects of L-Histidine 
consumption might not be clearly observable in a short period of time without further 
work. As the acute effects of L-Histidine ingestion on the current study outcomes was not 
conclusive, a further study was designed and carried out to investigate the effects of the 
same dose of L-Histidine ingestion over a longer period of supplementation (10 days) 
among healthy men. The dose of L-Histidine and the standardised measurement protocols 
for simultaneous measurements of RMR, MST and CT from the current study were kept 
unchanged in the following study.   
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3.3 Chronic ingestion of L-Histidine and its effects on energy expenditure, 
thermogenesis and blood glucose regulation in healthy humans 
 
The minimum period of L-Histidine supplementation in humans to observe any possible 
metabolic effects, is unclear. The pilot study (Chapter 3.2) established the protocol for the 
concurrent measurement of RMR, MST and CT. The results obtained in the pilot study 
showed no significant effect of an acute period of L-Histidine supplementation on the 
measured parameters. L-Histidine is a precursor of neuronal histamine (Panula, 2007), 
which exerts various metabolic effects on factors affecting energy balance and blood 
glucose regulation via diverse mechanisms (Kasoaka et al., 2004; Masaki et al., 2001; 
Morimoto et al., 1999; Sakata et al., 1997; Yasuda et al., 2004a; Yoshimatsu et al., 2002b; 
Yoshimatsu et al., 1999). In spite of the clear actions of L-Histidine/histamine in animal 
models, its effects have not yet been researched in humans. Given the mechanistic 
understanding of L-Histidine, there is likely to be some metabolic effect following its 
ingestion. Therefore a logical step in investigation is to increase supplementation duration. 
The exact in-vivo pathway of L-Histidine partitioning (uptake rate and pathways) in 
humans is unclear. It is however plausible that relevant receptors need to be exposed to 
histamine derived from dietary L-Histidine for longer periods of time to be upregulated 
and consequently affect components of energy balance. For example, acute effects of 
opiates ingestion inhibits the functional activity of cAMP by inhibiting adenylyl cyclase 
(enzyme that catalyses the synthesis of cAMP), but with chronic exposure to opiates 
inhibition of cAMP pathway gradually recovers due to increased tolerance, thus affecting 
energy balance differently following acute and continued exposure (Nestler and Chao, 
2006). This therefore was the rationale for the design of the current study following on 
from the previous study investigating the effect of L-Histidine ingestion over a short period 
(3.25 hours). The supplementation period was chosen to be 10 days L-Histidine ingestion. 
As the study design was cross-over in nature, each participant needed to ingest either 
placebo L-Histidine (for 10 days each) and also maintain a wash out period (10 days) ie, 31 
days for the complete study.  
 
As it is also well established that increasing the length of the study and number of study 
visits increases the drop out rates among study participants (Stewart et al., 2004), 
supplementation for 10 days was ideal as the ingestion and wash out periods could be the 
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same and the visits to the laboratory was only thrice in 31 days. The dose of L-Histidine 
(25 mg/kg) was well tolerated among study subjects in the pilot study and was maintained 
in the current study. This study was designed to address this gap in knowledge by 
investigating in healthy male subjects the effects of oral ingestion of L-Histidine (25 
mg/kg) over a period of 10 days. The outcome measures studied were changes in body 
weight, RMR, MST, CT, body fat composition, fasting blood glucose and total cholesterol 
concentrations. 
 
3.3.1 Hypothesis 
Supplementation with L-Histidine for 10 days will affect RMR, MST, CT and fasting 
blood glucose concentrations in healthy men.  
 
3.3.2 Aim 
The aim of this study was to determine the effects of 10-day oral ingestion of L-Histidine 
(25 mg/kg/day) on RMR, MST, CT, RER, blood glucose and total cholesterol 
concentrations in healthy male subjects.  
 
3.3.3 Methods 
3.3.3.1 Participant recruitment and profile 
Ten lean, healthy male participants were recruited for the study by advertisements placed 
around the campuses of the University of Westminster, London, UK (section 2.2 for 
detailed inclusion and exclusion criteria). The sample size calculations (section 2.22.1) 
were based on changes in fasting blood glucose concentrations. The results of the 
calculation estimated that at least 9 participants were needed to show any statistical 
significance post L-Histidine ingestion. By the end of the study, 1 participant had dropped 
out and 9 completed the study. The mean pre-treatment anthropometric data of participants 
who completed the study are as shown in Table 3.6. 
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Table 3.6 – Mean anthropometric data of participants who completed the study at the 
pre-treatment test session: 
 Mean ± SEM Range 
Age (years) 24.8 ± 2.0 19 - 36 
Weight (kg) 75.4 ± 1.3 69.3 - 82 
Body fat 120 16.0 ± 1.0 11.4 – 20.4 
BMI (kg/m2) 23.8 ± 0.6 21.9 – 24.9 
n 9  
3.3.3.2 Study design 
The study was approved by the Ethics Committee at the University of Westminster, 
London, UK (application number 04/05 – 62; Appendix 2). Written informed consent 
(Appendix 3) was sought from all participants after having explained the research study to 
them using an information sheet (Appendix 6).  
 
The supplementation of L-Histidine (Lamberts Healthcare Ltd, UK) and placebo (Casilan-
90, Complan foods Ltd, UK) followed a randomised, cross over and single blinded 
experimental protocol. A wash out period of 10 days was given in between the two 
ingestion periods, to eliminate traces of the previous supplement ingestion as justified 
previously (Chapter 3.2.3.2, para 2). The placebo and L-Histidine were both prepared as 
capsules for easy ingestion. Size 0, gelatine capsules (G. Baldwin & Co, London) with a 
fill capacity of 500 mg, were used. The L-Histidine dosage was 25 mg/kg and the 
isonitrogenous and isocalorific dose of placebo was determined to be 45 mg/kg. All 
participants were required to visit the laboratory on 3 separate test occasions, each lasting 
up to 2 hours, having fasted for a minimum of 12 hours before each visit. In the first 
laboratory session (day 1), body weight, RMR, percentage body fat, fasting blood glucose 
(FBG) and total cholesterol (TC) concentrations were measured along with MST and CT 
(sections 2.5, 2.7, 2.6, 2.11 and 2.12 respectively for detailed methods of measurement). 
The participants were given a 3-day food diary (Appendix 15) with a photographic food 
atlas (Appendix 16) to record their prospective food intake over the last 3 days of each 10-
day ingestion period (section 2.20 for details of formulation and analysis of diet diary). 
Every effort was made to ensure maximum reporting accuracy through the use of 
photographic food atlas and a clear explanation of portion size issues and requirements for 
written diary entries (details of the analysis software and construction of the food atlas are 
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given in section 2.20.2; Histidine quantification of reported dietary intakes was performed 
by using the INTERMAP database (section 2.20.2 for further details). At the end of the 
first test session, participants were given either placebo or L-Histidine capsules according 
to the randomisation to be consumed for the next 10 days. The participants were asked to 
report back to the laboratory on the 11th day for intermediate testing (2nd test session, day 
11) where all meaurements were repeated as in session 1. Following this test session, 
participants were asked to maintain a wash-out period of 10 days (days 11-20) after which 
they were asked to ingest the second set of capsules for the next 10 days (day 21-30) and 
maintain a food diary for the final 3 days of supplementation and report back to the 
laboratory on the next day for the final (3rd) test session (day 31). In the final test session, 
all measurements were repeated as in the first two test sessions to determine the effects of 
the supplementation. 
 
3.3.4 Data analyses 
Statistical analyses were performed using the Statistical Programme for Social Sciences 
(SPSS) 14.0 for Windows (Section 2.22.2). Analyses of data were carried out by following 
the general linear model of one-way repeated measures analysis of variance (ANOVA) to 
assess possible differences between the placebo and L-Histidine supplementations in all 
measured parameters over time. A difference of p ≤ 0.05 was regarded as statistically 
significant.  
 
3.3.5 Results 
Post L-Histidine ingestion, there was a significant decrease in body weight among 
participants when compared to body weight measured pre-treatment (pre-treatment: 75.4 ± 
1.3 kg compared to post L-Histidine: 74.4 ± 1.2 kg; p = 0.008; Figure 3.3). There was no 
significant change in body weight post placebo intake in comparison with pre-treatment 
measurements (pre-treatment: 75.4 ± 1.3 kg compared to post placebo: 74.9 ± 0.9 kg; 
Figure 3.3). There was no effect of order of supplementation due to randomisation. 
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Figure 3.3 - Mean body weight (± SEM) at the end of 10 days supplementation with 
either placebo or L-Histidine compared to pre-treatment 
 
n = 9; * Significantly different from pre-treatment (p = 0.008).  
 
Figure 3.4 -Mean of means data for mean skin (MST; ± SEM), core (CT; ± SEM) 
over a 45 minute sampling period pre-treatment, post placebo and post L-Histidine 
ingestion  
 
n = 9; Ambient temperature (AT; ± SEM) over a 45 minute sampling period pre-treatment, post placebo and 
post L-Histidine ingestion was 22.8 ± 0.6, 23.5 ± 0.4, 22.4 ± 0.6 °C  respectively. 
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MST and CT remained unchanged from pre-treatment readings, after placebo and L-
Histidine supplementation (Figure 3.4). Ambient temperature was maintained at 22.9 ± 
0.5°C during all test sessions (Figure 3.4). There was no effect of L-Histidine ingestion on 
RMR (Table 3.7). There were no changes in RER following placebo and L-Histidine 
supplementations compared to pre-treatment values (Table 3.7). No change was measured 
in total body fat percentage post placebo and post L-Histidine supplementation in 
comparison to pre-treatment values (Table 3.7). Consumption of total energy and 
macronutrients remained unchanged during both periods of supplementation (Table 3.8). 
Dietary histidine intake did not vary significantly during the last 3 days of either L-
Histidine or placebo supplementation (Table 3.9). 
 
 
Table 3.7 - Mean resting metabolic rate (RMR; ± SEM), respiratory exchange ratio 
(RER; ± SEM) and percentage body fat (± SEM) pre-treatment, post placebo and 
post L-Histidine supplementation. 
Parameter Pre-treatment 
Post placebo 
supplementation 
Post L-Histidine 
supplementation 
RMR (kcal/ day) 1666.4 ± 44.7 1751.8 ± 61.4 1762.1 ± 92.0 
RER 0.83 ± 0.01 0.82 ± 0.01 0.83 ± 0.01 
Body Fat (%) 16.0 ± 1.0 15.6 ± 1.1 15.5 ± 1.0 
n = 9; There were no significant differences. 
 
 
Table 3.8 - Mean daily dietary intake (± SEM) and nutrient intake expressed as a 
percentage of total energy intake (%TEI) during the final three days of placebo 
supplementation compared to mean dietary intake in the final three days of L-
Histidine supplementation 
 Total Energy 
Intake 
(kcal) 
Protein 
%TEI 
Fat 
%TEI 
Carbohydrate 
%TEI 
Placebo  1970.7 ± 218.9 18.1 ± 1.5 30.1 ± 2.1 50.3 ± 2.4 
L-Histidine  2086.3 ± 266.6 16.5 ± 1.6 36.2 ± 2.5 45.8 ± 3.3 
n = 9; There were no significant differences; † Likely validity of reported kcal intake discussed in appendix 
13. 
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Table 3.9 - Mean dietary histidine intake during the final three days of placebo 
supplementation compared to mean dietary histidine intake in the final three days of 
L-Histidine supplementation 
Supplementation  Histidine intake (mg/day) 
Placebo  2149.8 ± 173.4 
L-Histidine  2484.3 ± 641.0 
n = 9; There were no significant differences. 
 
 
 
 
Figure 3.5 - Mean fasting blood glucose concentrations (± SEM) following placebo 
and L-Histidine supplementation compared with pre-treatment  
 
n = 9; * Significantly different from pre-treatment (p = 0.04).  
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Figure 3.6 - Mean total cholesterol concentrations (± SEM) measured pre-treatment, 
post placebo and post L-Histidine supplementation  
 
Complete data set (n = 3), all other samples were below the level of detection at either of the test sessions 
 
Post L-Histidine supplementation, there was a significant decrease in mean fasting blood 
glucose concentrations from pre-treatment values (pre-treatment: 5.4 ± 0.3 mmol/l 
compared to post L-Histidine: 4.8 ± 0.2 mmol/l; p = 0.04; Figure 3.5). There was no effect 
of placebo on fasting blood glucose concentrations. There were no significant differences 
in blood glucose concentrations between post placebo and L-Histidine supplementation. 
Meaningful interpretation of total cholesterol concentrations could not be made due to 
missing values during statistical analysis (Figure 3.6). 
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3.3.6 Discussion 
 
This study was conducted to assess the chronic effects of L-Histidine supplementation for 
10 days on metabolic indices of energy balance such as EE, thermogenesis and blood 
glucose regulation. There was a significant decrease in body weight and fasting blood 
glucose concentrations post L-Histidine ingestion when compared with pre-treatment. 
There were no significant effects of L-Histidine on RMR, MST, CT, RER and total 
cholesterol concentrations. There were no effects on any of the parameters measured 
following supplementation with placebo. There was no effect of the order of 
supplementation for any parameter measured. 
 
Effects of L-Histidine on metabolic indices of energy expenditure and thermogenesis 
(body weight, RMR, MST, CT, % body fat and RER)  
There were no effects of placebo supplementation on body weight. There was a significant 
reduction in body weight following L-Histidine ingestion when compared to pre-treatment 
measurement (pre-treatment: 75.4 ± 1.3 kg compared to post L-Histidine: 74.4 ± 1.2 kg; p 
= 0.008; Figure 3.3). Normally, a reduction in body weight is associated with either an 
increase in RMR, decrease of total body fat composition or a decrease in dietary intake. 
However, there were no significant differences in either RMR, total body fat percentage or 
the rate of fat oxidation (which would indicate an increase in lipolysis) in the current study. 
There were also no differences observed in nutrient and calorie intake between two periods 
of supplementation. The change in body weight over 10 days is small and it maybe that 
changes in RMR, RER and dietary intake are too small to detect statistically but sufficient 
to have a biological effect over time. As there was no change in obvious markers of energy 
balance, the change in body weight measured in the current study needs to be considered 
with care. Perhaps the change in body weight is due to the participants taking part in the 
study and bringing about lifestyle changes and by staying motivated. Further work, such as 
longer periods of supplementation, is required to demonstrate the chronic effects of L-
Histidine supplementation.  
 
Even though in this study there appeared to be no effect on RMR, fat oxidation and dietary 
intake, histamine has been shown to affect parameters of energy balance. Several studies in 
rodents have shown that histamine stimulates EE and lipolysis in adipose tissue by 
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activation of the SNS (Yoshimatsu et al., 2002b) suppression in food intake is mediated via 
H1 receptors in the hypothalamus (Fulop et al., 2003). The majority of studies performed 
in animal models clearly showing that histaminergic activity is associated with regulation 
of food intake (Gotoh et al., 2005; Morimoto et al., 1999), administer either histamine via 
intracerebral infusion (Masaki et al., 2001; Yoshimatsu et al., 1999) or histidine via 
intraperitoneally injections (Yoshimatsu et al., 2002a). There are very few human studies 
examining the anorexic effect of oral histidine ingestion. One such human study found that 
oral intake of very high doses (64.8 g/day) of histidine caused anorexia, taste and smell 
dysfunction along with cerebellar dysfunction and significant decreases in serum zinc 
concentrations (Henkin et al., 1975). However, data obtained from the current study is 
partly in accordance with findings from a study by Schechter and Prakash (1979) who 
found no change in appetite, taste and smell perception, food intake or body weight after 
oral intake of L-Histidine 4 g/day, for a period of 2 weeks by eight, healthy volunteers.  
 
Dietary histidine intake quantified with the aid of the INTERMAP database (personal 
communication (discussion followed by email on 16/6/09) with Dr Claire Robertson), 
showed no difference in histidine intake during either placebo or L-Histidine 
supplementation period and therefore no confounding effect of dietary histidine is 
envisaged. It should be noted however, that although histidine is generally accepted as an 
essential amino acid, few available databases (i.e. those incorporated in dietary analysis 
software systems) include histidine. It was therefore of considerable benefit to access 
quantitative information regarding histidine levels in a wide range of foods (1448) via the 
compilation as provided by INTERMAP study (personal communication (discussion 
followed by email on 16/6/09) with Dr Claire Robertson, UK Country Nutritionist; Schakel 
et al (2003)).  
 
There were no differences in MST and CT from pre-treatment measurements after 
ingestion with either placebo or L-Histidine. The present study attempted to measure 
changes, if any, in MST and CT post L-Histidine ingestion to observe changes in 
thermogenesis. Also, as there is no valid marker to depict upregulation of UCP expression 
apart from mRNA analysis and as this technique was beyond the scope of this study, these 
measurements attempted to infer that a possible increase in MST and/or CT might indicate 
upregulation of UCPs. UCP2 and UCP3, are abundant in WAT, skeletal muscle, the spleen 
and pancreatic β cells and are of particular interest because of their potential role in EE 
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(Thompson and Kim, 2004). They are found in the inner mitochondrial membrane and 
under control of noradrenaline released from the SNS, are able to uncouple the oxidation 
of fuels via the electron transport chain from ATP synthesis, thus dissipating energy as 
heat and potentially affecting metabolic efficiency (Dulloo and Samec, 2000). Previous 
studies have shown that infusion of histamine into the lateral cerebroventricle of mice 
upregulated gene expression for UCP3 in WAT (Masaki et al., 2001) and H1 and H3 
receptor knock out mice have decreased expression of UCP1 and UCP3 (Masaki et al., 
2004; Takahashi et al., 2002). It is unclear whether the activation/upregulation of UCPs 
could be detected by body temperature measurements by means of skin thermistors and 
rectal temperature measurement by rectal probe. Other methods of UCP analysis via 
muscle biopsy and northern blotting to quantify the amounts of RNA species for the UCP 
genes might provide accurate results for any increase in BAT or WAT UCP mRNA 
expression (Masaki et al., 2001). These measurement techniques were not possible to 
conduct in the present and following studies as there was neither ethical approval nor the 
medical expertise to conduct muscle biopsies and genetic analysis. These methods need to 
be considered by others conducting any future studies of this nature.   
 
There was no difference in fat oxidation post placebo or L-Histidine supplementation from 
pre-treatment. Further sensitive measures of lipolysis and techniques of measurement of 
EE might clarify the observed weight loss in study participants and clarify the cause and 
mechanism of weight loss observed. Techniques have been developed to quantify substrate 
turnover in abdominal subcutaneous adipose tissue in vivo after cannulation of the left 
superficial epigastric vein to allow sampling adipose tissue venous blood which might 
show more accurate and significant results (Frayn et al., 1993). The characteristics of the 
adipose tissue venous blood are quite distinct from those of the superficial (mainly skin) or 
the deep (mainly muscle) tissues of the forearm and appears to be typical of adipose tissue 
as a whole in terms of non-esterified fatty acid release. This method is difficult and time 
consuming and was beyond the practicalities of this study. Circulating glycerol and fatty 
acids could be good markers to indicate whole body substrate oxidation and are easily 
assayed. If these assay techniques were employed in the current study it might have shown 
significant differences.  
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Effect of L-Histidine ingestion on glucose regulation 
There was no effect of placebo on fasting blood glucose concentrations while there was a 
significant decrease in fasting blood glucose concentrations after L-Histidine ingestion 
when compared to pre-treatment measurements (pre-treatment: 5.4 ± 0.3 mmol/l compared 
to post L-Histidine: 4.8 ± 0.2 mmol/l; p = 0.04; Figure 3.5). This could be attributed to the 
fact that L-Histidine may indirectly enhance insulin’s action. L-Histidine is a zinc-
chelating agent and helps in intestinal zinc absorption (Horn et al., 1995). Zinc is involved 
in the regulation of insulin receptor–initiated signal transduction mechanisms (Song et al., 
1998). The role of zinc in insulin metabolism is well established and studies have 
demonstrated that the mineral increases insulin binding to receptors (Arquilla et al., 1978). 
It has been shown that zinc supplementation in genetically obese mice resulted in a 
reduction in plasma insulin and glucose concentrations and also attenuated the glycaemic 
response after the glucose load and this effect was due to enhanced insulin activity by zinc 
(Chen et al., 1998). Another hypoglycaemic mechanism of histidine has been shown by a 
study which observed that treatment of diet induced obese (DIO) and leptin resistant 
(db/db) mice with histamine lowered serum glucose and insulin concentrations as well as 
improving glucose tolerance (Masaki et al., 2001). This was a result of the decrease in 
circulating free fatty acids which is a major determinant of improving insulin sensitivity as 
it increases hepatic glucose output and decreases glucose disposal in the muscle. In the 
current study, neither zinc nor free fatty acid concentrations were measured as it was 
beyond the scope of the study. Future studies need to incorporate these measurements in 
order to fully determine the hypoglycaemic mechanism of L-Histidine.  
 
Effect of L-Histidine on total cholesterol concentration 
There were no statistical advantage to report for changes in the total cholesterol 
concentrations following both placebo and L-Histidine supplementations. Six participants’ 
blood cholesterol were recorded as ‘low’ during one of the three test sessions as the 
Accutrend GC meter employed to test blood cholesterol did not read values below 3.88 
mmol/l. These participants’ missing data were excluded during statistical analysis by 
SPSS. The number of full data sets included in the statistical analysis was only 3 and this 
sample size is small and it is understood that the reliability of such a data set is low and 
conclusions cannot be drawn from their analysis. However, the observation of no effect of 
histaminergic action on total cholesterol concentrations has previously been shown by 
Takahashi and colleagues (2002) in mice with targeted disruption of the H3 receptor (H3-/-). 
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These H3-/- mice presented with elevated concentrations of leptin and insulin (i.e. were 
leptin and insulin resistant), but no changes in cholesterol and triglyceride concentrations 
were observed. No human studies have examined this effect of L-Histidine on total 
cholesterol concentration and this study is the first to do so. Unfortunately, due to small 
dataset, conclusions could not be drawn. 
3.3.7 Conclusion  
Oral administration of L-Histidine for 10 days influenced body weight and fasting blood 
glucose concentrations. It would be expected that a change in body weight might be due to 
change in BMR, increased fat oxidation or decrease in dietary intake, but these changes 
were not observed. The change in body weight and fasting blood glucose concentrations 
were subtle though statistically significant. If calorie deficit were ongoing at the same rate, 
it stands to reason that if L-Histidine was supplemented for a longer period greater weight 
loss may be observed. While it would be of interest to measure changes in plasma insulin, 
leptin and free fatty acids which might show the mechamism of L-Histidine action, weight 
loss without compositional changes, suggests equal losses of fat and non-adipose body 
tissue/water. To further investigate this question it is likely that longer-term (than the 
present study) ingestion of L-Histidine could clarify its metabolic and consequential 
physical effects in humans (described in Chapter 3.4).  
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3.4 Metabolic effects of long term (8 weeks) oral ingestion of L-Histidine in 
overweight and obese men 
 
It has been previously shown that histamine infusion reduces fat accumulation and 
upregulates UCPs in leptin resistant obese mice (Masaki et al., 2001) and that leptin affects 
feeding behaviour through activation of the central histaminergic system via histamine 
receptors (Masaki et al., 2003; Morimoto et al., 1999; Sakata et al., 1997; Yoshimatsu et 
al., 1999) in obese mice. All of these studies demonstrating interaction between leptin and 
histamine pathways have been conducted on animal models and there is a need to assess 
the implication of these findings for humans. The following study was designed to study 
the metabolic effects of oral ingestion of L-Histidine for 8 weeks in overweight and obese 
men, who are most likely to be leptin resistant due to increased adipose tissue mass 
(Jequier and Tappy, 1999; Stanley et al., 2005; Trayhurn et al., 1999) when compared with 
healthy (normal weight) humans from the previous study.  
 
In the previous study (Chapter 3.3), body weight and fasting blood glucose concentrations 
decreased significantly post L-Histidine ingestion among healthy subjects. To investigate 
these effects further, the following study was designed to explore the effects of longer-term 
ingestion of L-Histidine on factors affecting energy balance and glycaemia in overweight 
and obese sample populations. Variations in physiology have been shown to alter nutrient 
utilisation and metabolism (e.g. during pregnancy, there is increased maternal plasma 
volume which alters the concentrations of nutrients such as zinc, folic acid etc in the blood 
(Campbell, 1988)). As there are alterations in the amount of fat mass in the study sample 
population due to overweight and obesity, the effects previously seen (chapter 3.3) may or 
may not be apparent in the current study population. Also, as the effects of L-Histidine on 
RMR, lipolysis were inconclusive from the findings of the previous study, it was supposed 
that data from further long-term (> 2 weeks) study investigating the metabolic effects of L-
Histidine supplementation would elucidate these metabolic effects noticeably. It was 
supposed that exposure to L-Histidine over a prolonged period might alter the uptake and 
transport of L-Histidine and may perhaps modify histamine interaction with the receptors 
resulting in augmented upregulation of histamine receptors and thereby affecting the study 
measures. The dose of L-Histidine was maintained at 25 mg/kg/day and was unchanged as 
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this dose is already twice the RDA nevertheless non-toxic and it is unclear whether any 
further increments in doses might cause deleterious effects.   
3.4.1 Hypothesis 
Long-term supplementation (8 weeks) of L-Histidine will increase components of energy 
expenditure (RMR, MST, CT) and reduce fasting blood glucose concentrations in 
overweight and obese but otherwise healthy men. 
3.4.2 Aim 
The aim of this study was to investigate the effects on RMR, MST, CT, fasting blood 
glucose (FBG), blood lipid, plasma insulin, leptin and non-esterified fatty acid (NEFA) 
concentrations of 8 weeks ingestion of L-Histidine (25 mg/kg/day) in overweight and 
obese men. 
3.4.3 Methods 
3.4.3.1 Participant recruitment and profile 
Twenty two male participants between the ages of 20-55 years were recruited by 
advertisements placed in the Metro and Evening Standard newspapers, London, UK. 
Inclusion criteria were a BMI of ≥ 25 and not suffering from any chronic disorder (such as, 
diabetes mellitus or hypertension) or ingesting any dietary or herbal supplements or 
medications (section 2.2 for further details).  
 
The sample size calculations (section 2.22.1) used changes in blood glucose 
concentrations, and resulted in nine participants to be recruited in each supplementation 
group. it was noted that as this calculation was based on just one parameter, it may not 
necessarily show significant effects on other metabolic parameters. As the study was 
randomised and parallel in design eighteen participants needed to be recruited, nine in the 
placebo group and nine in the L-Histidine group. Of the 22 participants initially recruited, 
18 participants completed the study while 4 participants dropped out during various stages 
of the study. All 4 of the participants who dropped out reported being unable to spare time 
for laboratory test sessions due to work commitments. Two participants from each group 
dropped out of the study and this was a random occurance as participants dropped out 
following varying test sessions (1 participant dropped out after the 1st test session whereas 
the remaining three participants dropped out following the 2nd test session).  
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Table 3.10 – Mean anthropometric data of the participants following random 
assignment to either placebo or L-Histidine supplementation prior to the 
supplementation period  
 Placebo Group L-Histidine group Statistical 
difference  Mean ± SEM Range Mean ± SEM Range 
Age (years) 39.56 ± 2.76 29 - 48 42.89 ± 2.50 30 - 50 NS 
Weight (kg) 99.67 ± 6.44 75.7 – 141.1 90.48 ± 6.10 68.5  – 115.4 NS 
Body fat (%) 27.24 ± 1.50 18.12 – 31.6 25.92 ± 2.06 21 – 34.6 NS 
BMI (kg/m2) 31.08 ± 1.82 25.2 – 43.8 28.41 ± 1.72 25 – 37.4 NS 
n 9  9   
NS = not significant; only participants who completed the study are included in this data set. 
 
Statistical analysis via paired samples t-tests (tested at 5% level of significance; SPSS 
14.0) of the difference in initial weight of participants (due to randomisation) found no 
difference between the groups (p = 0.130).  
3.4.3.2 Study design 
Participants were required to visit the laboratory on 3 separate occasions, over the test 
period of 8 weeks, each visit lasting up to 2 hours in a fasting state (Figure 3.7). The study 
was single blinded and each participant was randomised into either the placebo or L-
Histidine group for the duration of the study. Simple randomisation of participants was 
accomplished by choosing a folded note with the group specified on it among many similar 
unspecified pieces of folded notes. 
 
Measurements including RMR, MST, CT, TC, HDL, LDL, FBG and % body fat and blood 
pressure (BP) were recorded during the first laboratory session (pre-treatment) and 
repeated after 4 (second test session) and 8 weeks (third test session), as described in 
sections 2.7, 2.9, 2.14, 2.11, 2.19 respectively. The analysis of food intake was carried out 
with the use of a prospective 3-day food diary (section 2.20) at pre-treatment and at the end 
of 8 weeks to detect changes in nutrient intake. The doses of placebo and L-Histidine were 
kept isonitrogenous and isocalorific. Participants in the placebo group ingested Casilan-90 
(Complan foods Ltd, UK) 45 mg/kg/day and the participants in the L-Histidine group 
ingested 25 mg/kg/day L-Histidine (Lamberts Healthcare Ltd, UK) for the duration of the 
study (8 weeks). The placebo and L-Histidine were both prepared as capsules for easy 
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ingestion. Size 0, gelatine capsules (G. Baldwin & Co, London) with a fill capacity of 500 
mg, were used. 
 
In addition to measuring the previously studied metabolic parameters as outlined in 
Chapter 3.3, NEFA analysis, insulin and leptin assays were performed to provide an insight 
into the possible metabolic processes of oral ingestion of L-Histidine (sections 2.15, 2.16, 
2.17 and Appendices 19-21 for details on the methods used to assay NEFA, insulin and 
leptin). Whole blood was obtained by venepuncture at the beginning of each test session 
and collected in heparinised vacutainers. The vacutainers were centrifuged for 12 minutes 
at 3500 rpm and the plasma removed. The plasma was stored immediately at -80°C until 
required for further analyses of insulin, NEFA and leptin (section 2.13).  
 
Figure 3.7 - Diagrammatic representation of study design 
 
3.4.4 Data analyses 
Data are presented as mean ± standard error of mean (SEM). Repeated measures ANOVA 
using SPSS 14.0 for Windows was performed with post hoc tests to determine statistical 
significance in variations observed in the measured parameters. A p value ≤ 0.05 was 
considered statistically significant. Pearson’s correlation coefficient analysis was 
performed to analyse the correlation between study variables (e.g. correlation between 
18 participants 
Randomised
Placebo group L-Histidine group 
Pre-treatment (1st test session): 
RMR, MST, CT, FBG, TC, 
HDL, LDL, venepuncture and 
body fat %, BP measured. 
4 weeks (2nd test session): 
Measurements same as 1st 
test session. 
8 weeks (3rd test session): 
Measurements same as 1st 
test session. End of study. 
8 weeks 
4 weeks 4 weeks 
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plasma insulin and blood glucose). This analysis was also performed with the use of SPSS 
14.  
 
3.4.5 Results 
 
There were no significant differences in body weight between the two groups of 
participants pre-treatment (p = 0.315; independent samples T-test; Table 3.11). Overall, 
both groups had lost weight at the end of the 8 week period (p = 0.011). There was 
however no effect of L-Histidine ingestion on weight loss (p > 0.05; Table 3.11).  
 
 
Table 3.11 - Mean body weight (± SEM) following placebo and L-Histidine ingestion 
for 4 and 8 weeks compared to pre-treatment  
Body weight 
(kg) 
Placebo L-Histidine 
Mean of both 
groups 
Pre-treatment 99.67 ± 6.44 90.48 ± 6.10 95.07 ± 6.27 
4 Week 98.83 ± 6.47 89.96 ± 6.34 94.39 ± 6.41 
8 Week 98.54 ± 6.33 89.70 ± 6.37 94.12 ± 6.35 * 
n = 18 (9 in placebo group, 9 in L-Histidine group); There was a significant difference between mean body 
weight pre-treatment and post L-Histidine ingestion; *Significantly different from pre-treatment (p = 0.011). 
 
Data collected at 4 and 8 weeks post placebo and L-Histidine ingestion showed no changes 
in MST and CT when compared with pre-treatment data (Figure 3.8). The ambient 
temperature was maintained at a range of 22.7 ± 0.4°C during all test sessions to avoid 
cold-induced thermogenesis (Figure 3.8). There were no significant differences in RMR 
between the two groups (Table 3.11). Mean overall RER increased after 4 weeks when 
compared to pre-treatment RER (pre-treatment: 0.82 ± 0.01 compared to 4 weeks: 0.87 ± 
0.02; p = 0.006; Table 3.13). However, there was no significant difference between RER 
measured at 4 and 8 weeks. There was no difference between the groups therefore no effect 
of L-Histidine ingestion was detected (Table 3.13). There were no changes observed in 
body fat composition after 4 and 8 weeks ingestion with either placebo or L-Histidine 
when compared with pre-treatment measurements (Table 3.14).  
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Figure 3.8 - Mean of means of skin (MST; ± SEM) and core (CT; ± SEM) pre-
treatment and at 4 and 8 weeks following placebo and L-Histidine ingestion measured 
over a 45 minute sampling period  
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n = 18 (9 in placebo group, 9 in L-Histidine group); Ambient temperature (AT; ± SEM) pre-treatment and at 
4 and 8 weeks following placebo and L-Histidine ingestion monitored over a 45 minute sampling period was 
22.6 ± 0.2, 22.3 ± 0.3, 23.0 ± 0.2 and 23.7 ± 0.8, 22.3 ± 0.4, 22.5 ± 0.2 ° C respectively; There were no 
significant differences. 
 
 
 
Table 3.12 - Mean resting metabolic rate (RMR; ± SEM) pre-treatment and following 
placebo and L-Histidine ingestion for 4 and 8 weeks  
RMR (Kcal/day)  Placebo  L-Histidine  
Pre-treatment 2017.81  ± 143.71 1809.37 ± 78.63 
4 Week 1982.71 ± 125.48 1797.08  ± 88.67 
8 Week 2012.17  ± 117.76 1842.33  ± 91.13 
n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant differences. 
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Table 3.13 - Mean respiratory exchange ratio (RER; ± SEM) pre-treatment, 4 weeks 
and 8 weeks of ingestion with either placebo or L-Histidine  
 
RER Placebo L-Histidine 
Mean of both 
groups 
Pre-treatment 0.81 ± 0.01 0.82 ± 0.01 0.81 ± 0.01 
4 Week 0.86 ± 0.03 0.88 ± 0.02  0.87 ± 0.02* 
8 Week 0.83 ± 0.02 0.89 ± 0.02 0.86 ± 0.02  
n = 18 (9in placebo group, 9 in L-Histidine group); *Significant difference in overall mean RER measured at 
4 weeks in comparison with overall RER pre-treatment (p = 0.006).  
 
 
Table 3.14 - Percentage body fat (± SEM) measured by skin-fold measurements pre-
treatment and after 4 and 8 weeks ingestion throughout with either placebo or L-
Histidine  
Body Fat (%) Placebo   L-Histidine  
Pre-treatment 28.38 ± 1.11 25.14 ± 2.11 
4 Week 28.04 ± 1.22 24.44 ± 2.10 
8 Week 28. 63 ± 1.19 24.89 ± 2.45 
n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant differences. 
 
 
Table 3.15 - Mean daily dietary intake (± SEM) and nutrient intake expressed as a 
percentage of total energy intake (%TEI)† pre-treatment and at the end of 8 weeks 
following either placebo or L-Histidine ingestion  
Group Time 
Energy 
(kcal/day) 
Protein 
(%TEI) 
Fat 
(%TEI) 
Carbohydrate 
(%TEI) 
Placebo  Pre-treatment 2895.43 ± 236.20 14.01 ± 0.96 29.05 ± 3.84 48.50 ± 4.60 
 Post 8 weeks 3023.86 ± 282.63 13.80 ± 0.75 30.73 ± 2.72 47.22 ± 3.15 
L-
Histidine  
 
Pre-treatment 2007.00 ± 231.88 18.70 ± 2.23 32.53 ± 3.15 45.53 ± 2.71 
 Post 8 weeks 2230.29 ± 305.26 16.89 ± 1.68 32.35 ± 2.91 44.02 ± 3.37 
n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant differences in any of the 
nutrient intakes; † Likely validity of reported kcal intake discussed in appendix 13. 
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Table 3.16 - Mean dietary histidine intake pre-treatment and at the end of 8 weeks 
following either placebo or L-Histidine ingestion 
Group Time Histidine intake (mg/day) 
Placebo  Pre-treatment 2073.85 ± 446.99 
 Post 8 weeks 1923.82 ± 295.70 
L-Histidine  
 Pre-treatment 1913.49 ± 221.54 
 Post 8 weeks 2093.99 ± 258.63 
n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant differences 
 
Diet diaries were maintained for 3 days prior to the start of either supplementation and 
again for the last 3 days prior to the final test session (Table 3.15). There were no 
differences in the average total calories and percentage of nutrient intakes (carbohydrates, 
proteins, fat) consumed between the two supplementation groups or between the mean 
overall dietary intakes during the two sampling periods. Dietary histidine intake from pre-
treatment to post 8 weeks did not change over time or between groups (Table 3.16). 
 
There were no differences in fasting blood glucose or insulin concentrations between the 
placebo and L-Histidine groups (Table 3.17). There were no correlations between insulin 
and blood glucose concentrations due to supplementation or time (Pearson’s correlation 
coefficient). There were no differences in plasma leptin and NEFA concentrations between 
pre-treatment, 4 and 8 weeks and between placebo and L-Histidine (Table 3.17).  
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Table 3.17 - Mean fasting glucose (FBG; ± SEM), insulin (± SEM), leptin (± SEM) 
and non-esterified fatty acid (NEFA; ± SEM) concentrations in circulation measured 
pre-treatment and after 4 and 8 weeks of either placebo or L-Histidine 
supplementation  
Parameter Time Placebo n L-Histidine n 
FBG (mmol/l) 
Pre-treatment 4.91 ± 0.15 9 5.33 ± 0.34 9 
4 Week 4.93 ± 0.22 9 5.39 ± 0.23 9 
8 Week 5.15 ± 0.24 9 5.15 ± 0.16 9 
 
Insulin (mU/l) 
Pre-treatment 4.54 ± 0.83 6 4.09 ± 1.07 8 
4 Week 4.73 ± 1.02 6 3.97 ± 0.72 8 
8 Week 5.68 ± 0.74 6 3.83 ± 0.63 8 
 
Leptin (ng/ml) 
Pre-treatment 20.08 ± 5.29 6 11.37 ± 2.93 8 
4 Week 14.96 ± 2.12 6 10.56 ± 2.15 8 
8 Week 15.16 ± 2.31 6 10.69 ± 2.76 8 
 
NEFA (µmol/l) 
Pre-treatment 967.27 ± 117.92 6 820.88 ± 67.95 8 
4 Week 941.87 ± 145.34 6 847.32 ± 109.84 8 
8 Week 833.02 ± 105.50 6 850.38 ± 88.52 8 
There were no significant differences in any of the measured parameters;4 participants’ (3 in placebo group 
and 1 in L-Histidine group plasma samples were lost due to breakage of eppendorf tubes during freezing). 
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Figure 3.9 - Mean total cholesterol (± SEM), high density lipoprotein (HDL; ± SEM) 
concentrations pre-treatment and post ingestion of either placebo or L-Histidine for 4 
and 8 weeks  
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n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant differences. 
 
 
Table 3.18 - Mean low density lipoprotein (LDL; ± SEM) concentrations pre-
treatment and post ingestion of either placebo or L-Histidine for 4 and 8 weeks  
LDL 
(mmol/l) 
Placebo L-Histidine 
Mean of both 
groups 
Pre-treatment 3.9 ± 0.5 2.6 ± 0.3* 3.2 ± 0.4 
4 Week 3.4 ± 0.3 3.6 ± 0.4 3.5 ± 0.4 
8 Week 4.2 ± 0.5 3.9 ± 0.4 4.1 ± 0.4 ** 
n = 18 (9 in placebo group, 9 in L-Histidine group); * Significantly different from pre-treatment 
measurement of placebo group (p = 0.023); ** Significantly different from overall mean LDL concentration 
at pre-treatment (p = 0.039). 
 
There were no differences in total cholesterol or HDL concentrations between the placebo 
and L-Histidine supplemented groups (Figure 3.9). There was a significant difference in 
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LDL concentration between the pre-treatment measurements of the two groups. 
Participants in the L-Histidine group had a significantly lower concentration of LDL at the 
start of the study when compared to pre-treatment reading of participants in the placebo 
group (pre-treatment (placebo): 3.9 ± 0.4 mmol/l as compared to pre-treatment (L-
Histidine): 2.6 ± 0.3 mmol/l; p = 0.023, Table 3.18). Mean overall LDL concentrations 
increased after 8 weeks when compared with pre-treatment values, irrespective of the kind 
of treatment (pre-treatment: 3.2 ± 0.4 mmol/l as compared to overall mean 8 weeks: 4.1 ± 
0.4 mmol; p = 0.039; Table 3.18). 
 
Figure 3.10 - Mean systolic and diastolic blood pressure (± SEM) following 4 and 8 
weeks of either placebo or L-Histidine ingestion  
 
n = 18 (9 in placebo group, 9 in L-Histidine group); There were no significant effects of L-Histidine on blood 
pressure; Overall (n=18) mean systolic BP measured at 8 weeks was significantly lower from overall (n=18) 
mean systolic BP measured pre-treatment (p = 0.029). 
 
There was an overall decrease in systolic blood pressure in all participants after eight 
weeks, from overall mean pre-treatment measurement (pre-treatment: 122.72 ± 4.3 mm/Hg 
as compared to at 8 weeks for both placebo and L-Histidine combined: 118.13 ± 3.6 
mm/Hg; p = 0.029). There was no effect of L-Histidine supplementation on either systolic 
or diastolic blood pressure (Figure 3.10).  
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3.4.6 Discussion 
 
The results of the current study show that there were no significant differences in most of 
the measured parameters due to L-Histidine ingestion for a period of 8 weeks. However, 
there was an overall decrease in body weight, an increase in LDL concentrations and a 
decrease in systolic blood pressure among all participants at 8 weeks compared to pre-
treatment. 
 
Effect of 8 week L-Histidine ingestion on body weight and regulators of energy 
balance (RMR, MST, CT, RER, and dietary intake) 
Mean overall body weight had decreased at 8 weeks when compared with pre-treatment 
measurements, irrespective of type of supplementation. Decrease in body weight is usually 
associated with changes in other parameters which influence weight loss such as RMR, 
MST, CT, RER and dietary intake. There were no changes detected in any of these 
parameters at 8 weeks compared to pre-treatment measurements. The question therefore 
arises as to whether this decrease in body weight is genuine or an artefact of study 
participation. Possibly, the methods employed in this study to measure the parameters 
associated with weight change were insufficiently sensitive to detect very subtle changes.  
 
The effect of histidine on weight loss has been substantiated by studies conducted in 
animal models wherein it has been shown that intracerebroventricular infusion of 
histamine upregulates UCP1 mRNA in BAT and UCP3 mRNA in WAT and down-
regulates ob gene expression: all contributing to weight loss (Masaki et al., 2001; Masaki 
et al., 2003). Previous animal studies have measured changes in EE via Northern blot 
analysis for UCP mRNA analysis (Masaki et al., 2001; Yasuda et al., 2004). No data for 
measurement of EE via indirect calorimetry post histidine or histamine supplementation 
among either animal or human studies is available in the literature. Future studies of this 
kind could perform mRNA analysis to detect up-regulation of UCPs to further elucidate 
the effect of oral ingestion of L-Histidine in humans and any possible increase in RMR. 
 
Mean overall RER increased after 4 weeks in comparison with pre-treatment, indicating 
increased carbohydrate oxidation at 4 weeks. This could be due to the regulatory 
mechanism adapted by the body during the post-absorptive state. Perhaps performing 
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indirect calorimetry to calculate RMR and RER at different times of the day or after 
shorter periods of fasting might have led to differing results. No variation in MST, CT was 
observed over time or due to supplementations. There are also various other methods for 
measurement of CT which might detect changes more sensitively. One of these is the use 
of a radio sensitive pill which can be swallowed and then monitored by radio telemetry. A 
disadvantage of this is the unpleasant task is its retrieval once it has travelled the full 
course of the digestive tract. An alternate to this is the use of disposable pills (remains in 
an individual’s system for 18 to 30 hours, before passing out of the body safely. This need 
not be retrieved as it wirelessly transmits core body temperature as it travels through the 
human digestive tract. A sensor within the pill sends a signal that passes harmlessly 
through the body to the data recorder outside of the body) and a data logger worn by the 
subject for recording the transmitted signals (Edwards et al., 2002). Another option is to 
measure the temperature of mid-stream urine which gives reasonable indication of internal 
body temperature. This method can be unreliable if urine volume is small (Reilly and 
Waterhouse, 2005).  
 
There was no change in nutrient intake between the placebo and L-Histidine groups. It has 
been shown that dietary L-Histidine of 50 g/kg body weight for 8 days significantly 
reduced dietary intake in rats (Kasaoka et al., 2004) (compared to dose used in the current 
study - 0.024 g/kg body weight) and was attributed to activated histamine neurones in the 
brain. It is possible that an increase in L-Histidine over and above the dose in the current 
study might have shown reduction in dietary intake, but it is uncertain whether this dosage 
might show the same deleterious effects in humans as in rats (Aoyama et al., 1990).   
 
Effect of L-Histidine on fasting blood glucose, insulin, leptin, NEFA and lipids 
concentrations 
There were no differences in fasting glucose, insulin, leptin and NEFA concentrations in 
circulation between the placebo and L-Histidine groups over time. Others have previously 
shown hypoglycaemic and hypolipidaemic effects of histidine and/or histamine. One way 
in which histamine exerts a hypoglycaemic action may be via stimulation of zinc 
absorption, in turn regulating insulin receptor initiated signal transduction mechanisms and 
insulin receptor synthesis (as discussed in Chapter 3.3) an effect well established in animal 
models (Arquilla et al., 1978; Song et al., 1998). Hypoglycaemic and lipolytic effects of 
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histidine or histamine have been demonstrated to be a direct action of histamine via H1 and 
H2 receptors in animal studies.  
 
Histamine action via its receptors in the PVN of the hypothalamus stimulates secretion of 
corticotrophin-releasing hormone (CRH). CRH raises concentrations of cAMP causing a 
release in adrenocorticotropic hormone (ACTH). ACTH then acts on the adrenal glands, 
stimulating increase of glucocorticoids to increase lipolysis (Bugajski and Janusz, 1981; 
Grund et al., 1975; Grund et al., 1976; Yoshimatsu et al., 2002b). Histaminergic neurones, 
via activation of SNS suppress and regulate ob gene expression and hence leptin 
production (Yoshimatsu et al., 2001; Zhang et al., 1994). As circulating leptin 
concentrations normally reflect the quantity of adipocytes in the body (Frayn, 2003b) there 
may also be changes in overall body fat composition. The above described mechanisms 
have implications of increasing insulin sensitivity and reduction in blood glucose 
concentrations due to increase in lipolysis via decrease in body fat and circulating leptin 
concentrations. To investigate these phenomena further, measurements of cortisol (key 
glucocorticoid) or ACTH concentrations may be necessary in further studies of this nature. 
These measurements were not carried out during the course of this study due to technical 
and financial resource limitations.  
 
There were no changes in total cholesterol and HDL concentrations following either 
placebo or L-Histidine ingestion during the 8 week period. There was however, a 
significant increase in mean overall LDL concentrations after 8 weeks when compared 
with mean overall pre-treatment values, irrespective of the kind of ingestion (pre-
treatment: 3.2 ± 0.4 mmol/l as compared to overall mean 8 weeks: 4.1 ± 0.4 mmol; p = 
0.039; Table 3.18). L-Histidine is involved in both copper and zinc absorption and hence 
levels in blood (Aiken et al., 1992). In-vitro studies have also shown that histidine removes 
both copper and zinc from plasma albumin complexes with these metals (Henkin, 1974). 
Animal studies have previously shown the hyperlipidaemic effects of excessive dietary L-
Histidine along with significant reductions in plasma copper and zinc concentrations 
(Harvey et al., 1981), induction of hepatomegaly along with an increase in plasma 
cholesterol concentrations (Soloman and Geison., 1978), development of fatty liver due to 
increase in triacylglycerol (TAG) (Aoyama et al., 1995); Kasaoka et al., 2004). 
Measurements of changes in plasma copper or zinc concentrations could show distinct 
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mechanisms of hyperlipidaemic action of L-Histidine and needs to be considered as an 
outcome measure for future studies of this nature.  
 
Effect of 8 week ingestion of L-Histidine on blood pressure  
Systolic blood pressure significantly decreased from pre-treatment measurement after 8 
weeks of both placebo and L-Histidine ingestion. Diastolic blood pressure remained 
unchanged over 8 weeks and there was no effect of either placebo or L-Histidine ingestion. 
As weight loss occurred during both supplementations, systolic blood pressure decreased 
in both groups and the effect of L-Histidine ingestion, if at all, was not apparent. It is 
debatable whether this decrease in blood pressure was due to the participants being 
comfortable with the test procedure over time (Gordon et al., 1976). To establish whether 
this was indeed the case, the pre-treatment reading was omitted (presuming that 
participants were more anxious in the first test session) and only the second and third 
measurements during both treatments were analysed to observe any difference between the 
measures and there was no statistical changes between these readings.  
3.4.7 Conclusion 
Revisiting the study hypothesis, the effects of oral ingestion of L-Histidine for a period of 
8 weeks at 25 mg/kg on metabolic indices of energy balance (RMR, MST, and CT) and 
blood glucose concentrations were inconclusive. The significant reduction in body weight 
and diastolic blood pressure by the end of the study period need to be further investigated 
as these results could be as a result of lifestyle changes brought about due to participation 
in a study and constant monitoring of body weight.  
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3.5 Summary and further direction 
 
3.5.1 Summary of studies investigating oral intake of L-Histidine  
The studies carried out and presented in this thesis were designed to investigate possible 
histaminergic effects on metabolic parameters which influence energy balance, glucose and 
lipid regulation. Favourable changes among these parameters perhaps can aid moderation 
of obesity and its associated disorders. The results showed promising trends towards 
decreasing weight and fasting blood glucose concentrations. The regulatory effects, which 
are well documented and defined in animal models such as significant increase in EE and a 
decrease in food intake, was not clearly shown in these studies.  
 
The objective of the pilot study was to develop protocols of RMR measurement along with 
MST and CT measurements for all following studies. Temperature measurements, 
especially core temperature measurement was envisaged to be awkward and potentially 
invasive, but was found to be simple and uncomplicated. The simultaneous use of both the 
Deltatrac II and the Squirrel data logger for measurement of RMR and temperature 
measurements (CT and MST) were found to be easily achieved. A dose of 25 mg L-
Histidine /kg body weight was well tolerated in all subjects. The effect of this dose on 
RMR, MST and CT was inconclusive over an acute period of 3.25 hours which lead to the 
design of the next study to measure the effect of the same dose over a longer period (10 
days) of supplementation.  
 
The next study conducted, investigated effects of 10-day chronic ingestion of L-Histidine 
on RMR, body weight, MST, CT, FBG, body fat composition and blood lipids. L-Histidine 
ingestion (25 mg/kg body weight/day) for an uninterrupted period of 10 days by healthy 
men brought about a significant decrease in body weight. Decrease in body weight might 
have occurred due to activation of the SNS by histamine receptors. However, this was also 
accompanied by a decrease in FBG concentrations which is not consistent with increased 
adrenergic activity. This study did not demonstrate any variation in MST or CT. This 
suggests that oral L-Histidine ingestion at the doses and durations used in the present 
studies do not induce measureable changes in body temperature. It would be of value 
therefore in future investigations to have markers of metabolism to further understand the 
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mechanism of action. For example, with respect to the essential amino acid tryptophan, 
relative rates of conversion to niacin (a pyridoxal-phosphate dependant pathway) can be 
elucidated by measuring the intermediary metabolite kynurenic acid thereby identifying 
with relative precision where the metabolic bottleneck for this pathway occurs (Ruddick et 
al., 2006). The example of tryptophan metabolism is apro-po in this connection, as a 
separate transformation of this amino acid to serotonin occurs only after tryptophan has 
crossed the blood-brain barrier (Turner et al., 2006). In order to quantify serotonergic 
activity within the CNS, it is necessary to obtain samples of cerebro-spinal fluid (the 
metabolite of serotonin being 5-hydroxy-indolacetate). Such sampling requires a spinal tap 
to be carried out and hence data is rarely forthcoming. With respect to the present study, 
similar considerations are in evidence as metabolites of histidine like tryptophan may 
reflect a number of different metabolic processes occurring at multiple sites in the body. 
Measurement of central histaminergic activity via biomarkers would require CNS specific 
markers. It remains therefore a research challenge to access a suitable subject base 
(undergoing spinal tap procedures for other reasons) and/or animal studies where real-time 
brain slice data could be obtained (Sakata et al., 1997; Yoshimatsu et al., 1999). 
Subsequently, the next study was designed to measure further effect of L-Histidine 
supplementation over a longer period (8 weeks) with additional analyses of key metabolic 
hormones – insulin and leptin along with NEFA to understand possible mechanisms of 
action. 
 
The longer-term (8 weeks) study of L-Histidine ingestion was designed and conducted in 
overweight and obese men. By the end of this study, a significant decrease in weight was 
observed after 8 weeks irrespective of type of test supplement ingested. Systolic BP was 
significantly decreased after 8 weeks of both placebo and L-Histidine ingestion. On the 
whole, the effects of L-Histidine ingestion of 25 mg/kg body weight/day among 
overweight and obese men for 8 weeks were inconclusive among measured metabolic 
parameters. One consideration for the interesting decrease in body weight observed among 
all participants after 8 weeks could be the time of the final laboratory test. This laboratory 
session was carried out during the third and fourth week of January, following the festive 
period, possibly when people seem to make changes in their lifestyle pattern (healthier 
eating and increased physical activity). This could have led to decrease in body weight 
among both groups of participants. Future studies of this nature need to be aware of the 
time of year during which the study is conducted.  
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The sample size calculation for both the above studies was based on the study conducted in 
humans investigating the blood glucose lowering effect of the dipeptide His-Pro (L-
Histidine and Proline; Song et al., 1998), which at the time of commencement of these 
studies was the only human study conducted to test the effects of Histidine on one of the 
proposed study measures. Results from Chapter 3.3, have shown significant differences in 
body weight and FBG and these changes were taken to calculate sample sizes to determine 
the number of subjects needed to show significant differences. The calculations are as 
below: 
 
Calulations based on the difference in body weight- 
 
 
 (z2α + z2β) σ 2 
n > 2                  δ0 
 
Using the equation with z2α = 1.96, z2β = 0.842, σ = 3.6, δ0 = 1, gives a result of 203.5. 
Future investigations on effects of oral ingestion of L-Histidine on changes in body weight 
may possibly need to recruit atleast 204 participants.  
 
Similarly, calulations based on the difference in fasting blood glucose concentrations-  
 
 (z2α + z2β) σ 2 
n > 2                  δ0 
 
Using the equation with z2α = 1.96, z2β = 0.842, σ = 0.5, δ0 = 0.6, gives a result of 10.90. 
Therefore, for further trials investigating the effects of oral ingestion of L-Histidine on 
changes in FBG may need to recruit atleast 11 participants.  
 
The sample size calculation done for L-Histidine studies used one parameter (blood 
glucose concentration) due to a lack of data from human trials investigating the metabolic 
effects of L-Histidine supplementation. Significant differences were observed in fasting 
blood glucose concentrations accordingly (chapter 3.3). If the calculation of sample size 
had been based on another parameter it is possible that a larger sample size may have been 
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required. It is possible therefore that due to this, different results may have been realised. 
Also, small sample size could be just one of the causes for inconclusive results from the 
current studies. Utmost care was taken to devise sample sizes in light of available relevant 
literature, but future studies need to recruit larger samples.  
 
Only a handful of studies have been conducted using oral supplementation of L-Histidine 
intake in humans and as a result the dose of active ingredient was based on the 
recommended daily intake of this essential amino acid. Increasing the dose from 25 
mg/kg/day might have shown more pronounced results but may perhaps result in side 
effects such as loss of taste and smell. The maximum supplementation period was 8 weeks 
and lengthening this phase (to > 3 – 6 months) may also show positive changes in 
metabolic factors.  
3.5.2 Further directions 
Inclusion criteria for future trials could include biochemical screening to identify clinically 
leptin resistant (> 31.3 μg/l) participants and to study the effects of L-Histidine ingestion in 
this group. As overweight and obesity increases, many people who are at a risk of 
developing chronic disorders (CVD, DM, hypertension etc) are thought to be leptin-
resistant and numerous animal studies carried on leptin-resistant models have shown 
positive effects of histidine and histamine ingestion on energy balance (Morimoto et al., 
1999; Yoshimatsu et al., 1999). Screening the participants before commencement among 
the present studies’ participants was could not be performed due to financial limitation. 
 
Previous animal and epidemiological human studies have shown that the anorexic effects 
of histidine are greater in females than in males (Nakajima et al., 2001; Okubo and Sasaki, 
2005) and that females are more sensitive to dietary histidine-induced anorexia than males 
as it is believed that oestrogen upregulates mRNA expression and/or activity of HDC 
(Martin and Bulfield, 1984). HDC is the primary enzyme regulating histamine biosynthesis 
from L-Histidine. Hence, increased activation of histamine neurons suppresses food intake 
more in females (Kasaoka et al., 2005). Inclusion of female subjects for the above studies 
might have shown differences in the measured parameters. On the other hand, the L-
Histidine studies conducted herein are the first to record MST and CT following L-
Histidine ingestion in order to investigate its potential thermogenic property. The variation 
in CT among women due to changes during the menstrual cycle would have led to 
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erroneous recordings; hence women were not included in the L-Histidine studies. The 
anorexic effects of L-Histidine ingestion among women need to be investigated further and 
future studies not measuring MST and CT following L-Histidine ingestion could include 
female participants.   
 
Any future studies should also consider the 24-hour rhythm of hypothalamic histamine 
concentrations. Currently, literature regarding this diurnal effect has been observed (Orr 
and Quay, 1975) in animals but needs to be further investigated in humans. This was not 
considered in the current studies as access to overnight testing facilities (to accommodate 
the participants for 24 hours) was unavailable to the researcher.  
 
Regulation of dietary histidine or histamine-inducing foods along with monitoring of 
physical activity over the course of the study period will eliminate any confounding factors 
for any potential metabolic changes observed. Further studies could utilise the USDA 
nutrient database or INTERMAP database which allows quantification of amino acids in a 
limited number of foods to prescribe quantity of dietary histidine ingestion. Prescription of 
dietary intake was not performed as the objective of the studies was to test L-Histidine 
ingestion among free-living subjects with their normal dietary intakes, but future studies 
might want to consider controlling dietary histidine intake.  
 
The use of Northern blot analysis to analyse mRNA for upregulation of UCPs was beyond 
the scope of this study, but if performed in future trials might be informative about 
promising data from WAT and facilitate correlation of MST and CT to its up-regulation.  
 
In conclusion, oral ingestion of L-Histidine requires further study before it can be 
concluded if it has the potential to affect components influencing energy balance. Once this 
is determined it will be necessary to carry out further experiments in humans to understand 
the exact mode of action in terms of the underlying mechanisms and the implications of 
long – term L-Histidine supplementation.  
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4 Metabolic implications of epigallocatechingallate ingestion  
Keeping with the overall theme of investigation of novel dietary intervention which may 
possibly influence energy balance and blood glucose regulation, the following two studies 
investigating the supplementation of EGCG among healthy men were carried out. The 
pharmacokinetics of EGCG in-vivo are well established as shown in the literature however, 
intervention studies are few among humans. The proposed studies are the first to examine 
the effect of EGCG on thermogenesis following varying periods of supplementation. 
Below is a review of literature of EGCG dietary quantification, its bioavailability, 
mechanism of action (in particular effects on energy balance, blood glucose and blood lipid 
concentrations) and finally data on possible toxicity are explored.  
 
4.1 Review of Literature 
Green tea produced from Camellia sinensis is a major source of dietary polyphenols, 
particularly flavonoids. During the process of manufacturing, fresh tea leaves are dried and 
steamed which inactivates the enzyme polyphenol oxidase, preventing oxidation from 
occurring and this non-fermentation process preserves the polyphenols in green tea (Wan 
et al., 2008). The main flavonoids present include catechins and the four major catechins 
are epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate 
(ECG) and epicatechin (EC) (Cabrera et al., 2006). Figure 4.1 illustrates the structure of 
green tea catechins. 
 
More than 50% of the total catechins present in green tea is composed of EGCG and a vast 
body of scientific research suggests that EGCG and other catechins are responsible for the 
potential health benefits (discussed in detail in the following paragraphs) attributed to 
green tea consumption (Nagle et al., 2006). Green tea polyphenols have also been proven 
to be potent antioxidants (Henning et al., 2004) which in turn benefit health and well-being 
by preventing widespread cellular destruction and maintaining a healthy immune system. 
There are also other reported benefits such as anti-mutagenic and anti-cancerous effects of 
green tea consumption (Cabrera et al., 2006). The anti-oxidant, anti-mutagenic and anti-
cancerous effects of green tea will not be discussed here as is beyond the scope of the 
study. 
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Figure 4.1 - Structure of green tea catechins 
 
Reference: (Bigelow and Cardelli, 2006) 
 
4.1.1 Quantification of catechins  
Tea consists of over 2000 different substances and flavonoids are the most abundant. 
Flavonoids are a vast group of low molecular weight, polyphenolic phytochemicals that are 
found in the leaves, flowers and outer parts of plants. Over 4000 flavonoids have been 
described to date and are sub-classified into flavanols, flavones, catechins, flavananes, 
anthocyanidins and isoflavanoids according to the level of oxidation of the C-ring 
(Wheeler and Wheeler, 2004). Catechins are abundantly found in different foods and 
beverages. High-performance liquid chromatography (HPLC) with ultra violet (UV) and 
fluorescence detection have been used to quantify the concentrations of catechins. A few 
examples of foods with high catechin content are Cox Apple (109 mg/kg), raw broad beans 
(493.7 mg/kg), dark chocolate (Albert Heijn (459.8 mg/kg)) and Bordeaux (Rineau, 1997 
(95.5 mg/l). The various sources of catechins from fruits, vegetables, foods and beverages 
are further shown in Appendix 17.  
 
Table 4.1 shows the difference in catechin content between caffeinated and decaffeinated 
green tea leaves. Green tea differs from black and oolong tea in the processing and 
manufacturing stage, which results in different properties and preservation of polyphenols. 
Catechins are lost during decaffeination due to exposure of tea leaves to ethyl acetate 
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solution which is used as a solvent. Apart from binding to the caffeine molecules, ethyl 
acetate also binds with the catechin molecules and following the rinsing and cleansing 
process, the catechins are washed out (Chang et al., 2000). A comparison of catechin 
content between black, oolong and green tea is shown in Table 4.2. 
 
Table 4.1 -Variation in flavanoid content of dried green tea following decaffeination 
Description Flavonoid Amount 
(mg/100g) 
Tea leaves, green, dry EC 791.46 
 ECG 1701.59 
 EGC 1695.02 
 EGCG 8294.91 
Tea leaves, green, dry, decaffeinated EC 423.02 
 ECG 522.01 
 EGC 1153.49 
 EGCG 1843.64 
EC: (-)-epicatechin; ECG: (-)-epicatechin 3-gallate; EGC: (-)-epigallocatechin; EGCG:  (-)epigallocatechin 
3-gallate; Reference: (USDA, 2003). 
 
Table 4.2 - Comparison of flavonoid content among brewed green, black and oolong 
teas 
Description Flavonoid Amount 
(mg/100g) 
Tea, green, brewed EC 8.47 
 ECG 20.95 
 EGC 17.08 
 EGCG 82.89 
Tea, green, brewed, decaffeinated EC 6.16 
 ECG 7.57 
 EGC 16.02 
 EGCG 26.05 
Tea, black, brewed, prepared with tap water EC 2.33 
 ECG 7.24 
 EGC 10.43 
 EGCG 11.48 
Tea, black, brewed, prepared with tap water, decaffeinated EC 0.49 
 ECG 0.64 
 EGC 0.55 
 EGCG 1.01 
Tea, oolong, brewed EC 2.59 
 ECG 6.73 
 EGC 6.00 
 EGCG 36.01 
EC: (-)-epicatechin; ECG: (-)-epicatechin 3-gallate; EGC: (-)-epigallocatechin; EGCG:  (-)epigallocatechin 
3-gallate; Reference: (USDA, 2003). 
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4.1.2 Bioavailability and absorption 
There are a limited number of studies published which measure the absorption, distribution 
and elimination of green tea and its catechins. Chen and colleagues (1997), found that 
injecting male Sprague - Dawley rats with decaffeinated green tea (DGT, containing 73, 68 
and 27 mg/g of EGCG, EGC and EC respectively) intravenously, increased the distribution 
rate constants between the extracellular fluid (ECF) and the intracellular fluid (ICF) for 
EGCG and were found to be three fold larger than the distribution rate constant from the 
ICF to the ECF, indicating that EGCG tends to distribute in the ICF. EGCG was retained in 
the body for a longer period of time (212 minutes) when compared with EGC and EC (45 
and 41 minutes) as it had a longer half-life and smaller clearance rate (Chen et al., 1997). 
The group also observed that EGCG had a lower bioavailability (0.1%) when compared to 
EGC (13.7%) and EC (31.2%) when given as part of DGT or as pure EGCG indicated by 
higher Cmax (maximum plasma concentration) values for EGC and EC than that for 
EGCG. EGC and EC, but not EGCG was recovered from animal urine samples. The area 
under the curve (AUC) was found to be higher for EGCG in the intestinal fluid samples 
after intravenous injection, suggesting that EGCG is excreted mainly through the bile. 
EGC and EC are likely to be excreted through both urine and bile as the AUC values of 
EGC and EC were similar in both kidneys and intestine in rats (Chen et al., 1999).  
 
A similar study investigating the bioavailability of green tea (GT, containing 213.6 mg/day 
EGCG, 76.5 mg/day EC, 269.6 mg/day EGC), black tea (BT, containing 230.8 mg/day 
EGCG, 39.8 mg/day EC, 103.4 mg/day EGC) and a green tea extract supplement (GTS, 
containing 193.3 mg/day EGCG, 38.3 mg/day EC, 24.9 mg/day EGC; provided via 
gelatine capsules) in thirty healthy humans showed that plasma bioavailability of EGCG 
(Cmax = 80 nmol/l) was lower than that of EGC (Cmax = 740 nmol/l) and EC (Cmax = 
330 nmol/l). The study investigators noticed that the absorption of polyphenols from the 
GTS was delayed, probably due to the gelatine capsule used to deliver the supplement, but 
was still higher than GT or BT administration. They hypothesised that GTS increases the 
bioavailability of tea flavanols in the absorption phase. It was concluded that polyphenols 
supplemented in the form of GTS showed increased bioavailability when compared with 
GT or BT consumption (Henning et al., 2004). An investigation of dose-dependant 
incorporation of tea catechins (EGCG and EGC) in human plasma found that oral ingestion 
of green tea extract (capsule form) dose-dependently increased plasma concentrations of 
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EGCG (Nakagawa et al., 1997). The study employed 3 doses of 225, 375 and 525 mg 
EGCG and found that EGCG concentrations detected in plasma corresponded to 0.2 - 2% 
of the ingested amount.  
 
Lee and colleagues (2002) studied the pharmacokinetics of tea catechins after ingestion of 
green tea (GT) and EGCG in humans. A single oral dose (20 mg/kg) of GT solids 
(containing EGCG, EGC and EC, 13.9, 11.0 and 3.2% of respectively) was given dissolved 
in 200 ml warm water. The plasma and urine concentrations of total EGCG, EGC and EC 
were quantified by HPLC. Peak plasma concentrations of these catechins were reached 1-2 
hours post ingestion and reached undetectable levels in 24 hours. Tmax (time when 
maximum plasma concentration is reached) for these catechins was in the range of 1.3 – 
1.6 hours. The half-life of EGCG was found to be 3.4 ± 0.3 hours. Urinary excretion of 
catechins were high in the first 3-6 hours and it was found that >90% of the urinary 
catechins were excreted in the first 8 hours after ingestion. In all their experiments EGCG 
was present in trace or undetectable amounts in the urine. They conclude that most of the 
ingested EGCG does not get into the bloodstream and the absorbed EGCG is preferentially 
excreted through the bile to the colon. Interestingly, a similar study investigating the levels 
of tea catechins in human blood and urine samples after ingestion of different amounts of 
green tea observed Cmax values at 1.4 - 2.4 hours post ingestion of 1.5 g/kg of 
decaffeinated green tea solids (DGT). When the dosage was increased to 3 g/kg of DGT, 
Cmax values increased 2.7 - 3.4 folds and increasing the dose to 4.5 g/kg DGT did not 
increase the Cmax value significantly. This suggests a saturation phenomenon. The half 
life of EGCG in this study was found to be 5.0 - 5.5 hours and this was higher than the 
half-life of EGC and EC (2.5-3.4 hours) (Yang et al., 1998). The doses used in the above 
studies vary considerably (approximately 0.014g/kg of green tea solids for an average 
weight of subject (70 kg) used in the study by Lee and colleagues (2000) as compared with 
a minimum dose of 105g/kg for the same average weight in the study conducted by Yang 
and colleagues (1998). It can be concluded that the half-life of EGCG to vary with 
ingestion dose and in the range of 3.4 – 5.5 hours.  
 
The potential in vivo bioactivity of tea flavanoids is dependant on the absorption, 
metabolism, distribution and excretion after ingestion. The GI tract plays an important role 
in the metabolism and conjugation of polyphenols before they reach the liver. In the small 
intestine, in particular in the jejunum and ileum, extensive glucuronidation by the action of 
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UGT (UDP-glucuronyltransferase) enzymes and O-methylation by the action of catechol 
O-methyltransferase (COMT) occurs. Unabsorbed, and taken up flavanols which are 
metabolised in the small intestine and liver are then transported to the large intestine where 
they are further metabolised into smaller phenolic acids by the gut microflora. These 
phenolic acids can sometimes be further conjugated and metabolised in the liver (Figure 
4.2). However, the extent of their absorption in the colon and the extent of absorption of 
the glucuronides and O-methylated compounds by cells and tissues are unknown. The 
remaining compounds pass out into the faeces (Spencer, 2003).  
 
Figure 4.2 - Possible routes of absorption and elimination of dietary polyphenols in 
humans  
 
 
 
 
 
 
Green tea and EGCG supplementation has been purported to augment key metabolic 
pathways involved in weight management as well as improving associated co-morbidities 
such as lipid imbalances and cardiovascular risk factors. Below is a detailed discussion of 
effects of green tea and EGCG supplementation in animal and human studies.  
Adapted from 
(Scalbert and 
Williamson, 2000) 
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4.1.3 Discovery of an EGCG receptor 
The anti-carcinogenesis effect of green tea consumption, and in particular of EGCG, is one 
of the earliest known metabolic implications and is well documented. A study conducted to 
identify the means through which EGCG inhibits cell growth in cancer cells led to the 
discovery of a receptor for green tea polyphenol-EGCG. This was a single target which 
allowed EGCG to bind to the cell surface and was found via subtraction cloning strategy 
involving DNA analysis (Tachibana et al., 2004). The cell surface candidate was found to 
be the 67-kDA laminin receptor (67LR). This putative receptor, 67LR, is expressed on a 
variety of tumour cells and its expression was strongly correlated with the risk of tumour 
invasion and metastasis. Cells transfected with 67LR were treated with two concentrations 
of EGCG (0.1 and 1.0μM; concentrations similar to the amount of EGCG found in human 
plasma after drinking more than two or three cups of tea at one time) to investigate whether 
the 67LR can bring about sensitivity to EGCG at physiologically relevant concentrations 
(Tachibana et al., 2004). It was found that the growth of these transfected cells was 
inhibited at both of these concentrations. This growth-suppressive effect was completely 
eliminated upon treatment with anti–67LR before the addition of EGCG. Also, the ability 
of 67LR to mediate a response to other tea constituents (caffeine and other tea 
polyphenols) was tested and it was found that none of these other compounds affected the 
growth of 67LR–expressing cells, nor could they bind to the cell surface. Together, these 
observations demonstrate that the cell surface 67LR is the target for EGCG. The 
investigation on the precise structure–activity relationship of green tea catechins with their 
cell-surface binding site has suggested that the galloyl moiety and the B-ring hydroxylation 
pattern contribute to the exertion of 67LR-mediated biological activities of tea catechins 
(Fujimura et al., 2008).  
 
The 67 Kda protein is not just found on tumour cells: muscle cells, macrophages, 
neutrophils, epithelial cells, interstitial cells, endothelial cells and hepatocytes all have a 
protein in this size range which binds laminin (the extracellular glycoprotein known to 
mediate cell attachment, movement, differentiation and growth) (Mecham, 1991). This 
widespread localisation of the receptor in the cells with various isoforms may explain 
numerous biological effects of EGCG (Figure 4.3).  
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4.1.4 Animal studies investigating effect of tea catechins on parameters of energy 
balance, glucose and lipid regulation 
Effects on parameters of energy balance: Rats fed on a high fat diet for a period of 14 days 
showed that supplementation with green tea extract (20 g/kg diet) not only increased 
energy expenditure but also prevented any increase in body weight as a consequence of the 
high fat diet (Choo, 2003). The administration of propranolol (a β-adrenoceptor antagonist) 
inhibited this weight suppressive effect of green tea, indicating that the increased 
thermogenic effect of green tea may exert its effects through β-adrenoceptor activation or 
consequences of such activation. 
 
In animal models tea catechins have been shown to exert a hypolipidaemic effect by 
increasing faecal excretion of total lipids and cholesterol (Muramatsu et al., 1986; 
Raederstorff et al., 2003). Supplementation of 1 and 2% tea catechins to lard-cholesterol 
fed rats, decreased plasma total cholesterol and cholesterol ester concentrations. The liver 
weight, liver total lipids and cholesterol concentrations in rats fed the lard-cholesterol diet 
increased more than in the control rats, but the addition of tea catechins to the lard-
cholesterol diet decreased those parameters, indicating that tea catechins exert a lipid 
lowering effect (Muramatsu et al., 1986).  
 
Evidence of a mixture of EGCG and ECG as a potent inhibitor of fat utilisation has been 
described in animal models when compared with other catechins. These catechins were 
more effective in reducing cholesterol absorption and also tended to decrease lymphatic 
absorption of triacylglycerols. When purified EC, EGC, ECG and EGCG (0.8%, 4.9%, 
20.6% and 44.1% respectively in a dose of 10g/kg of diet) were used, EGCG was more 
effective in precipitating cholesterol solubilised in mixed bile salt micelles as observed 
during in vitro study on micellar solubility of cholesterol (Ikeda et al., 2005). These results 
show that tea catechins, in particular EGCG, effectively reduce cholesterol absorption from 
the intestine by reducing solubility of cholesterol in mixed micelles. The observation 
accounts for the hypocholesterolemic effect of tea catechins (Ikeda et al., 1992 ). Yet 
another confirmation for the lipid lowering effect of green tea has been shown by a study 
supplementing tea catechins (at 1% of diet level) for 23 days (Ikeda et al., 2005). It was 
found that visceral fat deposition and the concentration of hepatic triacylglycerol were 
significantly lower in the tea catechin group than in the control group. The activities of 
EGCG Studies 
- 105 - 
fatty acid synthase and the malic enzyme in the liver were significantly lower in the 
catechin group than in the control group. In contrast, the activities of carnitine 
palmitoyltransferase (CPT) and acyl-CoA oxidase in the liver homogenate were not 
significantly different among groups. The authors conclude that the reduction in activities 
of enzymes related to hepatic fatty acid synthesis by the feeding of tea catechins causes 
reductions of hepatic triacylglycerol and possibly of visceral fat deposition.  
 
Hypoglycaemic effect: In vitro study investigating the effect of EGCG on high glucose-
induced apoptosis showed significant suppression of apoptotic features such as DNA 
fragmentation and damage to mitochondrial function (Oh et al., 2008). It is presumed that 
this is due to the scavenging of reactive oxygen species (anti-oxidant effect of EGCG). It is 
supposed that EGCG therefore might play a role in reduction of free radicals and oxidative 
stress occurring due to hyperglycaemia. A study examining the effects of green tea 
supplementation in rats on glucose tolerance and insulin sensitivity demonstrated that 12 
weeks supplementation of 0.5 g/day green tea lowered both fasting plasma glucose and 
insulin concentrations, when compared with the control group (Wu et al., 2003). This was 
a result of increased insulin sensitivity by increasing the glucose uptake and insulin 
binding of adipocytes. A similar study exploring the hypoglycaemic effects of Teavigo® 
(purified EGCG) in male diabetic (db/db) mice supplemented EGCG for 5 weeks at 
concentrations of 2.5, 5.0, or 10.0 g/kg of diet (Wolfram et al., 2006). Oral glucose 
tolerance test was performed post supplementation and it was found that EGCG 
supplementation improved glucose tolerance and elevated insulin secretion in a dose-
dependant manner. The authors suggested that these effects maybe due to a reduction of 
endogenous glucose production as they observed an upregulation in the glucokinase 
mRNA expression in the liver and an increase in glucose-induced insulin secretion.  
 
Effects on cardiovascular risk factors: A study conducted to determine whether black 
and/or green tea polyphenols can lower blood pressure in stroke-prone hypertensive rats 
(Negishi et al., 2004) found that both green and black tea polyphenols attenuated blood 
pressure increases through their antioxidant properties. They found that green tea 
polyphenols significantly increased catalase expression (the enzyme catalase helps 
maintain defence against reactive oxygen species). The study also found that both black 
and green tea polyphenols significantly decreased phosphorylated myosin-light-chain 
(MLC-p) expression. The major regulatory mechanism of smooth muscle contraction is 
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phosphorylation/dephosphorylation of the MLC. A marked reduction in plasma nitric oxide 
(NO) concentration and urinary NO excretion was observed among rats ingesting either 
green or black tea polyphenols. This data suggest that alleviation of oxidative stress by tea 
polyphenols reduces reactive oxygen species (ROS) -mediated NO inactivation and raises 
the bioavailability of NO in the black and green tea polyphenol groups. An increase in the 
NO bioavailability enhances NO-mediated vasodilatory tone, which could account for the 
observed decrease in blood pressure. It is evident from the results obtained in this study 
that the hypotensive properties of green tea polyphenols could be attributed to their anti-
oxidant properties. As the amounts of green tea polyphenols used in this study (3.5 mg/l) 
correspond to those in approximately in 1 litre of green tea, the authors suppose that 
regular consumption of green tea may provide some protection against hypertension in 
humans.  
 
4.1.5 Human studies investigating the effect of tea catechins on parameters of 
energy balance, glucose and lipid regulation and blood pressure 
Effects on parameters of energy balance: Metabolic effects of tea catechins have been 
ascribed to activation of the SNS. Green tea extract (containing 90 mg EGCG and 50 mg 
caffeine, 3 times/day) was more effective than an equimolar concentration of caffeine in 
increasing the 24 hour energy expenditure in humans and increased lipolysis, thus 
influencing body weight and composition (Dulloo et al., 1999). The authors reasoned that 
the polyphenols inhibit COMT enzyme which degrades noradrenaline. Thus its inhibition 
results in an increase in noradrenaline release and/or prolongation of its effect on 
thermogenesis and fat metabolism thereby resulting in increased energy expenditure. Long 
term supplementation (3 months) of EGCG (270 mg/day) along with caffeine (150 
mg/day) among overweight and moderately obese men and women brought about greater 
weight maintenance after weight loss, when compared to placebo (Westerterp-Plantenga et 
al., 2005). This supplementation of EGCG along with caffeine also increased 
thermogenesis, fat oxidation and reduced fasting blood parameters of glucose, insulin, 
triacyl glycerol and leptin, which are all important risk factors for metabolic disorders. The 
ingestion of green tea (375 mg catechins + 75 mg caffeine) for 87 days among overweight 
females brought about a significant increase in desire to eat when compared with placebo 
(Diepvens et al., 2005). Leptin concentrations were not measured in this study but the 
authors conclude that this effect could be due to down-regulation of leptin release through 
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stimulation of SNS by green tea catechins. Figure 4.3 shows the possible mechanisms of 
action of EGCG.  
 
Figure 4.3 - Possible anti-obesity mechanism following EGCG ingestion 
 
Adapted from Kao et al (2006). 
 
Hypoglycaemic effects: The hypoglycaemic effects of green tea catechins have been 
attributed to the promotion of insulin’s action, improved glucose tolerance and possibly 
increased insulin secretion. The effect of green tea ingestion on OGTT was studied among 
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healthy human volunteers (Tsuneki et al., 2004). It was found that glucose tolerance 
substantially improved after drinking a suspension of 1.5 g green tea powder (containing 
84 mg of EGCG) when compared with hot water administration. The authors attributed this 
anti-hyperglycaemic effect to the promotion of insulin’s action in the peripheral tissues 
such as skeletal muscles and adipocytes. Ingestion of 300 mg EGCG (Teavigo) in subjects 
exercising at moderate intensity at 45 minutes thrice a week, for 12 weeks reduced plasma 
glucose in overweight women with impaired glucose tolerance (Hill et al., 2007). It is 
thought that this effect is due to the effect of EGCG in increasing the uptake and 
translocation of the GLUT4 protein in skeletal muscle (Ashida et al., 2004). However, a 
more recent study has shown that ingestion of 800 mg EGCG for 8 weeks did not influence 
insulin sensitivity or secretion in men with overweight and obese men (Brown et al., 
2009). 
 
Effects on cardiovascular risk factors: The cardiovascular protective action of green tea 
ingestion has been attributed to its anti-oxidant effects. Other human studies investigating 
effects of green tea polyphenols on cardiovascular risk factors are mainly epidemiological 
in nature. Regular green tea consumption of 120 ml/day or more significantly reduced the 
risk of developing hypertension among a Chinese population (Yang et al., 2004). A similar 
study observing the effect of tea ingestion in older women (>70 years) found that habitual 
intake had a favourable effect on blood pressure (Hodgson et al., 2003). Both these studies 
showed an inverse dose dependent effect of green tea polyphenols on blood pressure and 
found that the higher the green tea intake (>150 ml/day), the lower was systolic and 
diastolic blood pressure. Consumption of 583 mg of green tea catechins per day for 12 
weeks had a greater reduction in systolic BP when compared to participants ingesting a 
lower dose (96 mg/day) (Nagao et al., 2007). Ingestion of pure EGCG (800 mg/day) in 
men has recently shown to decrease diastolic BP after 8 weeks (Brown et al., 2009). Long-
term, regular tea (black and green (daily intake exceeding 500 ml) ingestion has shown to 
attenuate increases in blood pressure in both animal and human studies (Hodgson et al., 
2003; Negishi et al., 2004). The cardio-protective effect of habitual green tea consumption 
is ascribed to the anti-oxidant property of tea catechins by authors of observational studies 
as above. It is necessary to consider potential confounding factors of lifestyle and dietary 
factors along with socioeconomic factors associated with habitual tea drinking before 
accepting these findings.  
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4.1.6 Toxicity 
The safety and tolerability of single doses of EGCG ranging from 50 mg to 1600 mg was 
studied in healthy humans and it was found that doses of up to 1600 mg purified EGCG 
were well tolerated (Ullmann et al., 2003). A pharmacokinetic study was performed to 
determine the systemic availability of green tea catechins after a single oral dose 
administration of EGCG and Polyphenon E (decaffeinated green tea catechin mixture) on 
twenty healthy subjects (Chow et al., 2001). The subjects were randomly assigned to one 
of the dose levels (200, 400, 600, and 800 mg based on EGCG content). Throughout the 
study, all side effects experienced by study subjects were recorded. Both tea polyphenol 
formulations administered as a single oral dose over the dose range studied were well 
tolerated by the study participants. Some subjects experienced mild headache and fatigue, 
possibly related to the study products. The authors suggest that these adverse events could 
also have been consequences of the procedures and restrictions that the subjects 
encountered on the study days (such as refraining from beverages containing caffeine). 
They concluded that both tea polyphenol formulations administered as a single oral dose 
over the dose range studied were well tolerated by the study participants. 
 
A study was conducted to investigate the inhibitory effects and toxicity of green tea 
polyphenols on N-ethyl-N'-nitro-N-nitroguanidine (ENNG)-induced duodenal 
carcinogenesis in mice, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced 
carcinogenesis of the glandular stomach in rats and azoxymethane-induced colon 
carcinogenesis in rats (all three chemicals are potent carcinogens used to induce colon 
cancer in rats and mice) (Yamane et al., 1996). It was found that EGCG the doses of 
(EGCG supplemented in mice correspond to 500-600 mg actual intake) and green tea 
extract (1g of green tea extract/day) inhibited the chemical carcinogenesis of the 
gastrointestinal tract in rodents. The study concluded that a dose of 1g of green tea extract 
per day is an effective dose for clinical use in humans and non-toxic.  
 
The genotoxic potential of concentrated EGCG (Teavigo®) was tested in mouse lymphoma 
cell assays (Isbrucker et al., 2006a). Oral administration of 500, 1000 or 2000 mg 
EGCG/kg (actual intake of 25, 50 and 100 mg) to mice did not induce micronuclei 
formation in the bone marrow cells, an indication of reduced genotoxicity. Even 
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intravenous injection of 10, 25 and 50 mg EGCG/kg/day to rats showed no genotoxic 
effects. 
 
A single oral dose of 200 mg EGCG/kg in rats induced no toxicity whereas a single oral 
dose of 2000 mg EGCG/kg (corresponds to 400 mg of actual intake) was lethal. Chronic 
dietary administration of 500 mg/kg/day to rats for 13 weeks (corresponds to 100 mg/day 
of actual intake) was however non toxic. Similarly, no adverse effects were noted when 
500 mg EGCG preparation/kg/day was administered to pre-fed (dose provided 1 hour after 
feeding) dogs in divided doses (Isbrucker et al., 2006b). Another safety study investigated 
the potential effects of EGCG preparation of >91% purity on pregnant rats during 
organogenesis (Isbrucker et al., 2006c). Subcutaneous infusion (40 mg/kg/day EGCG) 
(actual doses correspond to 8 mg/day of subcutaneous infusion) did not induce direct 
embryo-fetal toxicity. Feeding pregnant rats diets supplemented at 1400, 4200 or 14000 
ppm (delivering average doses of 100, 300 and 1000 mg EGCG/kg/day respectively, actual 
doses correspond to 20, 60 and 200 mg/day) during organogenesis was non-toxic and 
showed no adverse effects on reproduction and fertility.   
 
4.1.7 Rationale for the studies 
There is a major interest in the study and development of novel, dietary non-
pharmacological compounds which have the potential to produce physiologically 
significant effects on thermogenesis, EE, satiety, fat oxidation and reduction of 
hyperglycaemia. Green tea and its principal catechin, EGCG, are believed to play an 
important role in energy regulation. The data in the literature regarding the effect of EGCG 
supplementation in humans and its mechanism of increasing EE and lipolysis is 
inconclusive. Further studies are therefore required to explore and understand the full 
metabolic potential of EGCG supplementation in humans. The second part of this thesis 
seeks to investigate some of the proposed effects of EGCG supplementation (increased 
RMR, thermogenesis, suppression of food intake and appetite, glucose and blood lipid 
regulation along with changes in key metabolic hormones insulin and leptin).  
 
The following two studies were designed and carried out to achieve the above mentioned 
purpose.  
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• A study designed to measure the acute effects of pure EGCG intake after a glucose 
challenge. This study aimed to test the insulin potentiating and hyperglycaemic 
actions of EGCG along with its efficacy on metabolic rate over a 2.5 hour period 
(Chapter 4.2). 
• A study to investigate the effect of varying dose of pure EGCG ingestion over a 7 
day period. This study aimed to measure chief metabolic parameters involved in 
energy balance (RMR, body weight, insulin, leptin, NEFA) and cardiovascular 
well-being (blood pressure, heart rate and plasma lipids) (Chapter 4.3). 
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4.2 Acute effect of epigallocatechingallate supplementation on metabolic 
indices of energy balance 
 
A comprehensive review of literature shows that green tea and its principal polyphenol, 
EGCG, has several metabolic actions (Chapter 4.1). Research concerning the absorption, 
distribution and elimination of polyphenols has been well documented in animal models 
(Chen et al., 1997). The pharmacokinetics of tea catechins in humans has only been 
studied, in detail, in recent times to comprehend the action and interaction of tea catechins, 
especially of EGCG and its metabolic effects (Lee et al., 2002; Yang et al., 1998). A 
previous human study has found positive correlations with green tea extract ingestion and 
both increased EE and enhanced fat oxidation over a 24 hour period (Dulloo et al., 1999). 
EGCG ingestion has also been shown to enhance insulin activity (Anderson and Polansky, 
2002). No previous human studies have attempted to investigate the above mentioned 
effects of the principle green tea catechin (EGCG) alone without the interaction with other 
catechins and caffeine on components of EE, especially thermogenesis. The present study 
was designed to test whether intake of 150 mg pure EGCG during an acute period of 
ingestion, would reproduce any of the previously documented metabolic effects. This study 
and the study described next (Chapter 4.3) are novel as they also attempted to study the 
effects of pure EGCG ingestion on thermogenesis.  
 
4.2.1 Hypothesis 
Ingestion of 150 mg/day pure EGCG will increase RMR, MST and CT over an acute 
period (2.5 hours) and also lead to euglycaemia following an oral glucose tolerance test 
more rapidly when compared to placebo.  
 
4.2.2 Aim 
This study aimed to investigate the acute effects of oral supplementation of EGCG 
following an oral glucose challenge on RMR, MST, CT, plasma concentrations of insulin, 
leptin, NEFA and indicators of appetite regulation.  
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4.2.3 Methods  
4.2.3.1 Participant recruitment and profile 
The sample size calculation (key parameter considered-weight change; section 2.22.1) 
showed that a minimum of 8 subjects were needed to show statistical significance at 95% 
confidence interval in the study parameters. Subjects were recruited by advertising in the 
London Evening Standard and London Metro newspapers along with posters and flyers 
displayed and distributed in the University of Westminster, Cavendish campus, London, 
UK. Participants with chronic disorders such as diabetes, hypertension and heart disease 
were excluded. Smokers and professional athletes or people with daily training schedules 
were also excluded from taking part in the study (refer to section 2.2 for detailed inclusion 
and exclusion criteria). Eleven, healthy men were recruited for the study to offset any 
attrition during the study (3 failed to complete the study). A study-specific inclusion 
criterion was the habitual non-consumption of green tea. This was to avoid possible 
confounding effects of chronic intake of high levels of EGCG. Data was however gathered 
from eligible participants regarding habitual black tea consumption. It should be noted 
however that EGCG levels in black tea are over 7 times lower in black tea than in green tea 
(see Table 4.2) and would be unlikely to impact on any changes elicited via the EGCG 
doses utilised in the present study. EGCG is only known to occur in measurable quantities 
in Camellia Sinensis plant and therefore no other food-stuffs ingested could influence 
outcomes of the present study.  
 
Table 4.3 - Mean anthropometric data (± SEM) of only participants who completed 
the study at pre-treatment 
Parameter Measurement Range 
Age (years) 31.5 ± 3.1 18 - 47 
Height (metres) 1.8 ± 0.02 1.70 - 1.94 
Weight (kilograms) 73.7 ± 2.0 66.2 – 86.5 
BMI (kg/m2) 23.6 ± 1.0 18 - 25 
n 8  
4.2.3.2 Study design 
The study protocol was approved by the University of Westminster Ethics Committee 
(application number 06/07/27, Appendix 8). This study was a randomised, cross over, 
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single blinded study. None of the participants recruited for the study consumed green tea 
habitually. The current study was designed to assess the acute effects of EGCG ingestion 
in men over a short period of time (2.5 hours). The dose of 150mg was chosen (as detailed 
in section 2.4) to be tested during the acute ingestion phase. Pure EGCG was obtained 
from DSM nutritional products, Switzerland, marketed under the brand name Teavigo®. 
This is 94% purified EGCG, caffeine free and is available as a white powder.  
 
Participants arrived at the laboratory fasted (overnight, minimum of 12 hours) for two test 
sessions, separated with a wash out period of 1 week in between the test sessions. On 
arrival at the laboratory for the first test session, informed consent (Appendix 9) was 
sought from the participants and the study protocol explained in detail with the aid of 
research study information sheet (Appendix 10).  
 
Participants were randomly assigned to either the placebo or the EGCG supplementation 
during the first test session. During these test sessions either 150mg of placebo (Casilan 90, 
Complan foods ltd, UK) or 150mg of Teavigo® (DSM nutritional products, Switzerland) 
powder was mixed with 410ml Lucozade Energy Original (LEO, GlaxoSmithKline 
Company, UK; providing 75 g of glucose). EGCG was chosen to be given with a fluid as it 
has been shown that EGCG was better absorbed when given through drinking fluid (Chen 
et al., 1997). Also, although LEO contains a small amount of caffeine, the same amount 
was delivered whether EGCG was ingested or not (hence, any differences noted in 
parameters measured would be superimposed on an equal baseline). One of the study aims 
was to test the participants’ blood glucose response to a glucose load therefore an oral 
glucose tolerance test (OGTT) was performed. OGTT protocol was taken from those set 
with the American Diabetes Association (ADA), whose guidelines specify testing the 
blood glucose response every 30 minutes to an oral load of 75 g glucose (LEO drink) over 
a span of 2 hours (ADA, 2002).  
 
Participants filled in a visual analogue scale (VAS) in order to assess hunger and satiety 
before the supplementation and at the end of each test session. Blood glucose 
concentrations were measured via HemoCue® at the start of the test session and every 30 
minutes upto 2 hours after ingestion (section 2.11). Indirect calorimetry (Deltatrac II) was 
used to measure RMR for two 45 minutes intervals (30-75 minutes and 105-150 minutes 
post ingestion) with measurement beginning 30 minutes post ingestion. A break of 30 
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minutes was given in between the two sampling periods (section 2.7). Heart rate was 
recorded using a Polar heart rate monitor throughout the test session (section 2.18). The 
participants wore comfortable, light indoor clothes during the test sessions and had 
soothing music played via headphones to help them relax as well as keep out any unwanted 
noise stimulus. Blood pressure was monitored towards the end of each test session to 
detect any changes due to supplementation (section 2.19). Whole blood samples were 
collected by venepuncture in heparin containing tubes (BD Vacutainer® Plasma Tube, 
Becton Dickinson UK Limited) once at the beginning and again at the end of the test 
session to detect any changes in insulin, NEFA and leptin concentrations (Figure 4.4). The 
filled vacutainers were immediately centrifuged at 3500 rpm for 12 minutes and the plasma 
supernatant was transferred into 1.5 ml eppendorf tubes and stored at -80°C until further 
analysis (sections 2.16, 2.15, 2.17 and appendices 19, 20, 21 for further details of assays)  
4.2.4 Data analyses 
Data are presented as mean ± standard error of mean (SEM). SPSS 14 was used to analyse 
data. Paired samples t-tests were performed between groups to detect any statistical 
significance. The results were concluded as statistically significant when p ≤ 0.05. 
Pearson’s correlation co-efficient analysis was performed to determine any significant 
correlation between inter-dependant factors (e.g. correlation between plasma leptin and 
body fat composition). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EGCG Studies 
- 116 - 
Complete consent forms, VAS + venepuncture blood sample + blood glucose (BG) tested (0 mins) 
Subjects 
(Screening) 
150mg EGCG 
Drink LEO +supplement (10 minutes to drink) 
Relax for 30 minutes at the end of which BG tested (at 30 mins) 
RMR, MST, CT (30 – 75 Minutes) at 60 mins BG tested 
Break for 30 minutes, at 90 mins BG tested 
RMR, MST, CT (105 – 150 Minutes) at the end of which BP tested, VAS form filled, BG tested at 
120 mins + venepuncture blood sample taken 
End of test session 
Start of test session 
150mg placebo 
Figure 4.4 - Schematic representation of test session 
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4.2.5 Results 
 
There were no significant differences between RMR, MST and CT measured at 30 – 75 
and 105 – 150 minutes post placebo and post EGCG ingestion (Figure 4.5 and Figure 4.6 
respectively). The ambient temperature was maintained from 22.5 ± 0.4°C to avoid 
inducing shivering thermogenesis (Figure 4.6). There were no differences in RER 
measured between 30 – 75 and 105 - 150 minutes following placebo or EGCG ingestions 
over a period of 2.5 hours (Table 4.4). There were no changes between macronutrient, total 
calorie and tea consumption prior to the two test sessions (Table 4.5, Table 4.6).   
 
Figure 4.5 - Mean resting metabolic rate (RMR; ± SEM) at 30 - 75 minutes and 105 - 
150 minutes post placebo and post EGCG ingestion  
 
n = 8; There were no significant differences. 
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Figure 4.6 - Mean skin (MST; ± SEM), core (CT; ± SEM) temperatures at 30 – 75 and 
105 - 150 minutes following ingestion of either placebo or EGCG   
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n = 8; There were no significant differences; Ambient temperature (AT; ± SEM) for 30 – 75, 105 – 150 mins 
post placebo intake was 22.7 ± 0. 5, 22.6 ± 0.4 ° C respectively; post EGCG ingestion was 22.4 ± 0.3, 22.4 ± 
0.5° C for 30 – 75, 105 – 15 mins respectively. 
 
 
 
 
 
 
Table 4.4 - Mean respiratory exchange ratio (RER; ± SEM) at two intervals (30 - 75 
and 105 - 150 minutes) post placebo and post EGCG ingestion  
 RER 
30 – 75 mins 105 - 150mins 
Post placebo ingestion 0.89 ± 0.02 0.93 ± 0.03 
Post EGCG ingestion 0.91 ± 0.02 0.91 ± 0.02 
n = 8; There were no significant differences. 
 
 
 
 
 
EGCG Studies 
- 119 - 
Table 4.5 - Mean daily dietary intake (± SEM) and nutrient intake expressed as a 
percentage of total energy intake (%TEI)† 3 days prior to the placebo ingestion test 
session compared to mean dietary intake 3 days prior to the EGCG ingestion test 
session  
Ingestion 
Energy 
(kcals/day) 
Protein 
%TEI 
Fat 
%TEI 
Carbohydrate 
%TEI 
Placebo 2256.50 ± 224.02 20.7 ± 1.5 37.4 ± 2.2 40.3 ± 3.4 
EGCG 2606.50 ± 508.71 18.2 ± 2.1 40.3 ± 4.5 38.9 ± 5.5 
n = 8; There were no significant differences;  † Likely validity of reported kcal intake discussed in appendix 
13. 
 
 
 
 
 
 
Table 4.6 - Mean black tea intake (ml ± SEM) 3 days prior to the placebo ingestion 
test session compared to mean black tea intake 3 days prior to the EGCG ingestion 
test session  
Tea consumption prior to placebo test 
session (ml) 
Tea consumption prior to EGCG test 
session(ml) 
551.3 ±  250.3 481.3 ± 236.6 
 
N.B: n = 5 as 3 participants reported nil tea consumption over these days, There were no significant 
differences. 
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Figure 4.7 - Mean percentage change in visual analogue scale (± SEM) rating measure 
over a period of 2.5 hours for hunger, satiety, feeling of fullness and prospective food 
consumption from pre-treatment post placebo and post EGCG ingestion  
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n = 8; There were no significant differences. 
 
At the end of the EGCG test session participants tended to appear to be more hungry (p = 
0.053). Ratings of feelings of satiety, fullness and prospective food consumption were not 
different post placebo and post EGCG ingestion and also over time (2.5 hours) (Figure 
4.7).  
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Figure 4.8 - Mean blood glucose response (± SEM) to oral glucose tolerance test over 
2 hours following placebo and EGCG ingestion  
 
n = 8; There were no significant differences.  
 
 
Table 4.7 - Mean plasma insulin (± SEM), plasma leptin (± SEM) and plasma non-
esterified fatty acid (NEFA; ± SEM) concentrations measured pre-treatment and at 
the end of both placebo and EGCG test sessions  
 Insulin (mU/l) Leptin (ng/ml) NEFA (µmol/l) 
Pre-
treatment 
End of test 
session 
Pre-
treatment 
End of test 
session 
Pre-
treatment 
End of test 
session 
Placebo 5.50 ± 
1.27  
13.40 ± 
5.07  
12.88 ± 
10.09 
14.07 ± 
11.22  
755.19 ± 
105.63  
474.65± 
69.15*  
EGCG 7.64 ± 
2.89  
14.55 ± 
5.20  
7.03 ± 
3.56  
6.36 ±  
3.55   
721.83 ± 
105.61  
433.21 ± 
75.83** 
n = 8; *Significantly different from pre-treatment (p = 0.0002); **Significantly different from pre-treatment 
(p = 0.0005). 
 
There was no difference in blood glucose concentrations measured every 30 minutes 
following an oral glucose challenge along with either placebo or EGCG (Figure 4.8). There 
were no differences in plasma insulin and leptin concentrations pre and post ingestion of 
either placebo or EGCG (Table 4.7). Correlation analysis revealed a significant correlation 
(p = 0.016; r = 0.806) between mean fasting blood glucose with fasting insulin 
concentration at the beginning of the EGCG test session. There were however decreases in 
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NEFA post placebo (p = 0.0002) and post EGCG (p = 0.0005) ingestion when compared 
with pre-treatment concentrations (Table 4.7).  
 
 
Figure 4.9 - Mean systolic and diastolic blood pressure (± SEM) following either 
placebo or EGCG ingestion  
n = 8; There were no differences between the two groups. 
 
 
Table 4.8 - Mean heart rate (HR; ± SEM) for a 2 hour period after ingestion of either 
placebo or EGCG  
Ingestion Mean HR (beats/minute) 
Maximum HR range 
(beats/minute) 
Placebo 60.63 ± 3.01 68 - 117 
EGCG 63.75 ± 2.25 62 - 123 
n = 8; There were no significant differences. 
 
There were no differences in either systolic or diastolic blood pressure post placebo or post 
EGCG ingestion and heart rate recorded over 2.5 hours of each test session (Figure 4.9 and 
Table 4.8 respectively).  
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4.2.6 Discussion 
 
The current study was designed to investigate the effect of an acute ingestion of 150 mg 
EGCG in healthy humans on RMR, MST, CT, post prandial glucose regulation, and index 
of lipolysis (NEFA) as markers of energy regulation and on the energy balance regulatory 
hormones- insulin and leptin.  
 
Effect of EGCG on RMR, MST, CT and RER  
There were no differences in RMR measured in two 45 minute sampling periods for up to 
2.5 hours post ingestion of either placebo or EGCG. This period of RMR measurement 
coincided with the maximum plasma concentration (Cmax) of EGCG, which has been 
observed to be 1.4 to 2.4 hours after ingestion in humans, with a half – life of 5 – 5.5 hours 
(Yang et al., 1998). Green tea ingestion increases 24-hour EE (Dulloo et al., 1999), but no 
data exists for any changes observed with green tea or EGCG ingestion following an acute 
period of ingestion in humans. It is possible that changes in RMR over a short period of 
time (2.5 hours) is not evident or is very subtle. It may be that addition of other catechins 
or caffeine may show measurable changes in RMR. Green tea unless decaffeinated, 
contains caffeine which may lead to increased EE. Caffeine content in the LEO drink used 
in this study was 46mg and as the same amount was ingested during both test sessions, any 
changes in RMR should be attributed to EGCG. Examining the data regarding metabolic 
effects of caffeine shows indefinite actions. Caffeine intake of 50mg did not affect EE or 
RER (Dulloo et al., 1999) whereas 4 mg/kg body weight (approximately 280mg for a 70 
kg man) increased metabolic rate significantly (Acheson et al., 1980). Caffeine content 
used in the current study was an average dose of 0.5 mg/kg body weight and reviewing the 
data from the above mentioned study, it is believed that this quantity would not lead to any 
increase in RMR.  
 
There were no changes observed in MST, CT and RER following placebo or EGCG 
ingestion over the period of 2.5 hours. Possibly, the effects were subtle and the 
measurement techniques employed were unable to detect minute changes. Analysis of 
mRNA for expression of any increases in UCPs might indicate changes in thermogenesis 
and should be considered by other researchers for future studies of this nature. Also, in 
light of the above previously discussed half-life and Cmax of EGCG it can be hypothesised 
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that with measurement of RMR for a further 60-90 minutes, a probable variation could 
have been observed.  
 
Participants maintained 3-day diet diaries prior to each test session so as to ascertain that 
the diet consumption remains similar prior to both test sessions and any significant changes 
in any macronutrients do not play a part to any changes in any metabolic indices. Results 
of dietary analysis revealed no significant differences in dietary intake prior to both test 
sessions. None of the participants consumed green tea and this criterion was purposeful 
during recruitment for the study as the confounding effect of habitual green tea intake was 
eliminated. Dietary intake diaries showed that consumption of black tea intake remained 
similar prior to both test sessions in participants who habitually drank tea. Therefore, 
catechin intake from this source was consistent throughout the study period.  
 
Background and hence baseline intakes of caffeine (a dietary component with possible 
effects on some of the measured parameters) did not to change during the study as subjects 
were instructed to continue their normal eating patterns. Therefore, in the same manner that 
the mode of delivery (LEO) of EGCG was uniform in caffeine delivery so was daily 
caffeine ingestion. Deviations in measures of RMR and glucose tolerance that may have 
been observed would then be attributable to the EGCG intervention. It would not have 
been appropriate to attempt to change habitual caffeine intake, as long-term adaptation to 
this compound would mean that abrupt cessation to participate in the study would have 
produced a withdrawal syndrome (Ozsungur et al., 2009). Such a syndrome would induce 
changes likely to confound study findings. In addition and in common with other 
pharmacologically active agents, sudden changes in intake could mask or distort the 
frequently reported synergy between caffeine and EGCG with respect to its physiologic 
and metabolic activity (Dulloo et al., 1999; Dulloo et al., 2000). 
 
Effect of EGCG on blood glucose, insulin, leptin and NEFA concentrations in 
circulation 
There was no difference observed in post prandial glucose following either placebo or 
EGCG ingestion. Several studies have investigated the effect of green tea supplementation 
on insulin sensitivity and glucose tolerance in both animals and humans. Green tea 
ingestion (containing 84 mg of EGCG in an acute dose) improved glucose tolerance 
compared to placebo in humans and this effect has been observed to be due to promotion 
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of insulin action in the peripheral tissues such as skeletal muscles and adipocytes (Tsuneki 
et al., 2004). In diabetic mice, glucose tolerance and insulin secretion was improved due to 
reduction of endogenous glucose production and increase in glucose-induced insulin 
secretion after ingestion of Teavigo® (Wolfram et al., 2006). Improved insulin action was 
not evident in this study and it is plausible and debatable that this mechanism could be 
better observed if EGCG was supplemented for a few weeks before the OGTT challenge. 
Plasma leptin concentrations were not different between the placebo and EGCG groups. 
There is a lack of data regarding leptin changes following acute intake of EGCG in the 
literature. It is also arguable whether any leptin changes occurs or could be observed over a 
2.5 hour period at all. A statistically significant reduction from baseline was observed in 
plasma NEFA during both test sessions. This reduction was expected as a consequence of 
OGTT, as glucose provision promotes glucose oxidation and glucose and lipid storage, and 
inhibits fatty acid oxidation (Randle, 1998). This is attributed to a decrease in glucagon 
concentrations with increasing glucose concentrations in the blood, in turn impeding 
ketogenesis.  
 
Effect of EGCG intake on appetite regulation 
The present study assessed in participants, a range of hunger-satiety related subjective 
impressions over a period of 2.5 hours. The tests were carried out following an overnight 
fast and with all subjects missing their normal breakfast and reporting hunger (via VAS) at 
the start of the test period (all the participants reported regularly consuming three meals 
daily, including breakfast). Subjective impressions (VAS) given prior to testing (ingestion 
of test fluid) did not differ statistically significantly for any of the parameters measured. 
Therefore, no influence of prior fluid ingestion (only water permitted) was evident.  
 
All subjects consumed isocaloric/isovolumetric test drinks (287 kcals/410 ml) therefore 
post-prandial differentials in subjective sensations could be related to EGCG ingestion. By 
the end of the test session (2.5 hours later), gastric emptying would be complete (Stenson, 
2006) and any effects would likely stem from post absorptive events according to test drink 
composition (ie EGCG content). Analysis revealed a strong trend for participants to feel 
more hungry post EGCG ingestion (p = 0.053) when compared with post placebo ingestion 
although this did not reach statistical significance. Similar observation of increased 
appetite was observed in a study investigating long-term supplementation of green tea in 
humans related to down-regulation of leptin release through stimulation of SNS by green 
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tea catechins (Diepvens et al., 2005). No other significant differences according to test 
group were observed. 
 
Results obtained from animal studies have shown EGCG and/ or green tea supplementation 
may modulate leptin-independent appetite pathways and reduce food intake (Kao et al., 
2000). This mechanism is uncertain in humans and needs to be further investigated. Yet 
again, no data exists from previously conducted animal or human studies regarding 
appetite regulation following an acute ingestion of green tea or EGCG and further studies 
will clarify acute effect of EGCG in humans.  
 
Effect of acute EGCG intake on blood pressure and heart rate 
Blood pressure measured at the end of two test sessions showed no difference after either 
supplementation. Heart rate monitored through out the test session also showed no major 
difference between supplementations. Habitual green tea intake is believed to have 
hypotensive effects in Chinese medicine and its ingestion has been extensively researched 
for this purpose (Cabrera et al., 2006). This blood pressure attenuation effect of green tea is 
attributed to its anti-oxidant properties (Negishi et al., 2004). Reduction in risks of 
cardiovascular disease is important for overall well being and it may well be obvious that 
these cardiovascular effects are more apparent following long-term ingestion rather than an 
acute intake.  
4.2.7 Conclusion    
Results obtained from the present study indicate that there are no effects on glucose 
tolerance, RMR, MST, CT, RER, insulin secretion and lipolysis of ingestion of a single 
dose of 150 mg EGCG over a 2.5 hour period. This study is novel as there have been no 
studies previously conducted to measure the acute effects of 150 mg pure EGCG over 2.5 
hours among healthy humans. Due to this, data obtained from the current study cannot be 
compared with previous findings. Several studies do indicate metabolic effects (increased 
BMR, lipolysis, reduced blood glucose concentrations) of habitual green tea and/or EGCG 
ingestion. Therefore, a longer term study was designed to further evaluate effect of EGCG 
at both differing doses (< and > 150mg) and over a longer period of supplementation (7 
days). It was hypothesised that an increase in the dose of EGCG and / or the extension of 
period of supplementation might show notable changes in metabolic parameters such as 
RMR and lipolysis, which were not apparent in the present study. Consequently, a one 
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week supplementation study with differing doses was designed and is described in the 
following chapter (4.3).  
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4.3 Dose response effects of epigallocatechingallate supplementation over a 7 
day period on metabolic indices of energy balance  
 
Studies have previously demonstrated that ingestion of EGCG increases plasma EGCG 
concentrations dose-dependently (Nakagawa et al., 1997). Following on from the previous 
study (Chapter 4.2) of acute oral ingestion of pure EGCG, this study was designed to 
investigate the effects of pure EGCG ingestion over a longer period at varying doses. By 
extending the intervention period the induction of metabolic processes of significance may 
become manifest through increases in flux through relevant pathways not possible in a two 
and a half hour period.  
4.3.1 Hypothesis 
Ingestion of EGCG (75, 150 and 300 mg/day, each for a period of 7 days) daily will dose 
dependently decrease body weight, increase RMR, increase lipolysis, reduce fasting blood 
glucose concentrations and decrease lipid concentrations in circulation.  
4.3.2 Aim 
The aims of this study were to measure the dose-dependant responses of EGCG ingestion 
on body weight, RMR, MST, CT, % body fat, fasting blood glucose and fasting lipid 
concentrations, blood pressure and heart rate, NEFA along with key metabolic hormones - 
insulin and leptin. 
4.3.3 Methods  
4.3.3.1 Participant recruitment and profile 
The sample size calculation was based on a difference in body weight (section 2.22.1) and 
showed that at least 8 participants were needed to observe a change in body weight. 
Eleven, healthy men between the ages of 20-55 years were recruited for the study by 
advertising in local newspapers, the Metro and Evening Standard (section 2.2 for inclusion 
and exclusion criteria). Out of the eleven participants, 8 completed the study and 3 
participants dropped out during the course of the study. The study protocol was approved 
by the Ethics Committee of University of Westminster, London, UK (Application number 
06/07- 27, Appendix 8).  
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Table 4.9 - Mean anthropometric data (± SEM) of only participants who completed 
the study  
Parameter Measurement Range 
Age (years) 39.0  ± 2.9 31 - 54 
Height (centimetres) 175.7 ± 2.2 168.1 – 182.2 
Weight (kilograms) 75.2 ± 2.6 65.9 – 87.1 
BMI (kg/m2) 24.4 ± 0.5 22.2 – 24.9 
n 8  
 
4.3.3.2 Study design 
This study was single blinded and crossed-over in design. Each participant acted as their 
own control and the order in which they took each dose over the three test sessions was 
randomised. Each supplementation dose was for a period of 7 days with a wash out period 
of 7 days between each dose. All participants were randomly assigned to 75, 150 or 300 
mg/day of pure EGCG (Teavigo®, DSM nutritional Ltd, Switzerland; section 2.4 for dose 
calculation) made up as gelatine capsules (size 0: G. Baldwin & Co, London). It was 
carefully explained to participants that it was important to take the capsules daily at the 
time advised (with breakfast). All reasonable measures to ensure compliance were carried 
out, including checking via a telephone call to each participant mid-way through each 
study week, and verification of compliance again at the end of the study. Subjects were 
trusted to be honest with the investigator as biomarker assays of compliance were beyond 
budgetary constraints of the study.  
 
The participants visited the laboratory for 4 test sessions over a period of 35 days (Figure 
4.10). At the start of each test session, body weight was recorded and body composition 
measured via skinfold measurement (section 2.6). Participants’ RMR was then measured 
with the use of Deltatrac II (section 2.7). During this time, participants wore a Polar heart 
rate monitor and were connected to the Squirrel data logger, recording their heart rate and 
MST and CT respectively (section 2.18, 2.9). At the end of each test session, blood 
pressure was measured (section 2.19), fasting blood glucose was analysed by a finger prick 
blood sample with the use of HemoCue® analyser (section 2.11) and venepuncture blood 
samples were obtained to measure fasting blood lipids, plasma insulin, leptin and NEFA 
concentrations (section 2.13). The filled vacutainers were immediately centrifuged at 3500 
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rpm for 12 minutes. The plasma was transferred into eppendorf tubes and stored at -80°C 
until further analysis (section 2.16, 2.17 and 2.15 for further details of each of the assays). 
Following on, the previously completed 3-day diet diaries (section 2.20) procured from 
them. The second, third and final test sessions followed the same protocol of 
measurements (Figure 4.10). At the end of the first, second and third test sessions, 
participants were given the next of the randomised doses and further instructions regarding 
the wash out period and the start of EGCG ingestion were discussed.  
 
Figure 4.10 - Schematic overview of dose dependant EGCG study design  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.4 Data analyses  
All data in tables and figures are presented as mean ± standard error of mean (SEM). Data 
analyses were performed using SPSS 14.0 for Windows (SPSS Inc. Illinois). Data were 
Day 1 
First test session in Human and Health Sciences Lab, University of Westminster. Take first dose of 
EGCG for 7 days
Day 8 
Second  test session in Human and Health Sciences Lab 
Day 15 
Begin intake of second dose of EGCG for next 7 days
Day 8 - 14: washout
Day 22 
Third test session in Human and Health Sciences Lab 
Day 22 -28: washout
Day 29 
Begin intake of third dose of EGCG for next 7 days 
Day 36 
Final test session in Human and Health Sciences Lab, University of Westminster. 
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analysed using a repeated measures ANOVA and a p value of ≤ 0.05 was considered 
significant. Correlation analyses between inter-dependant variables (e.g. insulin and fasting 
blood glucose concentrations) were performed using Pearson’s correlation coefficient. A p 
value of ≤ 0.05 was considered as significantly correlated (section 2.22.2). 
 
4.3.5 Results 
 
There were no differences in body weight following ingestion for 7 days of 75, 150 or 300 
mg/day EGCG from pre-treatment (Table 4.10). Mean RMR measured following ingestion 
of 150mg EGCG was significantly lower than pre-treatment measurement (p = 0.008; 
Figure 4.11). There were no differences between RMR measurements following ingestion 
of 75 and 300mg EGCG in comparison with pre-treatment (Figure 4.11). MST and CT 
remained unchanged from pre-treatment readings, after 75, 150 and 300mg EGCG 
ingestion (Figure 4.12). Ambient temperature was maintained at 22.3 ± 0.4°C during all 
test sessions (Figure 4.12).  
 
 
 
Table 4.10 - Mean body weight (± SEM) pre-treatment and following 7 day ingestion 
of 75, 150 and 300mg EGCG  
Test session Weight (kg) 
Pre-treatment  75.15 ± 2.58 
75mg EGCG 75.11 ± 2.46  
150mg EGCG 74.85± 2.68 
300mg EGCG 74.76 ± 2.63 
n = 8; There were no significant differences. 
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Figure 4.11 - Mean resting metabolic rate (RMR; ± SEM) pre-treatment, post 
ingestion of varying doses of EGCG (75, 150 and 300mg; for 7 days each)  
 
n = 8; *Significantly different from pre-treatment measurement (p = 0.008).  
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Figure 4.12 - Mean skin (MST; ± SEM) and core temperatures (CT; ± SEM) 
measured pre-treatment and following 75, 150 and 300mg EGCG ingestion 
 
n = 8; There were no significant differences; Ambient temperature (AT; ± SEM) measured pre-treatment and 
following 75, 150 and 300mg EGCG ingestion was 22.5 ± 0. 6, 22.2 ± 0.3, 21.9 ± 0.4, 22.7 ± 0.3° C 
respectively. 
 
There were no differences in RER post 75, 150 and 300mg EGCG ingestion from pre-
treatment (Table 4.11). Percentage body fat remained stable from pre-treatment 
measurements following ingestion of 75, 150 and 300mg EGCG (Table 4.11).  
 
 
Table 4.11 - Mean respiratory exchange ratio (RER; ± SEM) and % body fat pre-
treatment, post 75, 150 and 300mg EGCG ingestion 
Test session RER Body Fat (%) 
Pre-treatment 0.84 ± 0.03 19.7 ± 1.5 
75mg EGCG 0.80 ± 0.03 20.2 ± 1.6 
150mg EGCG 0.84 ± 0.03 19.7 ± 1.5 
300mg EGCG 0.82 ± 0.02 19.8 ± 1.5 
n = 8; There were no significant differences. 
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Table 4.12 - Mean daily dietary intake (± SEM) and nutrient intake expressed as a 
percentage of total energy intake (%TEI)† 3-days prior to each test session compared 
to 3-days prior to pre-treatment  
Test session 
Energy 
(Kcal/d) 
Protein 
%TEI 
Fat 
%TEI 
Carbohydrate 
%TEI 
Pre-treatment  2236. 7 ± 350.6 16.2 ± 1.1 31.7 ± 3.9 44.1 ± 3.2 
75mg EGCG 2470.3 ± 308.6 17.2 ± 2.2 30.9 ± 3.0 51.3 ± 2.7 
150mg EGCG 2314.5 ± 399.4 18.0 ± 3.1 32.2 ± 3.6 48.8 ± 2.8 
300mg EGCG 2827.67 ± 348.1 14.9 ± 2.8 30.6 ± 4.9 49.0 ± 3.5 
n = 8; There were no significant differences; † Likely validity of reported kcal intake discussed in appendix 
13. 
 
 
Table 4.13 - Total black tea intake (ml) 3-days prior to each test session among study 
participants during the course of the study  
Test session Pre-treatment 75mg EGCG 150mg EGCG 300mg EGCG Subjects 
1 250 250 0 250 
2 400 200 0 0 
3 600 1000 1000 600 
4 0 750 1250 800 
5 500 500 800 600 
6 0 0 0 0 
7 0 0 0 0 
8 0 0 0 0 
N.B: Due to disparity in reported tea intake over the sampling period, total intake has been reported without 
the calculation of SEM; complete data set for all 4 test sessions n=2; all other data sets were excluded 
during statistical analysis due to missing values; therefore, due to very small sample size no statistical 
inference made. 
 
Consumption of total calorie intake and macronutrients remained unchanged during all 
three periods of EGCG supplementation from pre-treatment (Table 4.12). None of the 
participants recruited for the study consumed green tea, but a few participants reported 
drinking black tea habitually. Only 2 participants reported intakes of tea during the entire 
course of the study (subject numbers 3 and 5 in Table 4.13). Three participants did not 
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report tea intake at any period of the study (subject numbers 6, 7 and 8 in Table 4.13) and 
three remaining participants reported tea intake prior to only 3 test sessions (subject 
numbers 1, 2 and 4 in Table 4.13).  
 
Table 4.14 - Mean fasting blood glucose (FBG; ± SEM), plasma insulin (± SEM), 
plasma leptin (± SEM) and plasma non-esterified fatty acid (NEFA; ± SEM) 
concentrations measured pre-treatment and after 75, 150 and 300mg EGCG ingestion  
Test session FBG (mmol/l) Insulin (mU/l)# Leptin (μg/l) NEFA (µmol/l) 
Pre-treatment 4.72 ± 0.17 3.40 ± 0.91 4.68 ± 1.44 568.23 ± 59.50 
75mg EGCG 4.81 ± 0.19 6.5 ± 2.15 ^ 4.39 ± 1.15 484.33 ± 79.67* 
150mg EGCG 4.72 ± 0.25 3.22 ± 0.68 4.47 ± 1.25 626.86 ± 69.17 
300mg EGCG 4.93 ± 0.19 4.88 ± 1.51 4.90 ± 1.33 655.73 ± 95.57 
n = 8 for FBG, leptin and NEFA; # n = 7 for insulin (one subjects’ plasma sample was lost due to breakage 
of eppendorf tube during storage at -80°C); ^ Range – 1.6-18.4; * Statistically significant from 150mg (p = 
0.014) and from 300mg (p = 0.026). 
 
There were no differences in fasting glucose, insulin and leptin concentrations in 
circulation between pre-treatment and varying doses of EGCG (75, 150 and 300mg) (Table 
4.14). Plasma NEFA concentrations post 75mg EGCG ingestion were significantly 
different (lower) from plasma NEFA concentrations post 150mg EGCG ingestion (p = 
0.014; Table 4.14) and post 300mg EGCG ingestion (p = 0.026). Plasma NEFA 
concentrations post 75mg, 150 and 300mg EGCG did not differ from pre-treatment 
measurements (Table 4.14). There were no differences in total cholesterol, HDL and LDL 
concentrations between pre-treatment and varying doses (Figure 4.13).  
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Figure 4.13 - Mean total cholesterol (TC; ± SEM), high density lipoprotein (HDL; ± 
SEM) and low density lipoprotein (LDL; ± SEM) concentrations pre-treatment and 
post ingestion of 75, 150 and 300mg EGCG  
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n = 8; There were no significant differences. 
 
Figure 4.14 - Mean systolic and diastolic blood pressure (± SEM) pre-treatment and 
following 75, 150 and 300mg EGCG ingestion 
 
n = 8; *Significantly different from pre-treatment value (p = 0.042). 
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Table 4.15 - Mean heart rate (HR; ± SEM) pre-treatment and following 75, 150 and 
300mg EGCG ingestion  
Test session Mean HR 
(beats/minute) 
Maximum HR range 
(beats/minute) 
Pre-treatment 63 ± 2 64 - 88 
75mg EGCG 61 ± 2 67 - 92 
150mg EGCG 61 ± 4 66 - 91 
300mg EGCG 62 ± 4 59 - 88 
n = 8; There were no significant differences.  
 
Systolic blood pressure measured post 75mg EGCG ingestion was lower than pre-
treatment (p = 0.042; Figure 4.14). There were no changes in systolic blood pressure 
following 150 and 300mg EGCG ingestion compared to pre-treatment measurements. 
There were no effects of varying EGCG dose on diastolic blood pressure and mean heart 
rate when compared with pre-treatment measurements (Figure 4.14 and Table 4.15, 
respectively). 
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4.3.6 Discussion 
 
This study investigated the dose dependant effect of pure EGCG in healthy men. It was 
hypothesised that oral intake of EGCG at 75, 150 and 300 mg/day, each for a period of 7 
days, would dose dependently affect energy balance by increasing RMR resulting in a 
decrease in both body weight and body fat composition. The variation in EGCG dose 
would also lower blood glucose concentrations, lipid profile and blood pressure (BP) 
following increase in EGCG doses along with variations in plasma insulin, NEFA and 
leptin concentrations. The results obtained from the study showed no difference in body 
weight, MST, CT, RER, body composition, dietary intake, lipid profile and heart rate 
following ingestion of varying doses of EGCG. There were significant decreases compared 
to pre-treatment measurement in RMR following 150 mg/day EGCG, decrease in systolic 
BP following ingestion of 75 mg/day EGCG and decrease in NEFA concentrations 
following 75 mg/day EGCG ingestion. 
 
Effect of EGCG on energy balance and thermogenesis 
Mean body weight did not change with varying EGCG dose from pre-treatment 
measurements. A decrease in body weight would be observed with an increase in RMR 
and/or decrease in total body fat percentage. Ingestion of 150 mg/day EGCG for 7 days 
significantly decreased RMR when compared with pre-treatment measurement (p = 0.008; 
Figure 4.11), but RMR measurements following other doses were not different from pre-
treatment. One would expect to see a decrease in RMR following a loss of lean body mass 
but this was not evident from the results of this study. There was no change in body fat 
composition throughout the period of study, for that reason no change in lean tissue was 
expected. There was no change observed in thermogenesis to enhance RMR. The reason 
for the decrease in RMR following 7 days of ingesting 150 mg EGCG/ day is inexplicable. 
This study is the first to study dose response effect of pure EGCG ingestion among healthy 
humans. The chemistry of pure EGCG in vivo over a 7 day period might vary from the in 
vivo reactions following ingestion of all green tea catechins. The effects and actions of 
isolated pure EGCG in humans are also not fully understood as most of the previous 
studies have used green tea supplementation which contains the four major catechins. It is 
possible that isolated EGCG ingestion might have varying effects on RMR. RMR 
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measurements following ingestion of 150 mg/day EGCG needs to be investigated further 
to conclude its effect fully.  
 
Data in the literature also provides inconclusive evidence towards increased metabolic rate 
following green tea extract (containing all catechins) and EGCG ingestion. Previous 
studies among obese subjects have demonstrated the effect of green tea extract (containing 
100 mg EGCG) on weight loss following supplementation for 8 to 12 weeks due to 
increased EE and lipolysis (Auvichayapat et al., 2008). Dulloo and others (1999) 
demonstrated the BMR enhancing effect of 90 mg/day EGCG over a 24 hour period while 
a 2 day supplementation of 300 mg/day of EGCG did not elevate BMR (Boschmann and 
Thielecke, 2007). In addition, a longer period of green tea extract supplementation (570 
mg/day and for 2 months) did not increase BMR over the period of study (Ota et al., 2005). 
Two main mechanisms have been proposed to explain the effect of green tea catechins and 
EGCG on increased metabolic rate. First, the effect of green tea catechins on the inhibition 
of COMT, the enzyme that degrades noradrenaline (Borchardt and Huber, 1975). This 
inhibition results in prolonged effect of noradrenaline on thermogenesis and fat oxidation 
(Dulloo et al., 2000). Second, it is suggested that the increase in metabolic rate might be 
due to a synergistic effect between EGCG and caffeine. Caffeine inhibits the 
phosphodiesterase-induced degradation of intracellular cAMP, thus elevating cellular 
concentrations of cAMP: a critical intracellular mediator for catecholamine action on 
thermogenesis (Acheson et al., 1980). The mechanism and rationale for both these 
observations is still unclear and needs to be further studied. Possibly, longer period of 
supplementation (> 3 months) may confirm elevation in BMR/RMR in humans following 
EGCG ingestion. 
 
Inspection of the background intake of tea showed that those participants who drank tea, 
maintained an intake of tea similar to their usual intake throughout the study period. 
Hence, it is presumed that dietary intake of tea would not influence RMR during the study. 
As the completed data set without any missing values was only 2, this was insufficient to 
perform statistical tests and draw inferences. Although this was disappointing, it is worth 
noting that three of the eight study participants were non-tea drinkers and one other subject 
failed to record only their baseline tea intake value. The remaining two subjects did 
however fail to record tea intake during EGCG ingestion phases of the study. It was not 
deemed approporiate to attempt to extrapolate intake levels from available data, rather 
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report the complete data where it was available. With respect to the impact that regular 
caffeine consumption per se in the form of tea might have on responses to intervention 
with EGCG, the data gathered suggests that this was not physiologically a significant 
factor (no differential in response magnitudes was observed between tea drinkers and non-
tea drinkers in terms of RMR).  
 
The purpose of MST and CT measurements were to detect any thermogenic effects of 
EGCG ingestion, possibly expending energy via heat release. There have been no studies 
conducted in humans to test effects of EGCG on body temperature and this study is the 
first to do so. Data obtained from the current study showed no changes in skin and core 
temperatures. Few studies have been conducted on animal models to measure changes in 
UCPs and thermogenesis following green tea or EGCG ingestion. Choo and others (2003) 
found that rats fed an extract of green tea at 20 g/kg diet for 14 days (approximately 600 
mg/day) had increased BAT thermogenesis through β-adrenoceptor activation. Klaus and 
others (2005) found that 0.5 and 1% (approximately 150 mg and 300 mg/day) 
supplementation of pure EGCG in the diet for a 4 week period resulted in an increase in 
UCP2 in the liver of rats, but observed that oral administration of EGCG (500 mg/kg; 
approximately 100 mg/day) over 3 days had no effect on body temperature. The studies 
conducted on animal models supplemented EGCG or green tea extract in higher quantities 
and comparatively, the maximum dose used in the current study is low. Moreover 
employing detection techniques of mRNA in WAT might detect dose-dependant changes 
of the effect of EGCG consumption on UCPs and should be included in future studies 
carried out by other researchers of this nature.  
 
Effect of EGCG on fasting blood glucose, plasma insulin, leptin concentrations 
There were no changes in fasting blood glucose (FBG) and plasma insulin and leptin 
concentrations from pre-treatment following varying doses of EGCG. A study conducted 
on rats fed a high fructose diet demonstrated that green tea extract (1-2 g/kg diet) regulates 
gene expression of the glucose uptake and insulin signalling pathway (Cao et al., 2007). 
This study is one among many animal studies which have shown anti-diabetic effects of 
polyphenols. Rats fed 1 and 2 g of green tea solid extract/kg diet for 6 weeks had higher 
levels of GLUT4 mRNA in liver and muscle. An increase in GLUT4 mRNA in muscles is 
physiologically significant as the GLUT4 protein is the insulin-responsive GLUT in the 
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muscle (Shepherd and Kahn, 1999). This increase in GLUT4 mRNA and ensuing transport 
of glucose into cells, thereby maintaining euglycaemia was achieved after ingestion of 
approximately 60 mg of green tea extracts/kg body weight per day (equivalent to humans 
drinking approximately 5 cups of green tea per day). Insulin enhancing properties of tea 
and its components were assayed in rat epididymal adipocytes. It was found that EGCG 
and ECG had a direct effect on insulin activity and had insulin-potentiating effect 
(Anderson and Polansky, 2002). However, there are no studies published to date at the 
molecular level in humans to analyse the effects of green tea extract or EGCG ingestion on 
glucose transport or insulin and further work is necessary to elucidate these actions. All 
participants in the current study were euglycaemic at the start of the study. It is uncertain 
whether any changes would be expected if pre-treatment blood glucose measurements were 
within normal levels. It would be interesting to study the variation in blood glucose 
concentrations if hyperglycaemic subjects are recruited.   
Leptin concentrations were unchanged from pre-treatment measurements following 
ingestion of varying doses of EGCG in the current study. Data obtained from mice trials 
investigating the effects of pure EGCG (Teavigo®) intake have found significant decreases 
in plasma leptin concentrations over a period of 3-4 weeks (Klaus et al., 2005; Wolfram et 
al., 2005). This effect has been similarly observed in long-term human trials 
(Auvichayapat et al., 2008; (Diepvens et al., 2006). In these studies participants had 
significant weight losses which were reflected in reductions in plasma leptin 
concentrations. A reduction in plasma leptin concentration is observed following loss of 
weight or body fat. In the current study, no change in body weight was observed following 
ingestion of varying doses of EGCG therefore no change was measured in plasma leptin 
concentrations. Moreover, as no variations in leptin concentrations were measured, there 
was no variation observed in dietary intake throughout the test period.    
 
Effects of EGCG on biomarkers of lipid metabolism 
Fresh green tea extract infused intraduodenally (doses equivalent to 1-2 cups of tea) in 
ovariectomised rats significantly lowered the lymphatic absorption of cholesterol in a dose 
dependant manner (Löest et al., 2002). Ovariectomised rats were used here to mimic the 
physiologic conditions of ovarian hormone deficiency or the postmenopausal state in 
which serum levels of cholesterol are elevated with increased risk of CVD (Rosenberg et 
al., 1981). Raederstorff and others (2003) found that a single oral dose of EGCG (0.1 g/kg 
body weight; approximately 20 mg/day) lowered the absorption of cholesterol in a dose 
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dependant manner in rats by increasing faecal excretion of total lipids and cholesterol. In 
the current study, ingestion of 75, 150 and 300 mg EGCG daily for 7 days did not bring 
about any change in total cholesterol, LDL and HDL concentrations in comparison with 
pre-treatment measurements. NEFA concentrations significantly decreased following 
ingestion of 75 mg EGCG indicating a reduction in lipolysis when compared to 
measurements following 150 and 300 mg EGCG ingestion (p = 0.014; Table 4.14). 
Numerous animal and human studies have shown an increased effect of EGCG and green 
tea consumption on fat oxidation after prolonged periods of supplementation (Klaus et al., 
2005; Venables et al., 2008; Wolfram et al., 2005). An optimum dose of EGCG or green 
tea extract (containing other catechins) needs to be deduced in order to observe potential 
lipid lowering and lipolytic effects of EGCG in humans. Perhaps, increasing the dose or 
supplementing for a longer period than in the current study would show significant 
differences. 
 
Effects of EGCG on blood pressure and heart rate 
The reduction of cardiovascular risk factors is vital for the prevention of CVD. 
Hypertension is one of the risk factors and is characterised by increased peripheral vascular 
resistance and oxidative stress in and around vascular endothelial cells (Nakazono et al., 
1991). Yang and others (2004) found that habitual tea consumption exerted a protective 
effect on the development of hypertension. Habitual consumption of green tea (120-599 
ml/day) decreased the risk of developing hypertension by 46% and was further reduced by 
65% for those who drank 600 ml/day for 1 year. This corresponds to an intake of 
approximately 170 – 200 mg of EGCG/day for a year. A possible hypothesis explaining 
the decrease in the incidence of hypertension due to green tea consumption could be that 
the polyphenols in green tea exert antioxidant and vasodilatory effects (Fitzpatrick et al., 
1995; Rice-Evans et al., 1995). In the present study, systolic BP was significantly 
decreased following supplementation with 75 mg EGCG/day for 7 days whilst diastolic BP 
remained unchanged when compared with pre-treatment measurements. The significant 
decrease in systolic BP observed in the current study following ingestion of the lowest 
dose of EGCG could be a false positive and a type 1 error. Analysis of data regarding 
randomisation of doses showed that 5 participants out of 8 received 75mg EGCG dose as 
their final dose and the measurements to record this doses’ effects were carried out in the 
final laboratory test session. It is possible that participants felt more relaxed and were more 
accustomed to the test sessions, which could have lead to lower BP. There were no 
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differences in mean heart rates measured following varying doses of EGCG from pre-
treatment values. Low HR has been shown to decrease progression of CVD (Giannoglou et 
al., 2008; Palatini, 2007; Palatini and Julius, 2004). Randomised controlled trials 
conducted by two research groups investigating the effect of green tea extract (containing 
100 and 200 mg EGCG, respectively) supplemented for 12 weeks among women (46 and 
60 subjects, respectively) found no significant changes in HR over time (Auvichayapat et 
al., 2008; Diepvens et al., 2005). The EGCG quantities employed in these studies ranged 
from 67 – 100 mg/day which might be very low or insufficient to induce any noticeable 
changes. Perhaps, ingestion of doses used in the current study over a longer period might 
demonstrate significant differences as well as further protective physiologic effects on 
hypertension and heart rate.  
4.3.7 Conclusion 
This study aimed to test the in vivo dose response to ingestion of pure EGCG for a period 
of 7 days. Results of the current study did not show any major significant differences in 
key metabolic parameters such as RMR, body fat percentage and dietary intake, all of 
which can affect/are components of, energy balance and therefore may influence risk 
factors associated with obesity. Further trials need to be carried out to observe the action of 
pure EGCG in humans to see if longer periods of supplementation and/or use of green tea 
extract (interaction with other catechins and caffeine) with pure EGCG would increase any 
measured metabolic parameters. 
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4.4 Summary and future directions 
 
4.4.1 Summary of studies investigating oral intake of EGCG  
The anti-oxidant effect of green tea intake has been widely studied, but few human studies 
have been performed to investigate the effect of its principal catechin, EGCG, on 
metabolism and its potential to influence components of energy balance. The second part 
of this thesis report pertains to studies conducted to investigate the effects of EGCG 
ingestion (75 – 300 mg/day) on weight, RMR, FBG, appetite, MST, CT, heart rate, blood 
pressure, associated regulatory hormones (insulin, leptin) and NEFA in healthy men. 
 
The first study investigated the effects of ingestion of an acute dose of 150 mg EGCG, 
over 2.5 hours, in healthy humans. An improvement in glucose tolerance following 150 mg 
EGCG ingestion was not detected when compared with placebo. Plasma insulin, leptin and 
NEFA concentrations were not different following either placebo or EGCG ingestion. It 
may be a possibility that an acute dose of 150 mg was not sufficient to induce changes in 
measured study parameters. Following on from the results of this study, the next study was 
designed to measure the effects of a longer period of EGCG ingestion at varying doses on 
RMR, MST, CT and other metabolic parameters. 
 
The effects of chronic ingestion (7 days) of EGCG was examined, with the aim to study 
effects of differing doses (75, 150 and 300 mg/day) on body weight, thermogenesis, RMR, 
blood glucose and lipid regulation. There were no effects of varying EGCG dose on body 
weight, FBG, body fat composition, MST, CT, dietary intake and leptin. A dose of 75 mg 
EGCG brought about a statistically significant decrease in NEFA concentrations and 
systolic BP. A dose of 150 mg EGCG ingested for 7 days decreased RMR lower than pre-
treatment measurement. These results are difficult to interpret as no changes were 
measured in any of the associated parameters (such as an increase in food intake or weight 
due to decrease in RMR). Perhaps the changes associated with these parameters might 
have been subtle and have had physiological significance but were not statistically 
significant. In conclusion, the effects of EGCG ingestion need to be studied further in 
detail to arrive at conclusions regarding their efficacy in influencing components of energy 
balance and blood glucose regulation.  
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There is some discrepancy between the results from human studies and cultured cell and 
animal models with respect to the effects of EGCG or green tea intake. Two possible 
causes towards the differing activities of EGCG and other catechins according to study 
type, may relate to issues of metabolism and bioavailability in vivo. Studies have 
demonstrated that green tea catechins undergo methylation, glucuronidation and sulfation 
in in-vitro systems and in both animals and humans (Spencer, 2003). Several processes 
including intestinal, microbial and hepatic metabolisms and chemical degradation have 
been found to be involved in the fate of green tea, and to be responsible for its low 
availability in animals, presumably occurring also in humans (Feng, 2006).  
 
Other studies have shown that the low systemic availability of orally ingested tea catechins 
could be a result of slow absorption, high first pass effects, and wide tissue distribution 
(Zhu et al., 2000). Studies investigating dosing conditions and oral bioavailability in 
healthy men found that there was >3.5-fold increase in the average maximum plasma 
concentration of free EGCG when a green tea extract (up to a dose that contains 800 mg 
EGCG) was taken in the fasting condition than when taken with food (Chow et al., 2005). 
Greater oral bioavailability of free catechins can be achieved by taking the EGCG capsules 
on an empty stomach after an overnight fast. In the dose dependant study (Chapter4.3), 
participants were instructed to take the capsule at least 30 minutes before breakfast. Half of 
study participants reported taking the EGCG capsule along with or before lunch and 
reported that taking it mid-day helped them remember the intake.  
 
Data regarding role of dietary proteins in the absorption and bioavailability of tea 
flavonoids are inconclusive. One study reports that proteins can bind with flavonoids 
effectively and could inhibit absorption of tea flavonoids (Shi and Kakuda, 2006). Other 
studies report data that proteins do not inhibit the absorption and bioavailability of tea 
flavanols in humans, as results obtained from investigations in healthy men revealed that 
catechins from green and black tea were rapidly absorbed and addition of milk did not 
impair the bioavailability of tea catechins (Hof et al., 1998; Hollman et al., 2001). As the 
intake of dietary protein did not vary significantly during the course of both studies, the 
usual intake appears not to have hindered the absorption of catechins in these studies. 
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4.4.2 Further directions 
The challenges of investigating single or composite dietary components in ‘intervention’ 
mode are multiple. The present thesis has attempted to move a step forward in the 
investigation of qualitative changes in diet with the aim of improving known risk 
parameters in human metabolism.  
 
While there is clearly a significant further body of work required in this field, the decision 
to start with food chemistry having a reasonable theoretical expectation of impact was 
taken. Within the time-frame and technical and financial limitations, real progress was 
made. Firstly, methodologically and in terms of protocol development and secondly in 
challenging the assumption (in the case of EGCG), that an isolated dietary component will 
necessarily have the quasi-pharmacologic effect that prior investigation might suggest. 
Such work is vital to avoid false claims regarding extracted ‘natural’ products, but equally 
allows for constructive thought towards new avenues for research. For example, examining 
the synergies and antagonisms that exist within the components of the biochemical milieu 
of complex foodstuffs, and also by establishing baseline dose and duration data, known to 
be or not to be of useful effect.  
 
Dose: Due to scarcity of data from human studies regarding optimum dose of pure EGCG, 
it is difficult to conclude the most potent dose. One human study tested the effects of a 
single dose of 1600 mg EGCG, which was well tolerated (Ullmann et al., 2003). Other 
animal studies have supplemented single doses of upto 400 mg EGCG, which was well 
tolerated in mice, but lethal in rats (Isbrucker et al., 2006a; Isbrucker et al., 2006b). These 
studies have tested single dose administrations and no data for longer periods of 
supplementation at these doses exist. The maximum dose used in the study might be too 
cautious and possibly doubling this dose may result in significant differences.      
 
Longer periods of supplementation: Epidemiological and longer term studies have shown 
that green tea consumption (>500 mg catechins) for >3 months appears to reduce body 
weight and fat in humans (Chantre and Lairon, 2002; Nagao et al., 2005). When subjects 
take supplements for >3 months it is possible that they may also incorporate other health 
promoting lifestyle changes into their routine such as inclusion of high fibre, low fat diets 
and increased daily physical activity to complement health benefits of tea catechin 
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supplementation. There are no studies performed to investigate the effects of long-term 
ingestion of pure EGCG and as previously conducted green tea supplementation studies 
have influenced components of energy balance, further investigation on green tea’s 
principle catechin over a prolonged period of ingestion is necessary. 
 
Use of green tea extract: Chen and others (1997) observed that EGCG displayed different 
pharmacokinetic behaviours when it was given to rats as one of the tea catechins in 
decaffeinated green tea (DGT) in comparison to when it was given as pure EGCG alone. 
Based on the AUC and Cmax produced per unit of EGCG, the authors concluded that DGT 
seemed to deliver EGCG into the bloodstream more effectively than when EGCG was 
given as a pure compound. They reasoned that this effect was largely due to the property of 
catechins to bind with proteins (Hagerman, 1989). Other tea catechins in DGT compete 
with EGCG for binding to plasma and tissue proteins, thus changing the EGCG 
pharmacokinetic behaviour and therefore prolonging EGCG action in the system. Possibly, 
interaction with other catechins is essential to cause metabolic changes and the effects of 
this interaction need to be investigated future studies.  
 
Use of caffeine with pure EGCG: The thermogenic effects of caffeine via the sympathetic 
system are well documented (Acheson et al., 1980; Astrup et al., 1990). Caffeine inhibits 
adenosine and phosphodiesterases and therefore intracellular concentrations of cAMP 
remain elevated for longer. cAMP is a critical mediator for the thermogenic effects of 
noradrenaline. EGCG inhibits COMT thus prolonging effect of noradrenaline and thus 
increasing cAMP and thermogenesis. When both these agents are combined during 
ingestion, there might be a perceivable increase in EE even after shorter periods of 
supplementation (Dulloo et al., 2000; Westerterp-Plantenga et al., 2006). As the focus of 
the present studies was to investigate the effects of pure EGCG in isolation, caffeine and 
other tea catechins were not supplemented to the study participants.  
 
In both the EGCG supplementation studies, metabolic rate was measured by indirect 
calorimetry using the Deltatrac, which most subjects find tiresome since it involves lying 
still under a hood, after a period of 50-60 minutes. Possibly, the use of a respiratory 
chamber over 24 hours or doubly labelled water might have lead to different results, 
particularly in the acute ingestion study. Both these techniques were unavailable for the 
above conducted studies.  
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Dietary intake before the start or during the study was not stipulated as the study was 
designed to test free-living conditions. A possible prescription and/or analysis of 
percentage intake of macronutrients intake along with maintenance of polyphenol content 
in the diet throughout the study might have shown interesting and differing results from the 
current data. However, the analyses of dietary data from the studies do not show any 
statistically significant difference in dietary intake throughout the study period from 
baseline.  
 
Future studies could involve the collection and analysis of urine and faeces collected over 
24-hour to measure catecholamines and to verify concentrations of EGCG by using high 
performance liquid chromatography to gather details regarding bioavailability and 
absorption of EGCG in humans over different phases of time and also to detect diurnal 
changes if any. Use of Northern blot analysis to study mRNA in order to explore the 
expression of UCPs in WAT would provide more explanations towards the mechanisms of 
EGCG actions in the human body.  
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5 Final conclusion  
The impact of foodstuffs and their constituent ingredients on human health is of interest to 
a wide range of scientists and clinicians, and increasingly to those budgeting health 
delivery systems. With an apparent burgeoning of health problems related to positive 
energy balance, much research (including the present investigations) is being carried out, 
and is needed to elucidate the effects of dietary composition on human well-being. With 
respect to the specifics of energy intake and expenditure, prior basic research into the 
composition of food (in bioenergetic terms) and the components of EE, have allowed 
progress in subtler investigations into the relative impact of individual dietary components 
on energy balance. It is in this context that the present research was carried out. A review 
of the extant literature in the area revealed much interesting work suggesting that there 
indeed may be potential to influence energy intake/expenditure in humans via dietary 
manipulation. The studies outlined in this thesis have been concerned with the effect of 
putative active agents, aimed at influencing aspects of metabolism in normal and 
overweight individuals; specifically to assess effects on EE and body weight. In addition, 
measures of blood glucose regulation were of interest as hyperglycaemia is frequently a 
dysregulation associated with chronic positive energy balance.  
 
While as stated, there is data to suggest that certain dietary agents may be of utility in the 
present context, there is also a clear paucity of well controlled human studies. This is in 
part due to the relatively new arena of nutritional intervention as a quasi-clinical science, 
and also due to the relatively recent emergence of overweight as a clinical as well as 
nutritional challenge (DOH, 2009; NICE, 2006). Having pared down the possible 
compounds meriting further investigation, it was decided as has been described, to evaluate 
the metabolic effects of two dietary interventions, L-Histidine and EGCG. Their effects on 
EE, lipolysis, modulation of blood glucose and cholesterol concentrations were the chief 
focus and measurements representing them were carried out in the studies. The stability of 
energy balance in the human body is regulated in large-part by neurochemical activity and 
both the dietary agents in question have the potential to influence neurochemical activity 
and affect various facets of energy balance and were therefore chosen to be studied. 
 
It was hypothesised that the supplementation with L-Histidine and EGCG among healthy 
subjects would increase EE, decrease fasting blood glucose and lipid concentrations and 
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affect other parameters of energy balance (such as reduction in dietary intake and increased 
lipolysis). The effects of both L-Histidine and EGCG on these parameters however were 
inconclusive, as shown by the results of the studies. This is perhaps surprising in view of 
the animal data available (Kasoaka et al., 2004; Masaki et al., 2001; Morimoto et al., 1999; 
Sakata et al., 1997; Yasuda et al., 2004a; Yoshimatsu et al., 2002b; Yoshimatsu et al., 
1999) which clearly suggests potential for modulation of these parameters.  
 
The pilot study into L-Histidine did however demonstrate that RMR, MST and CT 
measurements can be performed simultaneously. Following ingestion of L-Histidine for 10 
days, there was a significant decrease in body weight and fasting blood glucose levels but 
this was not apparent when the same dose was ingested for a longer period (8 weeks). In 
addition it has been shown that (at the dose used) there is no ‘sensitisation’ to Histidine 
with a longer duration (10 days/8weeks) failing to produce a more marked response in the 
parameters of interest. Upregulation of systems to enhance sensitivity (e.g. during nicotine 
addiction, sensitivity to nicotine is augmented by upregulation of nicotinic acetylcholine 
receptors which modulate the release of dopamine (Govind et al., 2009)) is not uncommon, 
but was not apparent in the present study of L-Histidine in connection with the parameters 
measured.  
 
Human studies have not previously been carried out to investigate effects of oral ingestion 
of L-Histidine on the above mentioned parameters and there are doubtless other avenues to 
explore with respect to this essential amino acid. Such ideas have been outlined in the 
discussion of the findings of the L-Histidine studies (section 3.5.1 and 3.5.2). It is likely 
that Histidine works synergistically with other compounds (e.g. with zinc (Song et al., 
2001) or agonistically (rather than its metabolite histamine acting directly as a 
neurotransmitter) at specific neural sites to enhance the effect of other energy regulating 
substances (e.g. involvement with leptin-induced decrease in food intake (Fulop et al., 
2003; Itateyama et al ., 2003; Morimoto et al., 1999; Toftegaard et al., 2003;Yoshimatsu et 
al., 1999). Such interactions will probably be the focus of future work as neurobiological 
investigative techniques progress, allowing clearer insights into CNS system specific 
processes and adaptations.  
 
EGCG supplementation in humans has been studied somewhat more in humans than has L-
Histidine supplementation. EGCG in animals and humans has demonstrated effects in 
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terms of increased EE and improved blood glucose and lipid profiles (where dysregulation 
was present), probably acting at its receptors (e.g. in adipocytes, liver and skeletal muscle; 
Fujimura et al., 2008). Some of the effects previously demonstrated in humans are: 
increased EE and lipolysis, thus aiding decrease in body weight by inhibiting COMT and 
prolonging the effect of noradrenaline (Dulloo et al., 1999; Westerterp-Plantenga et al., 
2005); promoting insulin action in skeletal muscles and adipocytes, by this means, exerting 
a relative hypoglycaemic effect (Hill et al., 2007; Tsuneki et al., 2004). Most of these 
studies however supplement other tea catechins along with EGCG, some also with 
caffeine. For these reasons, the exact dose and supplementation period required to affect 
parameters of energy balance remains unknown.  
 
The EGCG studies presented in the current text aimed to address these two aspects. 
Importantly, results from the present studies do not provide confirmation of previously 
demonstrated effects. Ingestion of 150mg EGCG over a period of 2.5 hours did not affect 
RMR or blood glucose response following OGTT. The ingestion of varying doses of 
EGCG (75, 150 and 300mg/day), each for a period of 7 days, did not bring about variations 
in body weight, RMR, blood glucose or lipid concentrations. The effects of pure EGCG on 
the parameters studied herein have not previously been studied, therefore is quite likely 
that previous studies (Dulloo et al., 1999; Tsuneki et al., 2004; Westerterp-Plantenga et al., 
2005) that have observed significant increases in EE and/or reductions in blood glucose, 
have done so through the action of other components of green tea. Frequently these include 
caffeine which is known to increase EE and lipolysis (Dulloo et al., 1999; Westerterp-
Plantenga et al., 2005).  
 
EGCG intake is safe and non-toxic and as is available as a white, odourless powder which 
could be used as an additive to many foodstuffs. If its effects on regulation of energy 
balance are established, it could potentially be a candidate for the status of a ‘functional 
food’ additive. However the present study has raised the caveat that when EGCG is 
dissected out from the biochemical milieu of its plant origin, much of the potency of 
expected effects seems to be lost. It remains the case however that EGCG appears capable 
of increasing insulin sensitivity as demonstrated by Tsuneki et al (2004) and demonstrates 
significant anti-oxidant capacity (Shi and Kakuda, 2006). It is probable that other 
important functional capacities will emerge through careful study of its action alone but 
also in combination with other compounds. Examples of nutritional compounds that ‘fail to 
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deliver’ when extracted and isolated are not uncommon, (e.g beta carotene and its anti-
oxidant effects (Palozza et al., 2003)). Thus the challenge for nutritional scientists and 
biochemists is great, inasmuch as dose and duration and also precise compositional 
considerations need painstaking consideration in terms of study design and 
implementation. 
 
Concluding Remarks 
 
The studies described in this thesis are novel. The effect of oral ingestion of L-Histidine on 
parameters of energy balance has not been studied previously in humans. Equally the 
methodological development and application of a novel multi-compartment model of 
energy expenditure, measured in real time post nutritional intervention, has been realised. 
Such measurements have potential application in any investigation where energy 
expenditure and its differential and site specific expression are of research interest.  
 
With respect to EGCG, the present data strongly suggest that as an isolate from Camellia 
Sinensis, this catechin may have physiological and clinical importance, but in which 
precise capacity remains unclear. The translation from epidemiological observation of 
dietary intake and related health status, to a reductionist biopharmacological model capable 
of clinical and/or public health application is clearly a lengthy and (frequently) iterative 
process.  
 
Nutritional biochemistry and its potential clinical utility are in a relative state of infancy 
compared to traditional physiology and clinical chemistry. It is hoped that research such as 
is presented in the present document represents a step towards the inclusion and 
recognition of human nutritional science as a key theme in the human physical and health 
sciences.  
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7 Appendix 
 
Appendix 1 - Dietary supplements to aid in weight reduction, available without prescription 
Described below are the representations of a few of the dietary supplements available to be purchased on the high street. The purported 
mechanism of action is described and quoted in the exact language of the manufacturers. Each supplement is also usually a combination of 
products and there is little evidence to support their efficacy in weight reduction  
Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
Lipobind fat 
binder  
Patented fibre complex 
from organic plant source 
2-3 tablets 
immediately 
after each meal 
Lipobind actively binds to fat as soon as they come into contact in the 
stomach, creating a fat-fibre. As the fat-fibre is formed, a gel surrounds it, 
creating a barrier from stomach acids and the break-down process. It is 
purported to decrease food cravings, suppresses the appetite and lowers blood 
cholesterol. 
Formoline 
L112 Weight 
Management 
Tablets 
β-1,4 polymer of D-
glucosamine and N-
acetyl-D-glucosamine 
from shells of crustaceans 
2 tablets, twice 
daily 
A naturally sourced fibre with an extremely high fat-binding capacity, which 
binds to (or adsorb) a substantial amount of dietary fats from food in the 
digestive tract. The active ingredient is not digestible and is excreted 
naturally, together with the bound fats, significantly reducing the calories 
your body can process from the food you have just eaten. 
Slimthru® 
Natural 
Weight Loss 
Liquid  
Fat emulsion (water 
26.7%, fractionated palm 
oil 2%, fractionated oat 
oil) 
7.5ml serving 
at breakfast and 
once at 
lunchtime 
Provides greater satiety and less hunger feeling between meals. 
Zotrim  
 
Yerba Mate  
Guarana (contains 
caffeine)  
Damiana 
1 tab tds These ingredients are designed to slow the rate at which the stomach is 
emptied. It makes one feel full more quickly and therefore eat less. This may 
help develop a regime for better management of the amount of food 
consumed. 
Adios 
 
Butternut 20mg, 
Dandelion root 30mg, 
1 tablet 3 or 4 
times a day at 
Adios help lose weight naturally by speeding up your body's metabolic rate 
and stimulating fat metabolism. 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
Dry extract boldo 4:1 
34mg, Dry extract of 
fucus 5:1 45mg 
mealtimes 
Adios Max  
 
Contains 120mg dry 
fucus extract (the 
equivalent of 600mg 
fucus - a species of sea 
weed) 
1 tablet tds Adios Max contains a natural herbal active ingredient called fucus dry extract 
which derives from a type of algae. The fucus dry extract helps loose weight 
by speeding up the body's metabolism as long as it is taken along side a 
calorie controlled diet. 
Lamberts 
Green Tea 
Extract2750mg 
250mg of catechins from 
whole green tea leaves 
and L-Theanine. 
1-2 tablet with 
every meal 
Increases metabolic rate. It is also a powerful antioxidant and free radical 
scavenger.  
Maximuscle 
Weight 
Management 
System CLA - 
1000 
800mg of CLA, 
Extracted from high 
quality safflower oil,  
Contains natural levels of 
Capric acid 
3- 6 caps daily, 
according to 
your 
requirements 
Supports lean muscle growth and weight management goals, contains 
naturally occurring fatty acids. 
 
Bioforce Helix 
slim tablets 
Extract of Helianthus 
tuberosus (Jerusalem 
Artichoke), 
microcrystalline cellulose 
and hydrated cotton seed 
oil. 
1 tablet, tds Helianthus slows down the rate at which sugars are broken down in the body 
prolonging the digestion of food, slowing down hunger pangs. Better 
metabolism of sugars also balances out swings in blood sugar levels, reducing 
sugar cravings that come when blood sugar levels drop. Helianthus contains 
plant sugars that feed friendly bacteria in the gut, and these bacteria break 
down undigested food particles. As Helianthus also contains water soluble 
plant fibres, it helps to bulk up waste matters travelling through the colon and 
thus improves bowel regularity. 
Dandelion 
50ml 
Tinctures of organically 
grown fresh leaves and 
roots of Taraxacum 
officinalis (Dandelion), 
extracted in alcohol (50% 
v/v). 
5 drops in  
water, 3 times 
daily 
Dandelion is an excellent cleansing agent, being one of the most effective 
detoxifying herbs. It possesses a wide range of active constituents and is also rich in 
minerals and nutrients. The root of the plant stimulates liver function. This has a 
primary use in improving digestion as a result of an increase in digestive juices. In 
addition, Dandelion leaves have diuretic and mild laxative properties. 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
Lamberts 
chromium 
complex 
100mg    Vitamin C 
5mg Thiamine 
5mg Niacin 
5mg Vitamin B6 
300mg Magnesium 
15mg Zinc 
500µg Copper 
200µg  GTF Chromium 
1 tablet daily 
with a meal 
Chromium helps the body to use insulin, so helps the body maintain normal blood 
sugar levels. In people with insulin resistance (syndrome X) it may help 
prevent the onset of diabetes, by allowing the body to use insulin more 
effectively. Because chromium has an effect on blood sugar levels it can also 
relieve headaches, irritability and mood swings caused by low blood sugar levels. 
It is also important for the break down of fat and protein in the body. Because 
chromium helps to break down fats, it may also lower total blood cholesterol 
levels, reduce LDL cholesterol and increase HDL cholesterol. 
Lamberts 5-
HTP 
L-5-Hydroxytrytophan 
100mg 
(natural extract from the 
seeds of Griffonia 
simplicifolia) 
 
3 tablets daily, 
half an hour 
before meals or 
half an hour 
before bedtime 
5-HTP is converted, in the brain, into serotonin, which influences everything 
from appetite, to mood, to sleep. 
Fat stripper Choline 150mg 
Inositol 150mg 
Betaine150mg 
Methionine 150mg 
L-carnitine 10mg 
Chromium Piccolinate 
50μg 
1-2 tablets 3 
tds (just before 
meals) 
Fat Stripper’s unique fat burner formula contains L-Carnitine which is a very 
strong fat oxidiser and fat burner, great for weight loss and fat loss; this 
product removes unwanted fat from the body.  
Nobese Octopamine 100mg 
Pomegranate Extract 
80mgs 
L-tyrosine 50mg 
Guarana 50mg 
L-carnitine 50mg 
Green Tea Extract 
50mg 
Ginger 10mg 
1-2 tablets, tds, 
15 minutes 
before meals 
Nobese is a fat metaboliser. It breaks fat down. Nobese is a diuretic. Once fat 
has broken down, it accelerates its exit through the water channels. Nobese is 
also a thyrothermogenic formula in that it assists your body in coming out of 
its lazy state and kicks it into high gear. Nobese leaves absolutely nothing to 
chance. It will work for anyone from very fat individuals to people who want 
to get rid of love handles to people who just want to tone up. 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
Sea Vegetable Extract 
30mg 
Shaper 100% Pure 
Pharmaceutical Grade 
Calcium Pyruvate 
250mg 
 
2-4 tablets, 2-4 
times a day 
with a meal or 
a full glass of 
water 
Two turns of the Krebs cycle metabolises each glycogen molecule (for 
energy). The faster the Krebs cycle can turn, the more energy you will have. 
Shaper will accelerate the turning of the Krebs cycle, meaning you will have 
more energy, safely and naturally. Shaper gives you more energy, less fat and 
better performance. 
Anti fat Betaine 75mg 
Cayenne 5mg 
Choline 75mg 
Chromium Piccolinate 
50μg 
Cinnamon Powder 75mg 
Inositol 75mg 
Methionine 75mg 
Mustard Seed Powder 
75mgs 
 
1-2 tablets, tds 
just 10-15 
minutes before 
meals  
Anti-Fat is a super-strong fat metaboliser and a thermogenic agent all in one! 
This product is similar to LA Muscle's FatStripper in that it is a fat 
"metaboliser". Anti-Fat contains many of the ingredients in FatStripper at a 
smaller dosage. Anti-Fat also contains 3 unique and extremely effective fat-
burning herbs. 
Sida Cordiflia 
by Reflex 
White Willow Bark 
(Salicin (Aspirin)) 100mg 
Sida Cordifolia 125mg 
Guarana (Caffeine) 450mg 
2 caps, tds A thermogenic fat burner. This product may suppress appetite, help burn body 
fat, and increase energy levels. 
 
 
Xenadrine 
EFX 
Vitamin C 100 mg  
Vitamin B6 10 mg  
Pantothenic Acid 12mg 
Magnesium 10 mg  
Proprietary Thermodyne 
Complex 1415 mg  
Tyroplex (proprietary 
blend of l-tyrosine and 
2 caps, tds  It is the first product ever to be powered by an ultra-potent blend of natural, 
clinically proven metabolic compounds that work synergistically to produce 
unprecedented fat-burning results - without containing ephedrine. It has an 
ability to increase metabolism and promote the fastest possible fat-loss, 
muscle-sparing results. Xenadrine-EFX is much more effective at promoting 
rapid fat loss because it directly targets a multitude of key metabolic 
pathways, simultaneously. And on the way, this one-of-a-kind supplement 
also greatly enhances mental focus and acuity, increases energy, suppresses 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
acetyl-l-tyrosine), Green 
Tea Extract (standardized 
for EGCG and caffeine), 
Seropro (proprietary 
cocoa extract 
standardized for PEA 
(phenylethylamine), 
tyramine and 
theobromine), Yerba 
Mate (standardized for 
caffeine), di-Methionine, 
Ginger Root 
(standardized for 
gingerols), Isotherm 
(proprietary blend of 
quercetin and fisetin), 
Bitter Orange 
(standardized for 
synephrine), DMAE (2-
dimethylaminoethanol), 
Grape Seed Extract. 
appetite and provides valuable antioxidant activity, all at the same time. 
Potter’s 
Femmeherb 
slim aid  
Dry Extract Boldo 
(5:1 concentrate) 27mg 
(Equivalent to 135mg 
Boldo, containing 0.5% 
alkaloids)  
Butternut Bark 10mg 
Dandelion Root 30mg 
Dry Extract Fucus 
(5:1 concentrate) 45mg 
1-2 tabs, tds Slim Aid is a traditional herbal remedy used as an aid to slimming. Fucus 
(seaweed) is a mild thyroid stimulant so helping to increase your metabolic 
rate. Boldo and Dandelion support liver function which is a vital organ in the 
digestive process. Butternut acts as a mild laxative helping you to gently 
remove waste products from the body. 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
(Equivalent to 225mg 
Fucus) 
Lean system 7 Green Tea leaf extract
300mg 
Yerba mate 500mg 
Guarana 700mg 
Chromium 200μg  
Dandelion 250mg 
Bioperine 5mg 
3 capsules, 
twice a day, 30 
minutes prior 
to meals and/or 
exercise. 
Lean System 7 is a dietary supplement to promote safe, effective fat loss (not 
to be confused with weight loss, which is normally mostly water and muscle 
loss). Lean System 7 provides a precise synergistic blend of seven powerful 
"fat-fighting" ingredients that have been shown in recent studies to help you 
get and stay lean - safely and effectively, without the use of harmful 
stimulants (like ephedrine). 
Eat and cheat 100% Pharmaceutical 
Grade Chitosan 
250mg 
 
4 tablets, 30 
minutes before 
fatty foods 
Eat & Cheat is a great supplement for anyone who wants to eat the occasional 
fatty food without getting fat. Eat & Cheat contains an exclusive active 
ingredient which binds to fat and removes it from your body before it gets 
stuck. 
Nordic 
BioFirm 
Chicory root (radix 
chichorii), 2000 mg, 
Citrus pulp, 780 mg, 
Nettle (urtica dioica), 740 
mg, Dandelion 
(taraxacum officinalis), 
600 mg, Citrus fibres 
(biopectin®), 600 mg, 
Psyllium (semen 
isphagula), 600 mg, 
Asparagus (asparagus 
officinalis), 510 mg, 
Globe artichoke (cynara 
scolymus), 444 mg, 
Celery seed (apium 
graviolens), 300 mg, 
Thyme (thymus vulgaris), 
2 tablets, tds Nordic BioFirm has developed a special form of pectin. This important 
ingredient ensures that there is a good supply of nutrients to the skin and 
helps to reduce the waste and fluid stored between the cells in the tissues. 
Therefore, BioFirm also helps to reduce cellulite and at the same time 
strengthens the connective tissue. BioFirm formula cleanses the body, firms 
the skin and tones the system. 
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Brand name Active compound Recommended 
dosage 
Purported action/mechanism* 
125 mg 
tds- three times a day; *Explanation of purported mechanism taken from description given with the supplement (their own words); Data obtained from internet searches 
from www.expresschemist.co.uk/category_1762_weightloss.html & http://www.boots.com/onlineexperience/flexible_template_2006.jsp?classificationid=1045793 
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Appendix 2 -Ethics application for L-Histidine study 
 
University of Westminster  
Ethics Committee 
Application for Approval of a Proposed Investigation, Demonstration, Research or Experiment 
 
Section 1 
To be completed by all applicants 
 
1.1 PROJECT TITLE: 
 
Effects on blood sugar dysregulation of resistance exercise and macro and micro 
nutrient manipulation. 
 
1.2 APPLICANT DETAILS 
Name:  
 
Varsha Rajashekar 
 
Email: 
 
V.Rajashekar01@wmin.ac.uk 
 
Address: 
B09-4, Alexander Fleming Halls of 
Residence, University of Westminster, 3 
Hoxton Market, London N1 6HG 
 
Telephone Number: 
07774516248 
 
 
 
Please tick relevant box: 
 
Undergraduate        Postgraduate       PhD Student        Staff  
 
 
Section 2 
To be completed when applicable. Please note all applicants with a supervisor(s) 
must ensure the supervisor signs the declaration.  
 
2.1 SUPERVISOR DETAILS 
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Name: 
Dr. Adam Cunliffe 
Email: 
A.Cunliffe@westminster.ac.uk 
 
School/Department: 
School of Biosciences 
Telephone Number: 
020-7911-5000 ext 3580 
 
Declaration:  
In accordance with the University’s Code of Practice Governing the Ethical 
Conduct of Investigations, Demonstrations, Research and Experiments I agree 
that the applicant named in 1.2 above should submit their proposal to the Ethics 
Committee for consideration. 
 
Signed:                                                             Date: 
 
 
Section 3 
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3.1 Does your work relate to any of the following areas? Please tick box: 
 
 Human Participants in Health and Community settings 
 
Work with prescription drugs 
 
Work involving foetal tissue 
 
Drug Studies on human participants  
 
Pre marketing drug trials 
 
3.2 Are you proposing work using participants from any of the following categories: 
 
Prisoners sectioned under the Mental Health Act  
 
Prisoners or arrestees 
 
Persons with severe mental illness 
 
Persons with learning difficulties or brain damage 
 
Persons with a reduced level of consciousness 
 
3.3 Any work where a qualified clinical person is required to:  
Be responsible for all work carried out 
 
Be in attendance when certain procedures are carried out 
 
Ensure that facilities for emergency medical care are at hand 
If you have ticked one or more boxes in Section 3, please contact your supervisor and discuss sending your proposal for external 
approval. More information can be found at: http://intranet.wmin.ac.uk/academicregistrars/staffinfo/ethics/Default.htm 
In addition please complete this form up to section 3, sign the final declaration in section 12 and send it to: Matt Such, Assistant 
Registrar (Student Information), Academic Registrar’s Department 9-18 Euston Centre, London, NW1 3ET.  
If you have not ticked any boxes in section 3 please continue to section 4 
Appendices 
 - 191 - 
Section 4 
 
4.1 Is your work related to any of the following areas? Please tick relevant box:  
 
 Any work involving patients 
 
 Non clinical work involving bodily fluids 
 
 Administering of a non food substance 
 
 Work with children 
 
 Deception of Participants 
 
 Data not already in the public domain that bears on the issues of criminality  
 
 Work which involves participants to reveal medical history 
 
 
If you have ticked one or more boxes in Section 4, your proposal will need approval 
from the University Ethics Committee please continue to fill out the rest of this form 
giving as much detail as possible Proceed to Section 5. Send the completed form to: 
Matt Such, Assistant Registrar (Student Information), Academic Registrar’s 
Department 9-18 Euston Centre, London, NW1 3ET. 
   
If you have not ticked any boxes in Section 3 or 4 does not need approval. Please 
consult the University of Westminster Code of Practice governing the Ethical 
Conduct of Investigations, Demonstrations, Research and Experiments and consult 
with your supervisor. 
  
 
 
 
Section 5 
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5.1 Please provide a brief description of your proposed work below: 
 
In the year 2000, the estimated figures of people suffering from diabetes worldwide 
were 171,000,000 and the estimated figures for the year 2030 is 366,000,000 
(http://www.who.int/diabetes/facts/world_figures/en/index.html). 
Several pathogenetic processes are involved in the development of diabetes. These 
include processes that destroy the beta cells of the pancreas with consequent insulin 
deficiency, and others that result in resistance to insulin action. The abnormalities of 
carbohydrate, fat and protein metabolism are due to deficient action of insulin on 
target tissues resulting from insensitivity or lack of insulin. 
 
Treatment of DM2  
The primary concern in the control of DM2 is the reduction of fasting 
hyperglycaemia, which accounts for most of the secondary complications. Behaviour 
modification coupled with pharmaceutical intervention can both delay the onset of 
diabetes, as well as ameliorate the disease state. Obesity is primary risk factor for 
DM2, and diet restrictions coupled with moderate exercise has been proven 
significantly to enhance insulin sensitivity in both insulin-resistant and diabetic 
patients. However, these treatments only slow the progression to frank diabetes, and 
do not fully restore patients to normal plasma glucose and insulin levels (Saltiel 
1996). 
 
Several drugs are also currently used to improve glucose metabolism in DM2 
sufferers. Insulin secretagogues, such as sulfonylureas, are used to increase insulin 
release and reduce plasma glucose levels. Metformin and thiazolidinediones are also 
being used in the treatment. However, none of these treatments individually cures 
DM2 (and are associated with side effects, anorexia, nausea, vomiting) diarrhoea 
although a combination of behaviour and drug therapies has given new hope that the 
disease can be controlled (Brady, J et al. August 1999). 
 
The uptake and oxidation of fatty acids is diminished in skeletal muscle of type 2 
diabetic subjects during the post absorptive state and during ß –adrenergic 
stimulation. A lowered capacity of skeletal muscle to take up or oxidise plasma fatty 
acids may divert fatty acids toward increased storage in skeletal muscle, which is 
strongly linked to insulin resistance or may divert fatty acids toward other tissues like 
adipose tissue (promoting large adipose tissue stores) or liver (increasing VLDL and 
glucose output) (Blaak, van Aggel-Leijssen et al. 2000). 
 
Generally, plasma FFA oxidation provides the majority of the energy needs during 
low-intensity exercise [<30% of maximal oxygen uptake capacity (O2 max)]. Total 
fat oxidation has been shown to increase with the duration of exercise. The latter has 
been attributed to a progressive increase in peripheral lipolytic rate with concomitant 
increases in plasma FFA, Ra, Rd, and/or Rox. There is evidence to show that 
peripheral lipolysis was high during low intensity exercise (25% VO2 max) and did 
not increase further with more intense exercise (Romijn, Coyle et al, 1993). 
 
Resistance training (which can be classified as low to moderate intensity exercise) 
may induce beneficial changes in insulin sensitivity via muscle mass development, 
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effectively increasing glucose storage, facilitating glucose clearance from the 
circulation, and reducing the amount of insulin required to maintain a normal glucose 
tolerance (Cuff, Meneilly et al, 2003). 
 
Dietary intervention and fat oxidation: 
 
Fat and carbohydrate are the principal substrates that fuel aerobic ATP synthesis in 
skeletal muscle (van Loon 2004). FA levels are strong predictors of muscle insulin 
resistance. Muscle fat content is increased in obesity and more so in type 2 diabetes. 
FFA levels are increased in most obese individuals and acute elevations in FFAs 
cause insulin resistance in muscle and the liver (Bloomgarden 2003). It has been 
argued that a shift to an increased oxidation of fat and decreased CHO use is desirable 
during exercise. 
 
There is adequate data to suggest that increase in fat availability and fat oxidation 
decreases CHO oxidation during exercise (Helge, Watt et al. 2001). Increasing fat 
availability may increase NADH and buffer the fall in the cellular energy charge, 
resulting in reduced glycogenolysis and PDH (pyruvate dehydrogenase) activation 
(Cuff, Meneilly et al. 2003; Spriet and Watt 2003; Jacobs KA, Paul DR et al. 2004). 
Therefore a high fat diet, hypocaloric diet can bring about increased fat oxidation 
which should have favourable consequences on insulin sensitivity as well as body 
weight (Kim, Park et al. 1999; Spriet and Watt 2003) and blood lipids (Cha, Sohn et 
al. 1999; Helge, Watt et al. 2001). 
 
Novel interventions:  
 
Drug treatments for hyperglycaemia and hyperlipidaemic states are costly and not 
without side effects. There is therefore ongoing interest in developing non-
pharmacologic nutritional interventions, which additionally may have low associated 
costs to healthcare providers. Following extensive literature research in this area, two 
potentially efficacious dietary agents have been identified and these are introduced 
below. 
 
Histidine and histidine containing compounds supplementation: 
 
L- Histidine is one such essential amino acid which is a precursor of neuronal 
histamine. Recent study findings indicate that L- histidine suppresses food intake 
through its conversion into histamine in the hypothalamus, which in turn interacts 
with leptin and key neuropeptides involved in the hunger – satiety cycle (Yoshimatsu, 
Chiba et al. 2002). A study conducted at the Penn state University on birds to test the 
appetite- suppressant effect of excessive dietary amino acids in reducing feed intake 
and, in turn, restricting the early rapid growth to minimize metabolic disorders, 
showed that high levels of methionine and histidine caused the greatest depression in 
appetite and that it is possible to use excessive individual amino acids in diets to 
suppress the appetite and early rapid growth to alleviate or minimize metabolic 
disorders (Acar, Patterson et al. 2001). 
 
There is also evidence to indicate that histidine accelerates lipolysis in white adipose 
tissue through activation of the sympathetic nervous system. The regulation of 
lipolysis appears to involve histamine neurons in the brain, probably through the 
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conversion of L-Histidine to histamine in the hypothalamus (Yoshimatsu, Tsuda et al. 
2002). 
 
A further study examined the acute and long-term effects of cyclo (his-pro) (CHP) 
plus zinc and L-Histidine treatment on glucose metabolism in genetically obese 
(ob/ob), type 2 diabetic mice. L - Histidine was effective in decreasing blood glucose 
concentrations in genetically obese (ob/ob), type 2 diabetic mice. These data support 
the hypothesis that histidine may be an important anti-hyperglycaemic agent (Hwang, 
Go et al. 2003). 
 
Histidine is considered an essential amino acid for children and conditionally essential 
amino acids for adults. This means that the body cannot produce (or produce 
sufficient) histidine, and it must be obtained from a dietary source. In children and 
under certain stress conditions the body’s machinery is unable to generate adequate 
levels and supplemental dietary sources may be required in adults. If obesity is 
viewed as a (metabolic) stress state, a clearer understanding of histidine’s effects as a 
dietary supplement is highly desirable. Histidine as a food supplement is not a drug, 
has not been associated with any toxicity, and is available for purchase in the high 
street without prescription in the UK and USA. 
 
Cordyceps sinensis supplementation: 
 
Cordyceps sinensis is yet another nutrient which is now under a lot of research 
worldwide. It is a fungus highly valued in China as a tonic food and herbal medicine 
(Zhu, Halpern et al. 1998). Cs-4 is a standardized mycelial fermentation product of 
Cordy-ceps sinensis, a fungus that has been used for various pharmacologic, 
metabolic, and ergogenic purposes. One study show that CordyMax Cs-4 is effective 
in lowering basal blood glucose and plasma insulin, improving glucose metabolism by 
enhancing insulin sensitivity, and improving oral glucose tolerance (Zhao, Yin et al. 
2002). Another study using a polysaccharide (CS-F30) obtained from the cultural 
mycelium of Cordyceps sinensis showed potent hypoglycaemic activity in genetic 
diabetic mice after intraperitoneal administration, and the plasma glucose level was 
quickly reduced in normal and streptozotocin-induced diabetic mice after intravenous 
administration. Administration of CS-F-30 to normal mice significantly increased the 
activities of hepatic glucokinase, hexokinase and glucose-6-phosphate dehydrogenase, 
although the glycogen content in the liver was reduced. Furthermore, CS-F30 lowered 
the plasma triglyceride level and cholesterol level in mice (Kiho, Yamane et al. 1996; 
Zhu JS 1998). 
 
Cordyceps is a safe, traditional Chinese herb. Investigators in numerous studies 
consider Cordyceps and its mycelial fermentation products very safe during clinical 
use (Zhu JS 1998). The present author has found no report of cordyceps toxicity in the 
literature to date. 
 
In view of the above theories of histidine being an appetite suppressor and an anti-
hyperglycaemic agent and the effect of cordyceps sinensis in enhancing insulin 
sensitivity, the study to check their supplementation in the diets of type II diabetic 
subjects is warranted. This kind of study has not been conducted previously and the 
proposed study will be one among the pioneering works done in this area. 
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Based on the above theories and results obtained, this study will provide non-
pharmacological and relatively inexpensive preventive measures to help maintain a 
euglycaemic condition. 
 
 
5.2 What are the specific aims of the work you plan to carry out? 
 
1. To study the differences in rate of fat oxidation during and after different duration 
of resistance exercise. 
2. To study the change in fat oxidation by altering the macronutrient (fat) intake. 
3. To study the effect of L-Histidine and histidine containing compounds and 
Cordyceps Sinensis supplementation on energy expenditure, and blood sugar levels.  
 
 
5.3 Please outline the design and methodology of your work 
 
Aim:  
To study the effects of resistance exercise and macro and micro nutrient manipulation 
on blood sugar regulation and energy expenditure. 
 
Subject recruitment: 
Initial investigations will be carried out in normal healthy volunteers, recruited from 
colleagues and students within the University of Westminster. Depending on the 
findings of these preliminary studies, further investigations will be carried out in 
populations with blood sugar dysregulation. Recruitment of such subjects will be of 
males and females with elevated fasting blood glucose and achieved via posters in all 
campuses of the university of Westminster, by advertising in daily papers (Evening 
Standard and Metro  - this is a free service for researchers) and by referral from 
collaborating bodies (Royal London Hospital, Marylebone Health Centre, Weight 
Concern). The criteria for recruitment will also include BMI values of 26 and above, 
25 years and above of age.  
 
In addition, using questionnaires (e.g. PAR-Q, fitness for exercise screening tool) and 
different measurement techniques (e.g. blood pressure, cholesterol), subjects will be 
assessed for any health related issues, which might make them unsuitable as test 
subjects (chest pains, respiratory difficulties, heart disease, thyroid disease, orthopedic 
problems). Participants will be excluded if they are taking medications, which are 
expected to alter the results of the study (including medication that would affect 
metabolism or weight loss (psychiatric medication, appetite suppressants, and thyroid 
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medication). Furthermore, subjects who are obese due to a confounding diagnosed 
disease e.g. Cushings syndrome will not be recruited. Any gross deviation from 
expected metabolic rate will quickly be identified by the study and appropriate referral 
made.  
 
The number of subjects required will be determined by sample size calculations once 
pilot studies have been carried out to determine the size of significant differences in 
energy expenditure and metabolic responses that may be observed after ingestion of 
specific macronutrients and after exercise of different intensity and duration. For the 
study to have a 5% significance level (a, two sided), and 80% power (1-b) the sample 
size will be calculated. The standardised difference (sD) will be calculated as the 
physiologically significant difference (PSD) divided by the standard deviations of the 
measures in question, which is energy expenditure and substrate oxidation. 
Plan of investigation: 
Phase I: Assign the subjects randomly into two groups, control group (CG) and 
experiment group (EG). Develop a protocol of resistance exercise of differing duration 
as well as devise a high fat diet for the EG and check the effects of the exercise and 
diet as against the control group. The daily energy intake will be assessed and 
individual energy intake will be determined by calculating the energy needs. The diet 
developed for the EG will be high in fat content but also will be hypocaloric in nature 
reflecting the desired reduction in weight. The fat percentage would be 50% of the 
total energy intake. Of this intake, unsaturated fatty acids will equal to 70-80%, 
equally distributed between poly and monounsaturated fatty acids.(McArdle, Katch et 
al. 2001) 
Phase II: Supplement L-Histidine in the EG and check its effect as an appetite 
suppressant, in blood sugar regulation and energy expenditure. The dosage 
supplemented will be 25mg/kg body weight. 
Phase III: Supplement Cordyceps Sinensis in the EG group and check its effects on 
blood sugar levels and energy expenditure.  The dosage for supplementation will be 2-
3 g/day. 
 
 
Methodology: 
 Determination of body weight (digital balance), height (stadiometer) and body 
composition (plethysmography, BOD-PODÒ) (Elia and Ward 1999; Miyatake, 
Nonaka et al., 1999; Fields and Goran 2000), changes in abdominal, subcutaneous fat 
by anthropometry. 
 Assessment of oxygen consumption, post prandial thermogenesis (PPT) and 
fat/ carbohydrate oxidation (respiratory quotient, RQ) using metabolic monitors 
(Deltatrac II, Oxycon Delta) (Dabbech, Boulier et al., 1996; Marques-Lopes et al., 
2001), body fat percentage calculated using the equations of Siri., 1956). 
 Blood samples for measurement of glucose (Accutrend), insulin, leptin, plasma 
lipids (multi-assay photometry), histidine, (Van Wymelbeke, Louis-Sylvestre et al., 
2001; Kousta et al., 2002; Marques-Lopes et al., 2003; Raben et al., 2003)  
               Dietary recall for assessment of habitual diet. 
 
 Total fat oxidation= 1.67* VO2 - 1.67 * VCO2with VCO2 and VO2 in litres 
per minute. The value 1.67 is derived from the volumes of oxygen consumed and 
carbon dioxide produced in oxidation of 1 g of fat. Because no estimation of protein 
oxidation is included in this calculation of fat oxidation, fat oxidation will be over 
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estimated. However, because fat oxidation is compared before and after exercise 
training, this over estimation will not influence the outcome (Van Aggel-Leijssen, 
Saris et al., 2002). 
 
Data analysis: 
Analysis of data obtained will be carried out. It is envisaged that the general linear 
model of the analysis of variance will be used to assess the effects of exercise and its 
duration, macronutrient content of meal on variation in fat oxidation, effect of 
micronutrient supplementation i.e. L-Histidine and Cordyceps Sinensis on energy 
expenditure, substrate oxidation and blood sugar levels.  These data will reveal which 
of the tested combinations of exercise and macro and micronutrient intake are most 
effective with respect to the parameters tested.  
 
 
5.4  
 
Start date:  January 1 2005 
 
Estimated duration of work: 24 months  
 
5.5 If your work is a multi-centered study, please provide details of any other 
organisations involved 
Contact Name 
 
Contact Name: 
Address Address: 
Telephone Telephone: 
Please attach a copy of any agreement between organisations 
 
Section 6 
 
6.1 Describe any potential physical/ emotional discomforts to participants in the 
investigation: 
 
A momentary discomfort whilst taking blood samples (a qualified phlebotomist will 
be taking the blood samples). 
Possible risk of slight bruising at site of venepuncture for up to 24 hours. 
Possible discomfort because of slight muscle soreness after exercise training in 
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untrained subjects. This passes within a day or two and does not persist if training 
continues. 
 
 
6.2 Aside from 6.1 above, describe potential hazards that may be suffered by the 
participants? Please give details of any measures taken eg. COSH, Risk 
Assessment etc 
 
COSHH form submitted  
 
 
6.3 Outline the degree to which these risks are balanced against potential 
benefits 
 
There should be no risks. Subjects will be monitored at all times during testing. A 
qualified first aider will be present during the initial 3 sessions. Resistance exercise 
selected will be light, easy and without risk. 
 
 
6.4 What criteria will be employed for deciding the end point at which: 
a) The investigation will stop because of unjustifiable further risks?  
b) One method is declared the preferred option and the investigation terminates?
 
Testing will be stopped immediately on request from subject. No risk should arise 
from the planned test procedures. 
 
 
6.5 What monitoring mechanisms will be in place to decide when participants 
should be withdrawn from the research? 
 
Testing will be stopped immediately on request from subject. 
 
 
6.6 What procedures and subsequent observations are to be made on 
participants for the purpose of detecting any complication arising from the 
investigation? 
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No complications envisaged. 
 
 
6.7 Do participants have any previous or existing professional relationship with 
the investigator? 
 
Yes. 
 
 
If yes, please explain the circumstances: 
 
Colleagues, peers, students. 
 
 
Section 7 
Consent of Applicants  
 
7.1 What type of consent will you seek? 
 
Written (including email) 
 
Verbal Only 
 
Not applicable (Please give justification below as to why consent is not applicable) 
 
 
7.2 How and where will you make contact with the participant in order to obtain 
consent? 
 
Contact with the subjects will be made by advertising the study via posters in all 
campuses of the university of Westminster, the London area in general, by advertising 
in daily papers (Evening Standard and Metro (this is a free service for researchers)) 
and by advertising in the premises of the collaborating bodies. 
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7.3 Is there a subject information sheet? 
 
Yes (Please enclose a copy with this application) 
 
No  
7.4 Is parental consent required?  
 
Yes 
 
No 
Section 8 
Confidentiality of Information 
 
8.1 Will the sharing of information be communicated to others working on the 
project? 
 
Yes (Please attach a copy of the Participant Confidentiality Code of Practice which   
              will be used) 
 
No (apart from project supervisors who are full time lectures in the school of 
Biosciences) 
 
8.2 Will the work include: 
 
named participants 
 
 participants whose names have been separately coded 
 
 unnamed participants        
   
 
8.3 Where will locked files of investigation materials be stored? 
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In the human performance laboratory at the University of Westminster,115 New 
Cavendish Street, London WIW 6UW. 
 
 
8.4 If the investigation involves storage of computerised data which might enable 
the participant to be identified, please name the investigator in charge of 
Computer Systems Security for the investigation. 
 
Varsha Rajashekar 
 
 
8.5 Does the investigation and any planned publication include the use of 
photographs or videos either of individuals or of tissues?   
Tissues   Yes  No  
Individuals:  Yes   No  
If yes to either of these, please provide a copy of the consent form which participants 
will be asked to sign for this purpose. 
 
Section 9 
Finance 
 
9.1 Will expenses be paid to participants? 
 
 Yes (Travel expenses will be paid) 
 
 No 
 
9.2 Will a reward over and above expenses be made to participants? 
 
 Yes (If yes, please give more details) 
 
 No 
 
9.3 Is this study initiated/sponsored by a pharmaceutical or other industrial 
company? 
 
 Yes (If yes, what is the name of the company?) 
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 No 
 
    
9.4 Detail any financial or other direct interest to you or to your department 
arising from this study. 
 
None 
 
9.5 Will this project increase work/cost to any other Department or School? 
 
 Yes (If yes, obtain and include the name and signature of the relevant Heads of 
School(s) concerned: 
Name Signature 
  
  
 
 No 
 
 
Section 10  
Insurance  
 
6 (i) Are manufacturers providing insurance cover? 
Yes  No  
If yes, please enclose a letter confirming insurance cover, including the names of all 
covered. 
 
6 (ii) Are all of the investigators employees or student s of the University of 
Westminster? 
Yes  No  
If no, please provide evidence of insurance cover, including: 
a) List of all people involved in the investigation; 
b) Details of the form this cover will take. 
 
6 (iii) Does the investigation involve the use of equipment or medicines? 
Yes    No   
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If yes, please details of manufacturer’s indemnity. 
 
6 (IV) Does the investigations involve the use of equipment or medicines which are 
manufactured on site but are not covered by insurance? 
Yes    No   
If yes, appropriate insurance cover must be arranged and written confirmation of such 
cover must be attached  
 
Section 11 
Declaration  
To be completed by all applicants  
 
Please Read and Sign: The information I have given on this form is true and to the 
best of my knowledge correct: 
 
Signed:                                                    Date: 
 
 
Send the completed form to: Matt Such, Assistant Registrar (Student 
Information), Academic Registrar’s Department 9-18 Euston Centre, London, 
NW1 3ET 
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Appendix 3 -Written Consent Form for L-Histidine study 
 
 
Title of Investigation: To study the effect of dietary supplementation of an amino acid on energy 
expenditure and blood sugar levels.  
 
Volunteer’s Name:   _____________________________________________________ 
Address: ________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
Tel: ___________________________ Email: _______________________________ 
Date of Birth: ___________________ Gender: M/ F 
 
I have read the attached information on the research in which I have been asked to participate and 
have been given a copy to keep. I have had the opportunity to discuss the details and ask questions 
about this information. 
The investigator has explained the nature and purpose of the research and I believe that I 
understand what is being proposed. I have been informed what the proposed study 
involves. 
I understand that my personal involvement and my personal data from this trial will remain 
strictly confidential. Only researchers involved in the investigation will have access. 
I hereby fully and freely consent to participate in the study, which has been fully explained 
to me. I understand that I am free to withdraw from testing at any time. 
 
Volunteer’s Signature: ……………………………………. Date:…………………. 
 
As the investigator responsible for this investigation, I confirm that I have explained to the 
participant named above, the nature and purpose of the research to be undertaken. 
 
 
Investigator’s Name: Varsha Rajashekar     Signature: 
…………………………………….. 
 
If you have any questions about this, please contact: 
Varsha Rajashekar on 020 7911 5000 ext 2830 or 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 
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Appendix 4 -Medical screening form  
 
 
Medical screening questionnaire 
 
 
Date:  
 
This form is used as a pre-participation health and risk factor screening device and should 
be completed prior to the commencement of test. 
 
The information obtained in this medical assessment will be kept as CONFIDENTIAL. 
Only the staff member related to the exercise test may have access to the information.  
 
 
Surname:___________________________________________________ 
 
Given names:________________________________________________ 
 
Date of birth: ________________________________________________ 
 
Address: ____________________________________________________ 
 
________________________________Postcode: ____________________ 
 
Contact Telephone: _______________ (Home)_________________(Work) 
 
 
 
(1) FAMILY MEDICAL HISTORY 
Has any near relative brother (B), sister (S), father (F), mother (M), grandparents (GP) 
suffered: 
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Please tick the appropriate column: 
 
 No Yes Relation Age Details 
Apoplexy (stroke)      
Congenital heart trouble      
Rheumatic heart disease      
Heart operation      
Angina      
Heart attack      
Sudden death      
High blood pressure      
High cholesterol      
“Hardening of arteries”      
Asthma      
Lung disorder      
Bronchitis, emphysema      
Hay fever      
Diabetes      
Gout      
Arthritis      
Epilepsy      
 
 
(2) PAST MEDICAL HISTORY 
Have you suffered any of the following conditions at any time? 
 
Please tick the appropriate column: 
 
 No Yes Details 
Rheumatic or scarlet fever    
Heart trouble or murmur    
Heart palpitation    
High blood pressure    
Heart attack    
Chest pain/ Angina    
Stroke    
Disease of arteries or veins    
Undue limiting shortness of breath with exercise    
Fainting or blackout    
Loss of consciousness or fainting with exercise    
Epilepsy    
Lung or bronchial disease     
Asthma    
Hay fever    
Anaemia    
Diabetes    
Thyroid disease    
Arthritis, rheumatism or gout spondylitis, disc    
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trouble or back injury 
Serious accident or injury    
Surgical operation    
Congenital abnormality    
Other serious illness (or conditions that may 
affect exercise) 
   
For female only: normal/ regular periods    
 
 
(3) PRESENT MEDICAL CONDITION 
 
Are you currently suffering or have you in the recent past suffered any of the following 
conditions? 
 
Please tick the appropriate column: 
 
 Immediately prior to 
the test 
 Yes No 
Cough   
Stuffy nose or sore throat   
Tonsillitis, glandular fever   
Hepatitis   
Diarrhoea/ vomiting   
Headaches   
Shortness of breath   
Pain in chest, left arm or neck at rest, or during physical 
activities 
  
Heart palpitations   
Cramp in legs   
Abnormal loss of blood   
Insomnia   
Indigestion of constipation   
Swollen, stiff or painful joints   
Backache   
Sports injury or other injury   
Other symptom or illness, or surgery   
Any deterioration in training or competitive performance   
Any other conditions that may contraindicate to exercise or 
affect exercise capacity 
  
For female only: currently in pregnancy   
If yes, provide details:   
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(4) CURRENT MEDICATION 
 
This section should also be checked IMMEDIATELY PRIOR TO THE TEST. State the 
name and dosage of any drugs or medicines that you are taking regularly: 
 
Drug Dose Time of last dose 
   
   
   
   
   
 
 
 
 
VOLUNTEER’ SIGNATURE:………………………………………………………... 
 
Thank you for completing this questionnaire. 
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Appendix 5 - Participant information sheet – Acute L-Histidine study 
 
Title of Investigation: To study the effect of a dietary supplement on energy 
expenditure and blood sugar concentrations 
 
Dear Participant, 
 
We invite you to participate in an investigation that we believe to be of potential 
importance. In order to help you to understand what the investigation is about, we are 
providing you with the following information. Be sure you understand it before you agree 
to participate. Please do ask any questions you have about the information, which follows. 
We will do our best to explain and to provide any further information you require. 
 
This study is examining the effects of a particular dietary supplement on blood sugar levels 
and energy expenditure. The proposed study hopes to address and hopefully clarify the best 
strategies for use of new non-drug therapies in overweight subjects and those with blood 
sugar control problems. 
 
We are interested to find out what a particular dietary supplement may have on your 
energy expenditure (calories burned per day) and blood glucose levels when ingested over 
a short period of time. In order to do this we will give you a dietary supplement dissolved 
in 150mls of water to take over a 15 minute period. Some volunteers will be given the 
‘active’ supplement and some will be given dummy (placebo) supplement. You will not 
know which is which. All supplements will contain only food ingredients and there is no 
known risk involved. 
 
As a subject you will be required to come in to the lab for 2 sessions over a period of 2 
weeks. 
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Session 1 
The first session involves measuring height, weight, your resting metabolic rate (RMR) 
and skin and core body temperature. 
 
The measurement of RMR will involve you lying on a bed for 45 minute period with 
breaks of 30 minutes, with a clear perspex hood over your head. You should be in a 
complete state of rest, but not asleep. To encourage this you will be supplied with a set of 
headphones with calming music playing, to block out any external stimuli. At the same 
time, you will be measured for the skin and core temperature. This is done by placing four 
small sensors in various places on your skin i.e. on the chest bone (sternum), forearm, 
thigh and calf. You will also be needed to insert a 10 cm flexible rectal probe in order to 
measure the core temperature. 
 
All equipment is designed to be comfortable during testing and you will be able to stop the 
testing by request at anytime. 
 
During this preliminary session you will also be made familiar with the various procedures 
to be followed in the subsequent sessions and this first session will take approximately 4.5 
hours of your time.  
 
PLEASE REMEMBER: You should not be under the influence of drugs, HUNGER or 
FULLNESS for this first session!!! 
 
Session 2: 
You will be given a different supplement to take and measurements as in session 1 will be 
performed.  
 
Risks: 
1. Air is drawn into the Perspex hood of the metabolic monitor through a valve in the 
loop of the hood. Should this valve become blocked- a problem that has NEVER 
occurred –an alarm will sound. Since a researcher will be in the room at all times 
whilst you are under the hood, there would be immediate assistance available. 
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2. To ensure your safety whilst participating in this study we will ask you to complete 
a health questionnaire, which will give us an indication of whether it is safe for you 
to participate in such activity.  
Note:  A qualified first aider will be present during all test sessions. 
 
CONFIDENTIALITY: 
Your confidentiality will be protected, both in terms of your personal involvement and 
your particular data from the study. Your name will not be associated with any of your data 
that will be used for subsequent analysis. 
 
You are free not to participate and may withdraw from the study at any time without any 
obligation.  
 
Understand that in the event of injury caused by the product defect of a manufacturer, you 
will be compensated. In the unlikely event of injury due to negligence, claims must be 
pursued through legal action. 
 
General information on patient's rights, particularly as regards participation in research 
studies may also be obtained from your local Community Health Council. 
 
Thank you very much for your interest in the study. 
If you have any questions about this, please contact: 
Varsha Rajashekar on 020 7911 5000 ext 3895 or 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 
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Appendix 6 -Participant information sheet – 30 day L-Histidine study 
 
Title of Investigation: To study the effect of a dietary supplement on energy 
expenditure and blood sugar concentrations 
 
Dear Participant, 
 
We invite you to participate in an investigation that we believe to be of potential 
importance. In order to help you to understand what the investigation is about, we are 
providing you with the following information. Be sure you understand it before you agree 
to participate. Please do ask any questions you have about the information, which follows. 
We will do our best to explain and to provide any further information you require. 
 
This study is examining the effects of a particular dietary supplement on blood sugar levels 
and energy expenditure. The proposed study hopes to address and hopefully clarify the best 
strategies for use of new non-drug therapies in overweight subjects and those with blood 
sugar control problems. 
 
We are interested to find out what effect a particular dietary supplement may have on your 
energy expenditure (calories burned per day) and blood glucose levels. In order to do this 
we will give you some supplement capsules to take over a 10-day period and instructions 
on how and when to take them. Volunteers will be given both the ‘active’ capsules and 
dummy (placebo) capsules randomly. You will not know which is which. All the capsules 
will contain only food supplements and there is no known risk involved. 
 
As a subject you will be required to come in to the lab for 3 sessions over a period of 4 
weeks. 
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Session 1 
The first session involves measuring height and weight, determining your body 
composition, your resting metabolic rate (RMR), measuring your skin and core 
temperature, total cholesterol and blood glucose.   
 
For the measurement of body composition, you will have to sit in a BodPod® (specially 
designed chair like device, in which the door can be opened from the inside) for about 3 to 
5 minutes. To ensure accurate measurement, you should wear closely fitted swimsuit, 
which you will need to bring along. Body fat composition will be determined by skinfold 
measurement technique as well. This involves pinching the skin at specific areas such as 
the upper back, mid upper arm, and waist area. This pinched up skin will be measured with 
the help of Harpenden callipers and would take less than a minute at each site. These tests 
and the equipments used are completely safe, comfortable and easy to carry out. 
 
The measurement of RMR will involve you lying on a bed for 45 minutes with a perspex 
hood over your head. You should be in a complete state of rest, but not asleep. To 
encourage this you will be supplied with a set of headphones with calming music playing, 
to block out any external stimuli. At the same time, you will be measured for the skin and 
core temperature. This is done by placing four small sensors in various places on your skin 
i.e. on the chest bone (sternum), forearm, thigh and calf. You will also be needed to insert a 
10 cm flexible rectal probe in order to measure the core temperature. Following this, 
analysis of glucose, cholesterol by finger prick blood sampling will be done. 
 
You will be given some supplement capsules to take over a 10 day period and instructions 
on how and when to take them and directions to maintain a 3 day food diary will be given. 
All the capsules will contain only food supplements and there is no known risk involved.  
 
All equipments are designed to be comfortable during testing and you will be able to stop 
the testing by request at anytime. During this preliminary session you will also be made 
familiar with the various procedures to be followed in the subsequent sessions and this first 
session will take approximately 3 hours of your time.  
 
PLEASE REMEMBER: You should not be under the influence of alcohol, drugs, 
HUNGER or FULLNESS for all sessions!!! 
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Session 2 and 3: 
Upon arriving at the lab, blood will be drawn for analysis and your height, weight, body 
composition, resting metabolic rate and temperature will be measured (Same as session 1), 
on order to determine the effect of the dietary supplement given. 
 
After completion of testing during the second session, you will be given some more 
supplement capsules to take over the next 10 day period and instructions on how and when 
to take them will be given. You also need to maintain a period of ‘wash-out’ for 10 days 
after the second session and begin taking the second batch of supplements after this and at 
the end of these 10 days you need to come to the lab for a final testing session. 
 
Risks: 
1. Air is drawn into the Perspex hood of the metabolic monitor through a valve in the 
loop of the hood. Should this valve become blocked- a problem that has NEVER 
occurred – an alarm will sound. Since a researcher will be in the room at all times 
whilst you are under the hood, there would be immediate assistance available. 
1. To ensure your safety whilst participating in this study we will ask you to complete 
a health questionnaire, which will give us an indication of whether it is safe for you 
to participate in such activity.  
Note: A qualified first aider will be present during all test sessions. 
 
 
 
Measurement of blood 
glucose and cholesterol 
by finger prick. 
3 hours
Arrive at lab 
Measurement of 
height and weight 
Complete health 
questionnaire 
Measurement of 
body composition 
Lie on bed with hood over the head 
for RMR measurement 45 minutes, 
also with temperature sensors 
attached.
Quick run through following 
protocols, information on 
how to keep a food dairy 
End of session 
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CONFIDENTIALITY: 
Your confidentiality will be protected, both in terms of your personal involvement and 
your particular data from the study. Your name will not be associated with any of your data 
that will be used for subsequent analysis. 
 
You are free not to participate and may withdraw from the study at any time without any 
obligation.  
 
Understand that in the event of injury caused by the product defect of a manufacturer, you 
will be compensated. In the unlikely event of injury due to negligence, claims must be 
pursued through legal action. 
 
General information on patient's rights, particularly as regards participation in research 
studies may also be obtained from your local Community Health Council. 
 
Thank you very much for your interest in the study. 
If you have any questions about this, please contact: 
Varsha Rajashekar on 020 7911 5000 ext 3895 or 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 
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Appendix 7 -Participant information sheet – 8 week L-Histidine study 
 
Title of Investigation: To study the effect of a dietary supplement on energy 
expenditure and blood sugar regulation 
 
Dear Participant, 
 
We invite you to participate in an investigation that we believe to be of potential 
importance. In order to help you to understand what the investigation is about, we are 
providing you with the following information. Be sure you understand it before you agree 
to participate. Please do ask any questions you have about the information, which follows. 
We will do our best to explain and to provide any further information you require. 
 
This study is examining the effects of a dietary supplement on blood sugar levels and 
energy expenditure. The proposed study hopes to address and hopefully clarify the best 
strategies for use of new non-drug therapies in overweight people and those with blood 
sugar control problems. 
 
We are interested to find out what a particular dietary supplement may have on your 
energy expenditure (calories burned per day), blood glucose levels, cholesterol, mean skin 
and core temperature. In order to do this we will give you some supplement capsules to 
take over an eight week period and instructions on how and when to take them. Some 
volunteers will be given the ‘active’ capsules and some will be given dummy (placebo) 
capsules. You will not know which is which. All the capsules will contain only amino acid 
food supplements and there is no known risk involved. 
 
As a participant, you will be required to come in to the lab for 3 sessions over a period of 
8 weeks. 
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Session 1 
During this preliminary session you will also be made familiar with the various procedures 
to be followed in the subsequent sessions and this first session will take approximately 2 
hours of your time. 
  
The first session involves measuring height and weight, resting metabolic rate (RMR), 
body fat measurement by skin fold measurements (anthropometry) along with 
measurements of fasting blood sugar, insulin, leptin, and cholesterol and your mean skin 
and core temperature.   
 
For the measurement of body composition, you will have to sit in a BodPod® (specially 
designed chair like device, in which the door can be opened from the inside) for about 3 to 
5 minutes. To ensure accurate measurement, you should wear closely fitting swimsuit, 
which you will need to bring along. This test and the equipment used are completely safe, 
comfortable and easy to carry out. Your body fat will also be measured by skin fold 
measurements by the use of equipment called the Harpenden callipers. Skin folds are 
measured at four different sites in the body i.e. the back (sub scapular), the front of the 
upper arm (biceps), back of the upper arm (triceps) and the waist area (supraspinale). 
 
The measurement of resting metabolic rate will involve you lying on a bed for 45 minutes 
with a clear perspex hood over your head. You should be in a complete state of rest, but 
not asleep. To encourage this you will be supplied with a set of headphones with calming 
music playing, to block out any distractions. At the same time, you will be measured for 
the skin and core temperature. This is done by placing four small sensors in various places 
on your skin i.e. on the chest bone (sternum), forearm, thigh and calf. You will also be 
needed to insert a 10 cm flexible rectal probe in order to measure the core temperature. 
 
All equipments are designed to be comfortable during testing and you will be able to 
stop the testing by request at anytime. 
 
After the RMR measurement, blood will be drawn from the vein (venepuncture) as well as 
from the finger (finger prick) for analysis of blood sugar, cholesterol, insulin, leptin. You 
will be given the supplement capsules to take over a four-week period and instructions on 
how and when to take them will be given. All the capsules will contain only food 
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supplements and there is no known risk involved. During the study, it is necessary for you 
maintain a three day food diary, once during the start of the study and again during the last 
three days of the study. You will be provided by a photographic food guide to help you 
maintain the food diary with ease. 
 
PLEASE REMEMBER: You should not be under the influence of alcohol, drugs, and 
should be in a fasted state for all the sessions. 
 
 
Figure: Summary of session 1. 
 
Session 2 and 3: 
Upon arriving at the lab, your  weight, body composition, resting metabolic rate and skin 
fold measurements and skin and core temperature will be measured and blood tests will be 
performed(Same as in session 1), in order to determine the effect of the dietary supplement 
given. 
 
 
 
 
 
 
 
 
 
 
Session 2 (Week 5) intermediate testing 
at the lab, continue taking supplement 
Session 1 (Week 1) testing at the lab, start 
taking supplement
Maintain food diary 
for first 3 days  
Maintain food diary 
for last 3 days  
Session 3 (Week 9) final testing at the 
lab, stop taking supplement 
Overview of 
week 1 to 8 
1.5 hours 
Arrive at lab 
Measurement of 
height and weight 
Complete health 
questionnaire 
Measurements of body fat by 
skin fold measurements 
Lie on bed with hood over the head for 
baseline measurement for 45 minutes 
along with the skin and core temperature 
sensors
Quick run through following 
protocols, supplement, information on 
how to keep a food dairy 
End of session Collection of blood by finger 
prick and venepuncture  
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Risks: 
3. The blood taken during the sessions will be from a vein in the arm. This will be 
carried out by someone highly experienced in taking blood. In some rare cases, you 
may have slight bruising for up to 24 hours. A total of 20ml of blood will be taken, 
which is a very small fraction (approximately 3%) of what an individual would 
give when donating blood and it is therefore extremely unlikely you would 
experience any adverse effects. 
4. To ensure your safety whilst participating in this study we will ask you to complete 
a health questionnaire, which will give us an indication of whether it is safe for you 
to participate in such activity.  
 
Note: A qualified first aider will be present during all test sessions. 
 
CONFIDENTIALITY: 
Your confidentiality will be protected, both in terms of your personal involvement and 
your particular data from the study. Your name will not be associated with any of your data 
that will be used for subsequent analysis. The data obtained from the study will be 
accessible only by the principal investigator and the supervisory team. 
 
You are free not to participate and may withdraw from the study at any time without any 
obligation.  
 
CLAIMS: 
Understand that in the event of injury caused by the product defect of a manufacturer, you 
will be compensated. In the unlikely event of injury due to negligence, claims must be 
pursued through legal action. 
 
FEEDBACK: 
Would you like to be aware of the results/outcome of the study? If you wish to receive 
feedback from the study we are most happy to provide it to you in the form of journal 
articles or any other publications arising from the data collected during the study. 
 
If you have any questions about this, please contact: 
Varsha Rajashekar on 020 7911 5000 ext 2830 or v.rajashekar01@wmin.ac.uk 
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Dr. Adam Cunliffe on 020 7911 5000 ext 3580 or a.cunliffe@wmin.ac.uk 
 
Thank you very much for your interest in the study. 
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Appendix 8 - Ethics application form for EGCG study 
 
OFFICE USE:        /   /   
University of Westminster 
University Ethics Committee 
 
Application for Approval of a Proposed Investigation, Demonstration, Research or 
Experiment  
 
Section 1 – to be completed by all applicants 
 
1.1 Project Title 
 
Effects of Micronutrient manipulation on energy expenditure and blood glucose 
regulation 
 
1.2 Applicant Details 
Name: 
 
Varsha Rajashekar 
 
 
Email: 
 
V.Rajashekar01@wmin.ac.uk 
 
Address: 
 
Flat 5, 37, Muswell Hill, London N10 
3PN 
 
Telephone Number: 
 
07774516248 
Please tick relevant box: 
 
Undergraduate Postgraduate   ;PhD Student   Staff  
 
    
 
Section 2 – to be completed when applicable 
 
Please note that all applicants with a supervisor(s) must ensure that the supervisor 
signs the declaration. All staff must obtain the signature of their Dean of School, or 
School Research Director, as appropriate.  
 
2.1 Supervisor Details 
 
Name: 
 
Dr. Adam Cunliffe 
 
Email: 
 
A.Cunliffe@westminster.ac.uk 
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School/Department: 
 
School of Biosciences/Dept of Human 
and Health sciences 
 
 
Telephone Number: 
 
020-7911-5000 ext 3580 
 
Declaration: 
 
In accordance with the University’s Code of Practice Governing the Ethical Conduct 
of Investigation, Demonstrations, Research and Experiments, I agree that the 
applicant named in 1.2 above should submit their proposal to the Ethics Committee 
for consideration. 
 
Signed: 
 
 
Date: 
 
 
 
Section 3 
 
 
3.1 Does your work relate to any of the following areas? Please tick box 
 
9Human Participants in Health and Community settings  
 
Work with prescription drugs 
 
Work involving foetal tissue 
 
Drug Studies on human participants  
 
Pre-marketing drug trials  
 
3.2 Are you proposing work using participants from any of the following 
categories? Please tick box:  
 
Prisoners sectioned under the Mental Health Act 
 
Prisoners or arrestees 
 
Persons with severe mental illness 
 
Persons with learning difficulties or brain damage 
 
Persons with a reduced level of consciousness  
 
3.3 Any work where a qualified clinical person is required to: 
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Be responsible for all work carried out 
 
Be in attendance when certain procedures are carried out 
 
Ensure that facilities for emergency medical care are at hand  
 
If you have ticked one or more boxes in Section 3, please contact your supervisor 
and discuss sending your proposal for external approval. More information can be 
found at:  
 
www.wmin.ac.uk/page-3380  
 
In addition, please complete this form up to Section 3, sign the declaration in Section 
11 and send it to:  
 
Carl Hornsey 
Assistant Registrar (Student Information) 
Academic Registrar’s Department 
University of Westminster 
115 New Cavendish Street 
London W1W 6UW 
 
 
If you have not ticked any boxes in Section 3, please continue to Section 4 
 
Section 4 
 
 
4.1 Is your work related to any of the following areas? Please tick relevant box: 
 
Any work involving patients 
 
;Non-clinical work involving bodily fluids 
 
Administering of a non-food substance 
 
Work with children 
 
Deception of participants  
 
Data not already in the public domain that bears on the issues of criminality 
 
;Work which requires participants to reveal medical history  
 
If you have ticked one or more boxes in Section 4, your proposal will need approval 
from the University Ethics Committee – please continue to fill out the rest of this 
form giving as much detail as possible.  
 
If you have not ticked any boxes in Section 3 or Section 4, your work does not 
require approval by the University Ethics Committee. Please refer to the 
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University of Westminster ‘Code of Practice Governing the Ethical Conduct of 
Investigations, Demonstrations, Research and Experiments’ and consult with your 
supervisor.  
 
Section 5  
 
5.1 Please provide a brief description of your proposed work below: 
 
Following extensive literature research in the area of drug treatments for weight 
reduction, hyperglycaemia and hyperlipidaemic states and the ongoing interest in 
developing non-pharmacological interventions, which, additionally, may have low 
associated costs to healthcare providers, a potentially efficacious dietary agent has 
been identified and is introduced below. Review of literature pertaining to the effects 
of green tea infusion or an extract of its major catechin EGCG, on key metabolic 
functions, has identified that human studies are limited and many gaps in the 
knowledge of this area exist. It was therefore selected for further research. 
 
Green tea extract: 
 
Green tea produced from Camellia sinensis is a major source of dietary polyphenol, 
particularly flavonoids. The main flavonoids present include catechins and the four 
major catechins are epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), 
epicatechin-3-gallate (ECG) and epicatechin (EC) (Cabrera et al., 2006).  
 
Wu and colleagues (Wu et al., 2003), in a study conducted on rats, examined the 
effects of green tea supplementation on glucose tolerance and insulin sensitivity. It 
was demonstrated that a 12 weeks supplementation of 0.5g.day-1 green tea lowered 
fasting plasma glucose, insulin, triglycerides and free fatty acids when compared with 
a control group. (Dulloo et al., 1999) identified that green tea extract was more 
effective than an equimolar concentration of caffeine in increasing the 24 hour energy 
expenditure in humans and also increased lipolysis, thus influencing body weight and 
composition. A study (Westerterp-Plantenga et al., 2005) conducted on overweight 
and moderately obese volunteers, both men and women, showed that long term 
supplementation of EGCG (45mg.day-1) along with caffeine (25mg.day-1) brought 
about greater weight maintenance after weight loss, when compared to placebo. This 
supplementation of EGCG along with caffeine also increased thermogenesis, fat 
oxidation and reduced fasting blood parameters of glucose, insulin, triacyl glycerol 
and leptin, which are all important risk factors for metabolic disorders.  
 
A study (Choo, 2003) conducted to examine the effects of green tea on rats fed on a 
high fat diet showed that supplementation with green tea extract not only increased 
energy expenditure, but also prevented any increase in body weight as a consequence 
of the high fat diet. The administration of propranolol (a β-adrenoceptor antagonist) 
inhibited this weight suppressive effect of green tea, indicating that the increased 
thermogenic effect of green tea exerts its effects through β-adrenoceptor activation. 
 
The effect of green tea supplementation and its mechanisms of increasing energy 
expenditure and lipolysis are still unclear, but it is being argued that the polyphenols 
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may inhibit catechol O-methlytrasferase (COMT). This enzyme degrades 
noradrenaline resulting in an increase in noradrenaline release or prolonging its effect 
on thermogenesis and fat metabolism (Dulloo et al., 1999). To observe the metabolic 
changes after green tea supplementation test sessions will involve assessing- 
• Energy expenditure by indirect calorimetry 
• Change in mean skin temperature (MST) and core temperature (CT), heart rate 
and blood pressure 
• Changes in insulin and leptin hormones 
• Oral glucose tolerance  
• Assessment of appetite by the use of visual analogue scales 
• Dietary analysis by the use if diet diary to assess change in food intake 
• Measurement of urinary catecholamines and metabolites. 
 
 
5.2 What are the specific aims of the work you plan to carry out? 
 
To investigate the effects of green tea, future work will involve studies to 
• Measure possible dose response relationships in terms of effects of green tea 
or its principal polyphenol (EGCG) on thermoregulation in lean, healthy men. 
• Investigate fasting glycaemic response and thermogenic response following 
acute (4 hours) supplementation with green tea. 
• Effects of chronic supplementation (10 days) of green tea on thermoregulation 
and energy expenditure in healthy women. 
 
 
5.3 Please outline the design and methodology of your work  
 
Subject recruitment: 
 
Recruitment of subjects will be achieved via posters placed in all campuses of the 
University of Westminster, by advertising in daily papers (Evening Standard and 
Metro - this is a free service for researchers). The criteria for recruitment of healthy 
volunteers will also include body mass index (BMI) values of 20 and above, 18-55 
years of age without any chronic disorders.  
 
In addition, using questionnaires (e.g. medical screening form) and different 
measurement techniques (e.g. blood pressure, cholesterol), subjects will be assessed 
for any health related issues, which might make them unsuitable as test subjects (chest 
pains, respiratory difficulties, heart disease, thyroid disease, orthopedic problems). 
Participants will be excluded if they are taking medications, which are expected to 
alter the results of the study (including medication that would affect metabolism or 
weight loss (psychiatric medication, appetite suppressants, and thyroid medication). 
Furthermore, subjects who are obese due to a confounding diagnosed disease e.g. 
Cushings syndrome will not be recruited. Any gross deviation from expected 
metabolic rate will quickly be identified by the study and appropriate referral made.  
 
The number of subjects required will be determined by sample size calculations once 
pilot studies have been carried out to determine the size of significant differences in 
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energy expenditure and metabolic responses that may be observed after ingestion of 
EGCG and green tea and after differing durations and doses. For the study to have a 
5% significance level (α, two sided), and 80% power (1-β) the sample size will be 
calculated. The standardised difference (sD) will be calculated as the physiologically 
significant difference (PSD) divided by the standard deviations of the measures in 
question, which is energy expenditure. 
 
Study 1 - Effect of EGCG in varying doses (75mg day-1, 150mg day-1, 300mg day-1) 
on metabolic rate, blood glucose and blood lipid regulation. 
 
Aim: 
To study the effects of different doses and arrive at the dose for best potency of 
EGCG. 
 
Subjects:  
Lean and overweight healthy men between the ages of 20-55 years. 
 
Study design:  
Chronic intake (7 day), double blinded crossover study with 7-day wash out period 
between administrations of each dose. 
 
Parameters measured:  
• Basal metabolic rate (BMR) by the use of Deltatrac (indirect calorimetry) 
• Mean Skin Temperature (MST) by skin thermistors 
• Core Temperature (CT) by rectal probe [Volunteers will insert the flexible 
probe of 10 cm themselves, in a private area. The probe will be thoroughly 
sterilised after each use. Participants are free not to use the probe in case of 
any discomfort] 
• Heart rate (HR) by Polar heart rate monitor 
• Body composition by bodpod 
• Diet analysis by the use of 3-day food diary during varied supplementation of  
EGCG 
• Use of visual analogue scales (VAS) for appetite analyses 
• Measurement of insulin, leptin by ELISA 
• Fasting blood glucose by Hemocue 
• Measurement of high density lipoprotein (HDL), low density lipoprotein 
            ( LDL), Total cholesterol (TC) by miniphotometer 
• Urinalysis to measure bioavailability of catecholamines 
• Use of flicker fusion test for assessment of cognitive function.  
 
  
Study 2 - To study the effects of EGCG in comparison to whole green tea on 
metabolic rate, blood glucose and lipid regulation.  
 
Aim: 
To study and compare the effectiveness of EGCG against whole green tea in regards 
to metabolism, blood glucose and lipid regulation. 
 
Subjects:  
Lean and overweight healthy men between the ages of 20-55 years. 
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Study design:  
Chronic intake (7 day), double blinded, placebo controlled, crossover study with 7-
day wash out period between supplementation. 
 
Parameters measured:  
• RMR 
• Mean Skin Temperature (MST) 
• Core Temperature (CT) 
• Heart rate (HR) 
• Body composition by bodpod 
• Diet analysis by the use of 3-day food diary during varied supplementation of 
EGCG 
• Use of visual analogue scales (VAS) for appetite analyses 
• Measurement of insulin, leptin by ELISA 
• Fasting blood glucose by Hemocue 
• Measurement of HDL, LDL, Total cholesterol (TC) by miniphotometer 
• Urinalysis to measure bioavailability of catecholamines 
• Use of flicker fusion test for assessment of cognitive function.  
 
Study 3 – To study the acute effects of EGCG on metabolic rate and response to 
glucose load. 
 
Aim: 
To observe the acute effects of EGCG consumption on metabolism, blood glucose 
and lipid regulation.  
 
Subjects:  
Lean to overweight healthy men between the ages of 20-55 years. 
 
Study design:  
Acute intake (4 hour), double blinded, placebo controlled crossover study with 7-day 
wash out period between supplementation. 
 
Parameters measured:  
• RMR 
• Mean Skin Temperature (MST) 
• Core Temperature (CT) 
• Heart rate (HR) 
• Body composition by bodpod 
• Diet analysis by the use of 3-day food diary  
• Use of visual analogue scales (VAS) for appetite analyses 
• Measurement of insulin, leptin by ELISA 
• Oral glucose tolerance test and measurement of fasting blood glucose by 
Hemocue 
• Measurement of HDL, LDL, Total cholesterol (TC) by miniphotometer 
• Urinalysis to measure bioavailability of catecholamines 
• Use of flicker fusion test for assessment of cognitive function.  
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Data analysis: 
Analysis of data obtained will be carried out. It is envisaged that the general linear 
model of the analysis of variance will be used to assess the effects of supplementation 
and its duration, macronutrient content of meal on variation in fat oxidation, effect of 
micronutrient supplementation i.e. green tea extract and EGCG on energy 
expenditure, substrate oxidation and blood sugar levels.  These data will reveal which 
of the tested combinations of exercise and macro and micronutrient intake are most 
effective with respect to the parameters tested.  
 
5.4 
 
Start Date: 
 
January 2007 
 
Estimated duration of work: 
 
5 months 
 
5.5 If your work is a multi-centred study, please provide details of any other 
organisations involved  
 
Contact Name 
 
 
Contact Name 
 
 
Address 
 
 
Address 
 
 
Telephone Number Telephone Number 
 
 
Please provide a copy of any agreement between the organisations  
 
Section 6 
 
6.1 Describe any potential physical/emotional discomforts to participants in the 
investigation:  
 
• A momentary discomfort whilst taking blood samples (a qualified 
phlebotomist will be taking the blood samples). 
• Possible risk of slight bruising at site of venepuncture for up to 24 hours. 
 
 
 
6.2 Aside from 6.1 above, describe potential hazards which may be suffered by 
the participants? Please give details of any measures taken e.g. COSH, Risk 
Assessment etc.  
 
COSHH form submitted and risk assessment performed. 
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6.3 Outline the degree to which these risks are balanced against potential 
benefits  
 
There should be no risks. Subjects will be monitored at all times during testing. A 
qualified first aider will be present during all test sessions. 
 
 
 
6.4 What criteria will be employed for deciding the end point at which: 
 
a) the investigation will stop because of unjustifiable further risk? 
b) one method is declared the preferred option and the investigation 
terminates? 
 
Testing will be stopped immediately on request from subject. No risk should arise 
from the planned test procedures. 
 
 
6.5 What monitoring mechanisms will be in place to decide when participants 
should be withdrawn from the research? 
 
Medical screening forms are used to monitor health and fitness of participants in order 
to assess health profile and suitability to continue in the study. Also, the principal 
researcher will follow up the participants closely via email and telephone to monitor 
progress in between test sessions. 
 
6.6 What procedures and subsequent observations are to be made on 
participants for the purpose of detecting any complication arising from the 
investigation? 
 
No complications envisaged which could arise from any equipment or 
supplementation used during the test sessions. 
 
 
6.7 Do participants have any previous or existing professional relationship with 
the investigator? 
 
 
No 
 
 
If yes, please explain the circumstances: 
 
Section 7 – Consent of Applicants  
 
7.1 What type of consent will you seek? 
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;Written (including email)  
 
Verbal only 
 
Not applicable (please give justification below as to why consent is not 
applicable)  
 
 
 
7.2 How and where will you make contact with the participant(s) in order to 
obtain consent? 
 
Contact with the subjects will be made by advertising the study via posters in all 
campuses of the University of Westminster, the London area in general, by 
advertising in daily papers (Evening Standard and Metro (this is a free service for 
researchers)). 
 
 
7.3 Is there a subject information sheet? 
 
;Yes (Please enclose a copy with this application) 
 
No 
 
 
7.4 Is parental consent required? 
 
Yes 
 
;No 
  
 
Section 8 – Confidentiality of Information  
 
8.1 Will the sharing of information be communicated to others working on the 
project? 
 
Yes (Please attach a copy of the Participant Confidentiality Code of Practice 
which will  
       be used) 
 
;No (apart from project supervisors who are full time lectures in the school of 
Biosciences) 
 
 
8.2 Will the work include: 
 
Named participants 
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;Participants whose names have been separately coded 
 
Unnamed participants 
 
 
8.3 Where will locked files of investigation material be stored? 
 
In a locked cabinet in lab C4.08, the metabolic lab, in new Cavendish building 
 
 
 
8.4 If the investigation involves storage of computerised data which might enable 
the participant it be identified, please name the investigator in charge of 
Computer System Security for the investigation? 
 
 
Varsha Rajashekar 
 
 
8.5  Does the investigation and any planned publication include the use of 
photographs or videos either of individuals or tissues? 
 
Tissues           Yes No ; 
Individuals       Yes               No ; 
 
If yes to either of these, please provide a copy of the consent form which participants 
will be asked to sign for this purpose. 
 
 
 
Section 9 - Finance 
 
9.1 Will expenses be paid to participants? 
 
Yes (If yes, how much?) 
 
;No 
 
 
9.2 Will a reward over and above expenses be made to participants? 
 
Yes (If yes, please give more details) 
 
;No 
 
 
9.3 Is this study initiated/sponsored by a pharmaceutical or other industrial 
company? 
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Yes (If yes, what is the name of the company?) 
 
;No 
 
 
9.4 Detail any financial or other direct interest to you or to your department 
arising from this study. 
 
None 
 
 
9.5 Will this project increase work/cost to any other Department or School? 
 
Yes (If yes, obtain and include the name and signature of the relevant Dean(s) of  
       School(s) concerned: 
 
Name Signature 
 
 
 
 
 
 
 
 
;No 
 
 
Section 10 – Insurance  
 
10.1 Are manufacturers providing insurance cover? 
Yes (If yes, please enclose a letter confirming insurance cover, including the 
names of all  
        covered) 
 
;No  
 
 
10.2 Are all of the investigators employees or students of the University of 
Westminster? 
 
;Yes 
 
No  
 
If no, please provide evidence of insurance cover, including: 
• list of all people involved in the investigation 
• details of the form this cover will take 
 
10.3 Does the investigation involve the use of equipment or medicines? 
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;Yes 
 
No 
 
If yes, please give details of manufacturer’s indemnity: 
 
All equipments are covered by the indemnity offered by the University of 
Westminster (see attached letter) 
 
 
10.4 Does the investigation involve the use of equipment or medicines which are 
manufactured on site but are not covered by insurance? 
 
Yes 
 
;No 
 
If yes, appropriate insurance cover must be arranged and written confirmation of such 
cover must be attached 
 
 
Section 11 – Declaration – this Section must be completed by all applicants 
 
 
Please Read and Sign 
 
The information I have given on this form is true and to the best of my 
knowledge correct: 
 
 
 
Signed: 
 
 
Date: 
 
 
Send the completed form to: 
 
Carl Hornsey 
Assistant Registrar (Student Information) 
Academic Registrar’s Department 
University of Westminster 
115 New Cavendish Street 
London W1W 6UW 
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Appendix 9 - Informed consent form for EGCG studies 
 
Written Consent Form 
 
Title of Investigation: To study the effect of dietary supplementation of a nutritional 
compound on energy expenditure and blood sugar levels.  
 
Volunteer’s name: _______________________________________________________ 
Address: ________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
Tel: ___________________________ Email: _______________________________ 
Date of Birth: ___________________ Gender: M/ F 
 
I have read the attached information on the research in which I have been asked to 
participate and have been given a copy to keep. I have had the opportunity to discuss the 
details and ask questions about this information. 
The investigator has explained the nature and purpose of the research and I believe that I 
understand what is being proposed. I have been informed what the proposed study 
involves. 
I understand that my personal involvement and my personal data from this trial will remain 
strictly confidential. Only researchers involved in the investigation will have access. 
I hereby fully and freely consent to participate in the study, which has been fully explained 
to me. I understand that I am free to withdraw from testing at any time. 
 
Volunteer’s Signature: ……………………………………. Date:…………………. 
 
As the investigator responsible for this investigation, I confirm that I have explained to the 
participant named above, the nature and purpose of the research to be undertaken. 
Investigator’s Name: Varsha Rajashekar     
Signature:…………………………………….. 
If you have any questions about this, please contact: 
Varsha Rajashekar on 020 7911 5000 ext 2830 or 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 
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Appendix 10 - Participant information sheet – acute EGCG study 
 
Title of Investigation: To study the effect of a dietary supplement on energy 
expenditure and blood sugar regulation 
 
Dear Participant, 
 
We invite you to participate in an investigation that we believe to be of potential 
importance. In order to help you to understand what the investigation is about, we are 
providing you with the following information. Be sure you understand it before you agree 
to participate. Please do ask any questions you have about the information, which follows. 
We will do our best to explain and to provide any further information you require. 
 
This study is examining the effects of a dietary supplement on blood sugar levels and 
energy expenditure. The proposed study hopes to address and hopefully clarify the best 
strategies for use of new non-drug therapies in overweight people and those with blood 
glucose control problems. 
 
We are interested to find out what a particular dietary supplement may have on your 
energy expenditure (calories burned per day), blood glucose levels, cholesterol, mean skin 
and core temperature. In order to do this we will give you a dose of supplement, in liquid 
form, to take during the test session. You will be given the ‘active’ supplement and also the 
dummy (placebo) supplement over the two test sessions. You will not know which is 
which. This helps us to get unbiased results for the study. The supplement and the placebo 
will contain only food supplements and there is no known risk involved. 
 
As a participant, you will be required to come in to the lab for 2 sessions over a period of 
2 weeks. 
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Session 1 
During this preliminary session you will be made familiar with the various procedures to 
be followed in the subsequent sessions and this first session will take approximately 2 ½ 
hours of your time. 
  
The first session involves measuring height and weight, determining your body 
composition, your resting metabolic rate (RMR), heart rate, body fat measurement along 
with measurements of fasting blood sugar, insulin, leptin, and cholesterol and your mean 
skin and core temperature, urinalysis for metabolites.   
 
For the measurement of body composition, you will have to sit in a BodPod (specially 
designed chair like device, in which the door can be opened from the inside) for about 3 to 
5 minutes. To ensure accurate measurement, you should wear closely fitting swimsuit, 
which you will need to bring along. This test and the equipment used are completely safe, 
comfortable and easy to carry out. Your body fat will be measured by skin fold 
measurements by the use of equipment called the Harpenden callipers. Skin folds are 
measured at four different sites in the body i.e. the back (sub scapular), the front of the 
upper arm (biceps), back of the upper arm (triceps) and the waist area (supraspinale). 
 
The measurement of resting metabolic rate will involve you lying on a bed for 45 minutes 
with a clear perspex hood over your head. You should be in a complete state of rest, but 
not asleep. To encourage this you will be supplied with a set of headphones with calming 
music playing, to block out any distractions.  
 
At the same time, you will be measured for the skin and core temperature. This is done by 
placing four small sensors in various places on your skin i.e. on the chest bone (sternum), 
forearm, thigh and calf. You will also be needed to insert a 10 cm flexible rectal probe in 
order to measure the core temperature. 
 
All equipments are designed to be comfortable during testing and you will be able to 
stop the testing by request at anytime. 
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When you arrive at the lab, blood will be drawn from the vein (venepuncture) as well as 
from the finger (finger prick) for analysis of blood sugar, cholesterol, insulin, and leptin. 
You will need to provide a urine sample. 
 
You will be given the supplement drink along with a glucose drink after which a test called 
oral glucose tolerance test will be performed during which a finger prick blood sample will 
be taken every 30 minutes for the two hour test session. The resting metabolic rate will be 
measured in between the glucose tolerance test. You will be required to fill out a 
questionnaire to measure appetite at the end of the session. 
 
Prior to the study, it is necessary for you to maintain a three day food diary. You will be 
provided by a photographic food guide to help you maintain the food diary with ease. You 
will also need to fill out a questionnaire assessing your appetite.  
 
At the end of the session another blood sample will be taken by venepuncture and you will 
need to provide a second urine sample. 
 
PLEASE REMEMBER: You should not be under the influence of drugs, and should be in 
a fasted state for all the sessions 
 
 
 
 
 
 
 
 
 
 
 
Figure: Summary of session 1. 
 
2.5 hours 
Arrive at lab 
Measurement of height 
and weight 
Complete health 
questionnaire 
Measurement of body 
composition by skin fold 
measurement  
Lie on bed with hood over the head for RMR 
measurement for 45 minutes, at three intervals 
along with the skin and core temperature sensors 
Measurements of blood glucose 
by finger prick blood sample in 
30 minute intervals from the 
start of the  test session 
Collection of blood by 
venepuncture and finger prick + 
urine sample 
End of 
session Collection of blood by venepuncture, 
after which ingest 150ml Lucozade 
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Session 2: 
 
Upon arriving at the lab, all measurements same as in session 1 will be conducted, in order 
to determine the effect of the second dietary supplement given. 
 
Risks: 
 
1. The blood taken during the sessions will be from a vein in the arm. This will be 
carried out by someone highly experienced in taking blood. In some rare cases, you 
may have slight bruising for up to 24 hours. A total of 20ml of blood will be taken, 
which is a very small fraction (approximately 3%) of what an individual would 
give when donating blood and it is therefore extremely unlikely you would 
experience any adverse effects. 
2. To ensure your safety whilst participating in this study we will ask you to complete 
a health questionnaire, which will give us an indication of whether it is safe for you 
to participate in such activity.  
Note: A qualified first aider will be present during all test sessions. 
 
CONFIDENTIALITY: 
 
Your confidentiality will be protected, both in terms of your personal involvement and 
your particular data from the study. Your name will not be associated with any of your data 
that will be used for subsequent analysis. The data obtained from the study will be 
accessible only by the principal investigator and the supervisory team. 
 
You are free not to participate and may withdraw from the study at any time without any 
obligation.  
 
CLAIMS: 
Understand that in the event of injury caused by the product defect of a manufacturer, you 
will be compensated. In the unlikely event of injury due to negligence, claims must be 
pursued through legal action. 
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FEEDBACK: 
 
Would you like to be aware of the results/outcome of the study? If you wish to receive 
feedback from the study we are most happy to provide it to you in the form of journal 
articles or any other publications arising from the data collected during the study. 
 
If you have any questions about this, please contact: 
 
Varsha Rajashekar on 020 7911 5000 ext 2830 or v.rajashekar01@wmin.ac.uk 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 or a.cunliffe@wmin.ac.uk 
 
 
Thank you very much for your interest in the study. 
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Appendix 11 - Participant information sheet – chronic EGCG study 
 
Title of Investigation: To study the effect of a dietary supplement on energy 
expenditure and blood sugar regulation 
 
Dear Participant, 
 
We invite you to participate in an investigation that we believe to be of potential 
importance. In order to help you to understand what the investigation is about, we are 
providing you with the following information. Be sure you understand it before you agree 
to participate. Please do ask any questions you have about the information, which follows. 
We will do our best to explain and to provide any further information you require. 
 
This study is examining the effects of a dietary supplement on blood sugar levels and 
energy expenditure. The proposed study hopes to address and hopefully clarify the best 
strategies for use of new non-drug therapies in overweight people and those with blood 
glucose control problems. 
 
We are interested to find out what a particular dietary supplement may have on your 
energy expenditure (calories burned per day), blood glucose levels, cholesterol, mean skin 
and core temperature. In order to do this we will give you three doses of the test 
supplement, in capsule form, each to be taken for 7 day periods. The supplement will 
contain only food supplements and there is no known risk involved. 
 
As a participant, you will be required to come in to the lab for 4 sessions over a period of 
5 weeks. 
 
Session 1 
During this preliminary session you will be made familiar with the various procedures to 
be followed in the subsequent sessions and this first session will take approximately 2 ½ 
hours of your time. 
  
The first session involves measuring height and weight, determining your body 
composition, your resting metabolic rate (RMR), heart rate, body fat measurement along 
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with measurements of fasting blood sugar, insulin, leptin, and cholesterol and your mean 
skin and core temperature, urinalysis for metabolites.   
 
For the measurement of body composition, you will have to sit in a BodPod (specially 
designed chair like device, in which the door can be opened from the inside) for about 3 to 
5 minutes. To ensure accurate measurement, you should wear closely fitting swimsuit, 
which you will need to bring along. This test and the equipment used are completely safe, 
comfortable and easy to carry out. Your body fat will also be measured by skin fold 
measurements by the use of equipment called the Harpenden callipers. Skin folds are 
measured at four different sites in the body i.e. the back (sub scapular), the front of the 
upper arm (biceps), back of the upper arm (triceps) and the waist area (supraspinale). 
 
The measurement of resting metabolic rate will involve you lying on a bed for 45 minutes 
with a perspex hood over your head. You should be in a complete state of rest, but not 
asleep. To encourage this you will be supplied with a set of headphones with calming 
music playing, to block out any distractions. You will also be wearing a heart rate monitor 
to measure resting heart rate. At the same time, you will be measured for the skin and core 
temperature. This is done by placing four small sensors in various places on your skin i.e. 
on the chest bone (sternum), forearm, thigh and calf. You will also be needed to insert a 10 
cm flexible rectal probe in order to measure the core temperature. 
 
All equipments are designed to be comfortable during testing and you will be able to 
stop the testing by request at anytime. 
 
After the RMR measurement, blood will be drawn from the vein (venepuncture) as well as 
from the finger (finger prick) for analysis of blood sugar, cholesterol, insulin, and leptin. 
You will need to provide a urine sample. Prior to the study and also during the study, it is 
necessary for you to maintain a three day food diary. You will be provided by a 
photographic food guide to help you maintain the food diary with ease.  
 
 
PLEASE REMEMBER: You should not be under the influence of drugs, and should be in 
a fasted state for all the sessions 
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Figure: Summary of session 1. 
 
Session 2 - 4: 
Upon arriving at the lab, all measurements same as in session 1 will be conducted, in order 
to determine the effect of the other doses of supplement given. 
 
 
Summary of study: 
 
 
 
 
 
 
 
 
 
 
 
Risks: 
1. The blood taken during the sessions will be from a vein in the arm. This will be carried 
out by someone highly experienced in taking blood. In some rare cases, you may have 
slight bruising for up to 24 hours. A total of 20ml of blood will be taken, which is a very 
Day – 1 
First test session in lab, take 
supplements for 7 days 
Day – 8 
Second test session in lab 
Day – 15 
Start supplements for next 7 
days 
Day 8 – 14: 
washout 
Day – 22 
Third test session in lab 
 
Day 22 – 
28: washout 
Day – 29 
Start supplements for next 7 
days 
Day – 36 
Final test session in lab 
 
2.5 hours 
Arrive at lab 
Measurement of height and 
weight 
Complete consent 
form (1st test session) 
Measurement of body 
composition by skin 
fold measurements 
Lie on bed with hood over the head for RMR 
measurement for 45 minutes along with the skin 
and core temperature sensors 
Collection of blood by venepuncture 
and finger prick + urine sample 
End of 
session 
Quick run through following 
protocols, information on how to 
keep a food dairy 
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small fraction (approximately 3%) of what an individual would give when donating blood 
and it is therefore extremely unlikely you would experience any adverse effects. 
 
2. To ensure your safety whilst participating in this study we will ask you to complete a 
health questionnaire, which will give us an indication of whether it is safe for you to 
participate in such activity.  
 
Note: A qualified first aider will be present during all test sessions. 
 
CONFIDENTIALITY: 
 
Your confidentiality will be protected, both in terms of your personal involvement and 
your particular data from the study. Your name will not be associated with any of your data 
that will be used for subsequent analysis. The data obtained from the study will be 
accessible only by the principal investigator and the supervisory team. 
 
You are free not to participate and may withdraw from the study at any time without any 
obligation.  
 
CLAIMS: 
 
Understand that in the event of injury caused by the product defect of a manufacturer, you 
will be compensated. In the unlikely event of injury due to negligence, claims must be 
pursued through legal action. 
 
FEEDBACK: 
Would you like to be aware of the results/outcome of the study? If you wish to receive 
feedback from the study we are most happy to provide it to you in the form of journal 
articles or any other publications arising from the data collected during the study. 
If you have any questions about this, please contact: 
 
Varsha Rajashekar on 020 7911 5000 ext 2830 or v.rajashekar01@wmin.ac.uk 
Dr. Adam Cunliffe on 020 7911 5000 ext 3580 or a.cunliffe@wmin.ac.uk 
Thank you very much for your interest in the study. 
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Appendix 12 - Analysis of variation (ANOVA) for data obtained from pilot study 
investigating L-Histidine ingestion (Chapter 4) 
 
ANOVA for RMR data: 
 
ANOVA for MST data: 
Category Degrees of freedom (n-1) Sum of squares Mean square f test 
Treatment  1 -4115.713617 -4115.71362 2.626215484
Subjects 4 3.416111167 0.854027792 0.000544951
Time 2 1.6511159 0.82555795 0.000526784
Residual 23 36044.8005 1567.165239   
Total 30 31934.15411     
 
ANOVA for CT data: 
Category 
Degrees of 
freedom (n-1) Sum of squares Mean square f test 
Treatment  1 0.015 0.015 5.24817E-06
Subjects 4 -24362.63951 -6090.660 -2.15610413
Time 2 0.1210847 0.061 2.14321E-05
Residual 23 64971.434 2824.845   
Total 30 40608.93022     
 
ANOVA for RER data: 
Category 
Degrees of 
freedom (n-1) Sum of squares Mean square f test 
Treatment  1 0.002977778 0.002977778 0.002898169
Subjects 2 0.040883333 0.020441667 0.019895176
Time 2 0.001416667 0.000708333 0.000689397
Residual 12 12.32962222 1.027468518   
Total 17 12.3749     
 
No significant difference was observed in any of the parameters due to treatment, over time 
and between subjects.  
 
 
Category Degrees of freedom (n-1) Sum of squares Mean square f test 
Treatment  1 12945.99 12945.99 0.002396941
Subjects 2 168569.34 84284.67 0.01560525
Time 2 22373.74 11186.87 0.002071241
Residual 12 64812549.09 5401045.758   
Total 17 65016438.16     
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Appendix 13 - Golberg cut-off points to identify validity of reported dietary intake 
 
 
10 day chronic L-Histidine intake (Chapter 3.3) 
 
Subject Goldberg’s cutoff point after 
placebo 
Goldberg’s cutoff point after 
histidine 
1 
2 
3 
4 
5 
6 
7 
8 
9 
0.7 
0.4 
0.5 
0.5 
0.9 
1.1 
0.7 
0.8 
0.9 
0.8 
0.3 
0.9 
0.9 
1.3 
0.6 
0.5 
1.3 
1.0 
 
The above table shows that 5 participants have underreported dietary intake prior to both 
the test sessions, and 4 participants seem to have underreported their intake prior to either 
one of the test sessions.  
 
 
8 week L-Histidine study (Chapter 3.4) 
 
 
Subject 
Goldberg’s cutoff point  
(Placebo group) 
Goldberg’s cutoff point  
(L- Histidine group) 
Pre-treatment Post 8 weeks Pre-treatment Post 8 weeks 
1 
2 
3 
4 
5 
6 
7 
8 
9 
1.1 
0.6 
0.6 
1.1 
0.5 
0.8 
1.1 
0.5 
0.9 
1.3 
0.7 
0.9 
1.3 
0.7 
0.8 
1.0 
0.7 
0.7 
0.4 
1.0 
0.7 
0.3 
0.5 
0.9 
1.2 
0.8 
0.5 
0.4 
0.6 
1.0 
0.4 
0.8 
1.4 
1.2 
0.8 
0.7 
 
Calculation of the cut-off points for participants in the placebo group showed that 3 
participants out of 9 had reported dietary intake during both sampling periods 
appropriately. All other participants (6) had underreported their dietary intake prior to both 
sampling periods. In the L-Histidine group, 1 participant had reported adequate dietary 
intake prior to both sampling periods, 5 participants had underreported dietary intake prior 
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to both sampling period and 2 participants  had underreported dietary intake prior to the 
last test session and 1 participant underreported dietary intake at pre-treatment.  
 
 
Acute EGCG study (Chapter 4.2) 
 
Subject Goldberg’s cutoff point 
prior to placebo ingestion 
Goldberg’s cutoff point 
prior to EGCG ingestion 
1 
2 
3 
4 
5 
6 
7 
8 
0.7 
1.3 
0.9 
0.7 
0.7 
0.8 
0.7 
0.8 
0.4 
0.9 
0.9 
1.6 
0.6 
1.3 
0.6 
0.5 
 
Applying the Goldberg cut-off points to the reported dietary intakes during the acute 
EGCG study, it was found that all participants except one had underreported their dietary 
intake prior to the placebo ingestion session. Prior to the EGCG ingestion session, 2 
participants had accurately reported heir dietary intake when 6 participants had under-
reported.  
 
Chronic EGCG study (Chapter 4.3) 
 
Subject Goldberg’s cutoff 
point at baseline 
Goldberg’s cutoff 
point after 75mg 
EGCG 
Goldberg’s cutoff 
point after 150mg 
EGCG 
Goldberg’s 
cutoff point 
after 300mg 
EGCG 
1 
2 
3 
4 
5 
6 
7 
8 
0.8 
0.8 
0.5 
0.7 
1.3 
0.9 
0.6 
0.9 
0.9 
0.7 
0.6 
1.5 
0.9 
1.0 
1.0 
0.8 
0.7 
0.6 
0.5 
1.0 
1.4 
1.0 
0.8 
0.9 
1.1 
0.7 
1.0 
1.2 
1.5 
0.8 
0.7 
0.7 
 
During this study, all participants ingested all 3 doses of EGCG (75, 150 and 300 mg/day), 
for 7 days each. None of the participants have accurately reported their dietary intake prior 
to all test sessions. 
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Discussion: 
The application of Goldberg’s cut-off points to identify under-reporting of dietary intake 
showed that majority of the participants underreported their dietary intake prior to/ 
following one or both supplementations. Having said that, the presumption of the 
intervention studies as conducted in this thesis is that all aspects influencing energy 
balance, such as dietary intake and physical activity remain similar to prior, to the 
commencement of the study. In other words no meaningful change in energy intake from 
before to during the study was expected, to confound any of the measured variables. The 
only change expected to participants’ daily routine was the intake of the supplementations 
during the course of the study.  
 
The results of the Goldberg cut-off need to be carefully considered as most of the 
participants have underreported. However, the use of Goldberg cut-off has been criticised 
as unreliable to use in studies with small sample sizes. This is due to the assumption that 
all participants’ activity levels are sedentary and for not accounting for medium and high 
activity patterns (Black, 2000a). Secondly, the Goldberg cut-off only identifies extremely 
inaccurate reporting (ie, ±2 SD for the agreement between EIrep/BMRest and physical 
activity level (PAL) although both underreporting and over reporting can occur to varying 
degrees (Black, 2000b). It has also been shown that underreporting is not random, but is 
related to characteristics such as obesity, smoking, dieting, and psychological factors. 
People with higher BMI and higher body fat percentage underreport (Klingberg et al., 
2008; Rasmussen et al., 2007). The reasons for underreporting in all studies could be first, 
all participants in the 8 week L-Histidine study were overweight and as it is well 
established that obese subjects commonly underreport (Goris et al., 2000), the study 
participants similarly may have under-reported. Second, as all participants were regularly 
weighed, they possibly felt the need to report healthier and low calorie eating pattern as 
psychological factors such as body shape concerns and mere participation in studies 
investigating weight loss have been known to influence dietary underreporting (Abbot et 
al., 2008; Johnson et al., 2005; Maurer et al., 2006). For the purpose of studies presented 
in the current text, dietary intakes have been underreported to a large extent. Majority of 
participants have underreported prior to all test sessions and as this is consistent, it is 
presumed not to affect any other measured parameters of the studies. Participants’ RMR 
and other measured parameters do not seem influenced by underreporting prior to one test 
session and having reported accurately prior to another.  Also, as Goldberg cut-off 
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calculations seem unsuitable for small sample sizes, the above presented results need to be 
considered carefully. Further substantiation of reported dietary intakes can be done by 
measuring 24 hour urinary nitrogen to validate dietary protein intake and and total EE 
measured by doubly labelled water method (Black et al., 1997); Livingstone and Black., 
2003). These validation techniques are above the scope and financial and technical 
capacity of the current studies and were therefore not performed following the studies 
proposed herein. 
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Appendix 14 -Visual Analogue Scales (100mm) 
 
(Questionnaires made as small booklets showing one question at a time) 
 
Questions on appetite and desire for specific food types: 
 
 
 How hungry do you feel? 
I am not  I have never 
hungry at all been more 
hungry 
 
 
 
 How satisfied do you feel? 
I am I cannot eat  
completely another bite 
empty 
 
 
 
 How full do you feel? 
Not at all Totally full 
full 
 
 
 
 How much do you think you can eat? 
Nothing at all A lot 
 
 
 
 Would you like to eat something sweet? 
Yes, very No, not at all 
much 
 
 
 
 Would you like to eat something salty? 
Yes, very No, not at all 
much 
 
 
 
 Would you like to eat something savoury? 
Yes, very No, not at all 
much 
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Would you like to eat something fatty? 
Yes, very No, not at all 
much 
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Appendix 15 - Diet diary 
 
Date: …………………..   Day of the week:…………………. 
 
On rising 
Time Food/ Drink 
Description and 
Preparation 
Amount 
 
    
Breakfast 
Time Food/ Drink Description and 
Preparation 
Amount 
 
    
Mid morning 
Time Food/ Drink Description and 
Preparation 
Amount 
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Lunch 
Time Food/ Drink Description and 
Preparation 
Amount 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Afternoon snack / Tea 
Time Food/ Drink Description and 
Preparation 
Amount 
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Evening meal 
Time Food/ Drink Description and 
Preparation 
Amount 
 
    
Later evening-up to last thing at night 
Time Food/ Drink Description and 
Preparation 
Amount 
 
  
 
 
 
 
 
 
  
Between meals, snacks and drinks (If not mentioned before) 
Food/ Drink Time Description and 
Preparation 
Amount 
 
Chocolate    
Toffees, sweets    
Crisps    
Peanuts    
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Other snacks    
Beer    
Wine    
Sherry    
Spirits    
Other cold drinks    
Tea    
Coffee    
Other hot drinks    
Ice cream    
Anything else?    
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Appendix 16 - Photographic food reference atlas  
 
 
 
 
Food Diary 
 
 
Name:…………………………………………………………………………………... 
 
 
 
 
 
 
 
 
Human and Health Sciences Department 
School of Biosciences 
115, New Cavendish Street 
London W1W 6UW 
Ph: 020-7911-5000 ext 2830 
Email: V.Rajashekar01@wmin.ac.uk 
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We would like you to keep this diary of everything you eat and drink over two weekdays 
and 1 day over the weekend. This is a very important part of the study and will add greatly 
to the study. It is important that you do not adjust what you eat and drink just because you 
are keeping a record. Please continue to eat whatever you wish. 
 
Instructions: 
 
As you will see, each day is marked in sections, beginning with the first thing in the 
morning and ending with bedtime. For each part of the day write down all food and drink 
consumed the amounts, and a description if necessary. If nothing is eaten or drunk during a 
part of the day, draw a line through that section. Record everything at the time of eating, 
not from memory at the end of the day. 
 
On the next few pages is a list of popular foods and drinks. Next to each item is the sort of 
thing we need to know so that we can tell what it is made of and how much you had. This 
list cannot cover all foods and drinks, so try to relate to a similar item if any that you have 
eaten are missing. Please give as much detail as you can. There is an example on page   
 
For some foods you may find it easier to describe how much you had by comparing it to 
one of the photographs on pages 
 
Many packet foods have weights printed on them, so please use these to show how much 
you ate. 
 
At the end of each day there is a list of snacks and drinks that can easily be forgotten. 
Please write any extra items in here if you have not already recorded them in some other 
part of the day. 
 
Pictures used in this diary have been reproduced with permission from the author of - A 
photographic atlas of food portion sizes and Food portion sizes: a user's guide to the 
photographic atlas.  
 
 
Appendices 
 - 260 - 
Food / Drink Description and Preparation Amount  
Bacon Lean or streaky; fried or grilled 
rashers 
Number 
Baked beans Standard or reduced sugar Tablespoons, tin 
size or picture 1 
beef burger ( Hamburger) Homemade, from a packet or take 
away; fried, microwaved or grilled; 
well-done or rare; large or small; with 
or without bread roll 
Number 
Biscuits Plain; savoury; cheese, crisp bread, 
sweet, chocolate, wafer; home-made; 
include biscuit like kit-kat and 
penguin; write in the name and brand 
if you can 
Number 
Bread ( also see sandwiches) Wholemeal, white or brown; currant, 
fruit, malt; large or small loaf; thick, 
medium or thin slices; sliced or 
unsliced; give brand if possible 
Number of slices 
Bread rolls Wholemeal, white or brown; alone or 
with filling (see sandwiches); crusty or 
soft; give brand if possible 
Number of rolls 
Breakfast cereal, bran, 
wheatgerm 
What sort: cornflakes, weetabix, 
muesli etc.; give brand name if 
possible 
Number of 
biscuits, 
tablespoons or 
picture 2 
Bun What sort: iced, currant, sweet or 
plain; large or small 
Number 
Butter for bread Ordinary or low fat dairy spread, write 
in the name and brand if you can 
Thick, average, 
thin spread 
Cake- small What sort and brand: cream, iced, sort 
of filling 
Number or picture 
3 
Cake –large What sort and brand: cream, iced, sort 
of filling 
Slices or pictures 
4 
Cheese What sort: cream, cottage, hard, soft; 
low fat; write in the name if you can 
Tablespoons or 
picture 5 
Chips Fresh, frozen, oven, microwave or 
crinkle cut; type of fat for cooking 
Picture 6 
Chocolate What sort: plain, milk, white, diabetic; 
give brand name 
Number or bar 
weight 
Chops What sort: lean or fatty; large or small; 
fried or baked; well done or rare 
Number 
Cider Sweet, dry, vintage, low alcohol Pints and half 
pints 
Coffee With milk; half milk/ half water; all 
milk 
Cups or mugs 
Condiments Pepper, salt or substitute ½ or ¼ teaspoon, 
pinch etc. 
Cooking oil Type; brand name Teaspoons 
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Food / Drink Description and Preparation Amount  
Cream Half, single, sour, whipping, double, 
clotted; low fat; fresh or substitute; 
sweetened or unsweetened 
Tablespoons 
Crisps  Brand name; low fat; low salt Packet weight 
Egg How was it cooked: boiled, fried, 
scrambled, poached, omelette etc 
Number 
Fish What sort: fried, boiled, grilled, 
poached, microwaved; with batter or 
breadcrumbs; tinned with oil or 
tomato sauce 
Helping or picture 
7 and 8 
Fish cakes or fingers What sort: large, medium or small 
size; fried or grilled 
Number 
Fruit- fresh What sort and variety eg. Cox apple; 
with or without skin 
Number or picture 
9 
Fruit- stewed or canned What sort and variety eg. Bramley 
apple; in fruit juice or syrup 
Tablespoons 
Fruit- juice What sort; sweetened or unsweetened Glasses or cups 
Gravy Thick or thin, instant or packet, made 
with or without dripping or meat 
juices 
Tablespoons 
Herbs Type, fresh or dried ½ or ¼ teaspoons 
Honey, jam Type, specify if low sugar Teaspoons 
Ice cream Dairy or non dairy; flavour or variety Tablespoons / 
quantity 
Liver, kidney Pig, lamb, ox; fried or stewed Quantity 
Margarine Hard, soft, polyunsaturated, low fat, 
very low fat; give brand name 
Thick, average or 
thin spread 
Marmalade Type and brand; specify if low sugar Teaspoons 
Mayonnaise Give name and brand; specify if low 
fat 
Teaspoons 
Meat pie, pastie, pastry What sort; individual or helping, fat 
used for pastry 
Number or picture 
10 
Meats What sort; lean or fatty; fried, 
microwaved, grilled, roast, barbequed; 
well done or rare; with or without 
gravy, cut used 
Slices, helping  
Milk-for drinking on its own 
or for cereals 
Full cream, silvertop, semi skimmed, 
skimmed, sterilized, UHT, flavoured, 
powdered, soya 
Pints, glasses or 
cups 
Minced beef On its own, with vegetables, fatty or 
lean 
Tablespoons  
Peanuts Dry roasted or ordinary salted Packet weight 
Pickled, smoked or salted 
foods 
What sort and brand; how eaten; eg. 
Pastrami, haddock, turkey breast, pate 
Tablespoons 
Porridge  With sugar or honey; with milk or 
cream 
Bowls 
Potatoes Baked, boiled, mashed, creamed, Tablespoons  
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Food / Drink Description and Preparation Amount  
fried/ chips, instant, roast; with butter 
Pudding What sort and brand: eg. Steamed 
sponge; with fruit; pie (what sort); 
jelly; blancmange; mousse; instant 
desserts; milk puddings, give recipe 
Tablespoons, 
slices or pictures--
-- 
Rice Brown or white; boiled or fried; rice 
pudding 
Tablespoons or 
pictures 11 
Salad Describe ingredients, with dressing; 
what sort of dressing (e.g. oil and 
vinegar, salad cream, mayonnaise) 
Tablespoons or 
picture 12 
Sandwiches and rolls Wholemeal, white or brown bread; 
type of filling; butter or margarine: 
large or small loaf; thick, medium or 
thin slices 
Number of rolls or 
slices of bread 
Sauce –hot (for vegetables, meat or fish; 
puddings) what sort; savoury or sweet; 
thick or thin, give recipe if possible 
Tablespoons  
Sauce – cold What sort: e.g. tomato ketchup, brown 
sauce, soy sauce; salad cream; sweet 
or savoury 
Tablespoons  
Sausages What sort: e.g. pork, beef, pork and 
beef; low fat; large or small; how 
cooked 
Number 
Sausage rolls Large or small, type of pastry Number 
Scones What sort: with currants, sweet or 
plain; cheese 
Number 
Snacks- in packets What sort: e.g. cheese straws, twiglets, 
pretzels (give brand name) 
Packet weight 
Soft drinks Squash, undiluted or diluted; fizzy 
drinks; low calorie; give brand name 
Glasses or cans 
Soup What sort; canned, packet, instant or 
vending machine, homemade; give 
brand name 
Tablespoons, bowl 
or mug 
Soya, Quorn Mince, burgers or tofu Number  
Spaghetti, other pasta Canned, boiled; white, wholemeal; in 
sauce 
Tablespoons or 
picture 13 
Spices Type ½ or ¼ teaspoons 
Spreads On bread, what sort and brand ½ or ¼ teaspoons 
Spirits What sort: e.g. whisky, gin, vodka, 
rum, at home or in pub 
Single measures as 
in pub 
Sugar Added to cereals, tea, coffee, fruit etc Heaped or level 
teaspoons 
Sweets What sort: e.g. toffees or boiled 
sweets; diabetic; give brand name 
Number 
Tea With or without milk; herb, 
decaffeinated 
Cups 
Vegetables What sort and variety; with butter, Tablespoons or 
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Food / Drink Description and Preparation Amount  
other fat or sauce; how cooked e.g. 
fried, boiled, microwaved or raw 
picture 14 
Water state whether tap, filtered or bottled  Glasses 
Wine, sherry, port White, red; sweet, medium, dry; low 
alcohol 
Glasses 
Yoghurt, fromage frais What sort: e.g. with fruit, natural, 
plain; flavour; low fat, greek, creamy, 
soya 
Cartons, 
tablespoons 
Homemade dishes Please say what the dish is called and 
give recipe or ingredients if possible  
Tablespoons or 
one of the pictures 
Ready made meals What sort; e.g. pizzas, microwave 
dishes, slimmers’ meals etc. please 
give main ingredients on packet and 
enclose label if possible 
Weight from 
packet 
Meals eaten away from 
home 
What sort: e.g. pizzas, Chinese, Indian 
dishes, fish and chips, hamburgers, hot 
dogs etc. please say what the dish is 
called and give ingredients where 
possible. Give the name of the 
restaurant if it a well known chain 
Tablespoons or 
one of the pictures 
 
Weights and measures:  
1 ounce = 28.35 grams  1 fluid ounce = 28.41 ml 
1 pint = 568.3 ml   1 litre = 1.76 pints 
 
1 pound = 453.6 grams  1 teaspoon = 5 grams 
1 gram = 0.0353 oz   1 kilogram = 2.20516 lb 
 
1 tablespoon = 15 grams  1 dessertspoon = 10 grams 
1 cup = 237 ml   1 quart = 947 ml 
 
Example:  
Time Food/ drink Description and 
preparation 
Amount 
 
12 pm Soup Campbell’s 
condensed cream of 
mushroom, diluted 
half ad half with 
1 medium bowl 
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water 
1 pm Bread White,  Hovis 2 medium slices 
 Butter Anchor salted Thick spread 
 Biscuits Jacobs cream 
crackers 
4 biscuits 
 Cheese Tesco matured 
cheddar 
Picture 2A 
 Tomatoes Fresh 2 medium 
3 pm cake Home made Victoria 
sponge with jam 
filling 
Picture 15 B 
 Tea Tetley’s tea bag 2 cups 
 Milk Full cream, Silver 
top 
Added to each cup 
 Sugar White granulated 2 heaped teaspoons 
in each 
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A 
C 
B
D
F
HG 
E 
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H 
C D
E F 
G 
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H 
A 
C D 
B 
G 
F E 
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6   
HG 
FE 
DC 
BA 
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HG 
FE 
DC 
BA 
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BA 
DC 
E F
H G
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E 
H
A B
C D
F
G 
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A 
HG 
FE 
DC 
B
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H
B
A 
D
F
C 
E 
G 
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hG 
FE 
D
C 
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A 
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HG 
FE 
D
C 
BA 
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BA 
DC 
F
E 
HG 
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Appendix 17 - Catechin and epicatechin content in raw and processed foods and 
selected beverages 
 Catechin content (mg/kg of fresh edible weight)a,b 
Product (+)-catechin (-)-epicatechin Others Total 
catechins 
Apple with skin  
Cox’s orange Pippin 12.8 ± 1.67 96.2 ± 18.37 NDc 109.0 
Elstar 12.4 ± 2.11 81.7 ± 12.41 ND 94.0 
Golden delicious 5.3 ± 0.70 74.2 ± 7.44 ND 79.5 
Granny smith  15.6 ± 4.33 74.8 ± 15.82 ND 90.3 
Apple without skin  
Cox’s orange Pippin 12.8 66.5 ND 79.3 
Elstar 11.0 ± 3.29 66.4 ± 3.86 ND 77.4 
Golden delicious 4.4 ± 0.26 50.7 ± 8.54 ND 55.1 
Granny smith  16.5 ± 5.19 65.3 ± 15.24 ND 81.1 
Applesauce 6.9 54.1 ND 61.0 
Apricot 49.5 ± 43.68 60.6 ± 78.49 ND 110.1 
Avocado  5.6 ± 2.91 ND 5.6 
Blackberry 6.6 ± 0.58 180.8 ± 21.39 ND 187.4 
Blueberry  11.1 ± 1.00 ND 11.1 
Broad beans, raw 128.3 ± 
160.60 
225.1 ± 184.78 EGC: 140.3 ± 
127.90 
493.7 
Prepared 81.6 ± 36.44 78.2 ± 40.93 EGC: 46.5 ± 
23.17 
206.3 
Canned ND ND ND ND 
Cherry, sweet 21.7 ± 9.18 95.3 ± 24.84 ND 117.1 
Canned ND 43.1 ND 43.1 
Cranberry ND 42.0 ND 42.0 
Currant, black 7.0 4.7 ND 11.7 
Currant, white 3.0 ND 7.0 10.0 
Currant, red 12.2 ± 4.35 ND GC: 12.2 ± 
10.85  
24.4 
Gooseberry 16.7 ± 3.63 ND GC: 4.4 ± 6.27 21.2 
Grape, black 89.4 ± 91.80 86.4 ± 71.20 ECG: 28.1 ± 
37.93 
203.9 
Grape, white 24.7 ± 10.59 10.2 ± 5.18 ECG: 4.3 ± 
8.54 
39.2 
Kidney-bean, canned 16.6  3.5 ND 20.1 
Kiwi fruit ND 4.5 ± 1.05 ND 4.5 
Mango 17.2 ± 15.72 ND ND 17.2 
Nectarine 27.5 ± 2.42 ND ND 27.5 
Peach 23.3 ± 5.66 ND ND 23.3 
Peach, canned 18.7 ND ND 18.7 
Pear with skin  
Conference  1.1 ± 0.36 29.5 ± 1.69 ND 30.6 
Cooking peard 9.6 ± 4.77 75.4 ± 32.42 ND 85.0 
Canned pear 1.8 2.6 ND 4.4 
Pear without skin  
Conference 0.4 ± 0.18 8.2 ± 2.72 ND 8.5 
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 Catechin content (mg/kg of fresh edible weight)a,b 
Product (+)-catechin (-)-epicatechin Others Total 
catechins 
Cooking peard 3.6 ± 0.18 29.6 ± 3.25 ND 33.3 
Prepared 3.3 21.2 ND 24.5 
Plum 33.5 ± 9.13 28.4 ± 31.89 ND 61.9 
Raspberry 9.7 ± 2.57 82.6 ± 13.06 ND 92.3 
Rhubarb 21.7 ± 11.39 5.1 ± 3.30 ECG: 6.0 ± 
3.71 
32.8 
Prepared 14.8 ± 10.61 3.8 ± 1.31 ECG: 4.9 ± 
6.06 
23.5 
Strawberry 44.7 ± 13.80 ND ND 44.7 
Chocolate, black 
(Albert Heijne) 
132.4 327.4 ND 459.8 
Chocolate, milk (Albert 
Heijn) 
38.3 124.9 ND 163.2 
Chocolate bar, Mars 21.7 62.5 ND 84.2 
Jam, apricot (Albert 
Heijn) 
4.7 5.0 ND 9.7 
Jam, cherry (Albert 
Heijn) 
1.6 9.0 ND 10.6 
Jam, forest fruit (Albert 
Heijn) 
0.7 15.7 ND 16.4 
Jam, strawberry (Albert 
Heijn) 
9.0 ND ND 9.0 
Raisins 29.7 7.1 ND 36.8 
a- Data include seasonal and regional variation, EGCG was not detected in any food; no catechins 
were detected in banana 
b- Annual mean ± SD, based on duplicate analyses for each season; food bought in only one season if 
no SD is given 
c- Not detected 
d- Different varieties 
e- Supermarket chain in Netherlands  
Adapted from (Arts et al., 2000a) 
 
Catechin content of selected beverages: 
 Catechin content (mg/l)a
Product (+)- catechin (-)-epicatechin Total 
catechins 
Red wine  
Bordeaux (Appellation Controlee, Rineau, 
1997) 
53.4 42.1 95.5 
Cotes-du-Rhone (Appellation Controlee, 
Les Vendanges, 1997) 
47.7 18.8 66.5 
Rioja (Siglo, 1996) 22.5 9.2 31.7 
Pinotage/ Merlot (Stellenbosch Welmoed 
Winery, 1997) 
25.2 18.9 44.1 
White wine   
Bordeaux Sauvignon (Appellation 
Controlee, Chateau de Nivelle, 1997) 
2.1 0.7 2.8 
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 Catechin content (mg/l)a
Product (+)- catechin (-)-epicatechin Total 
catechins 
Bordeaux (Appellation Controlee, Rineau, 
1997) 
4.7 1.0 5.7 
Other beverages  
Apple juice (Riedel) NDb ND ND 
Black grape juice (Albert Heijn) 8.0 ND 8.0 
White grape juice (Albert Heijn) 2.0 ND 2.0 
Iced tea (Lipton ice lemon, non 
carbonated) 
ND 0.8 0.8 
Lager beer (Heineken) ND ND ND 
Chocolate milk (semi skimmed, Nutricia) 16.1  5.0 21.1 
a- Average of duplicate analyses; GC, EGC, ECG, EGCG were not detected in any of the samples 
b- Not detected 
Adapted from (Arts et al., 2000b) 
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Appendix 18 -Reference values 
 
• Percent body fat: 
Body fat rating  Men Women 
Risky (high body fat) >30% >40% 
Excess fat  21-30% 31-40% 
Moderately lean 13-20% 23-30% 
Lean  9-12% 19-22% 
Ultra lean  5-8% 15-18% 
Risky (low body fat) <5% <15% 
 
• Blood glucose: 
Fasting blood glucose >= 7 mmol/l 
       Random blood glucose > 11 mmol/l  
 
• Total cholesterol:     
             Low       < 5.2 mmol/l 
            Average       5.2 – 6.2 mmol/l 
            High       > 6.2 mmol/l 
 
• HDL: 
Good: > 0.9 mmol/l 
Poor: < 0.9 mmol/l 
 
• LDL: 
Good: < 3.4 mmol/l 
Poor: > 4.1 mmol/l 
 
• Body mass index (BMI): 
Underweight  <20 
Normal   20 - 25 
Overweight   25- 30 
Obese   30 and above 
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• NEFA: 
Men – 0.1 – 0.6 μmol/l (2.8 – 16.9mg/dl) 
Women – 0.1 – 0.45 μmol/l (2.8 – 12.7mg/dl) 
 
• Expected reference values of insulin: 
2 – 25 mU/l with a mean of 9.2 mU/l  
 
• Expected reference values of leptin:  
Men – 3.84 ± 1.79ng/ml 
Women – 7.36 ± 3.73ng/ml 
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Appendix 19 -Detailed protocol for Insulin ELISA analysis 
 
Insulin, the principal hormone responsible for control of glucose metabolism, was 
measured using the Mercodia Insulin ELISA 10-1113-01 (Mercodia AB, Sweden). This is 
a solid phase two-site enzyme immunoassay, based on the direct sandwich technique in 
which two monoclonal antibodies are directed against separate antigenic determinants on 
the insulin molecule. During incubation insulin in the sample reacts with peroxidase 
conjugated anti-insulin antibodies and anti-insulin antibodies bound to micro-titration well. 
A simple washing step removes unbound enzyme labelled antibody. The bound conjugate 
is detected by reaction with 3, 3´, 5, 5´- tetramethlybenzidine (TMB). The reaction is 
stopped b adding acid to give a colorimetric endpoint that is read spectrophotometrically at 
450nm. 
 
Sample collection and handling: 
Blood was collected by venepuncture into heparin containing tubes (BD 
Vacutainer® Plasma Tube, Becton Dickinson UK Limited) to prevent coagulation and 
stored at -80°C until analysis.  
 
Procedure: 
All samples and reagents were thawed and brought to room temperature before use. All 
calibrators and samples were analysed in duplicates as below- 
 
1. Enzyme conjugate solution was prepared by diluting 1ml of Enzyme Conjugate 
11X in 10mls of Enzyme Conjugate Buffer and mixed gently. 
2. Wash buffer was prepared by diluting 40mls of Wash Buffer 21X solution with 
800mls distilled water. 
3. 25µl of each calibrator and sample was pipetted out into the appropriate microplate 
wells. 
4. 100µl of enzyme conjugate solution was added to each well. 
5. This was then incubated on a plate shaker for 1 hour at room temperature. 
6. After incubation, the reaction volume was aspirated and 350µl wash buffer was 
added to each well which was later aspirated well. This was repeated 5 times and 
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after the final wash, the plate was inverted and tapped firmly against absorbent 
paper.  
7. To this, 200µl Substrate TMB was added into each well. 
8. This was left to incubate for a further 15 minutes at room temperature. 
9. 50µl of Stop Solution was added to each well and placed on a shaker for 
approximately 5 seconds to ensure mixing. 
10. The optical density was then read at 450nm and results calculated with the help of 
calibration curve. 
 
Calculation of results: 
The concentration of insulin was obtained by computerised data reduction of the 
absorbance for the calibrators, except for calibrator 0, versus the concentration using cubic 
spline regression. 
 
 
 Example of calibrator curve 
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Appendix 20 - Detailed protocol for Leptin ELISA analysis 
 
Leptin is a 16 kDa protein hormone that plays a key role in regulating energy intake and 
energy expenditure, including the regulation (decrease) of appetite and (increase) of 
metabolism. To measure this key marker of metabolism, Leptin (Sandwich) ELISA EIA-
2395 (DRG Instruments GmbH, Germany) was used.  
 
This is a solid phase enzyme-linked immunoabsorbent assay based on the sandwich 
principle. The microtitre wells are coated with a monoclonal antibody directed towards a 
unique antigenic site on a leptin molecule. When an aliquot of sample containing 
endogenous leptin is incubated in the coated well with a specific rabbit anti-leptin 
antibody, a sandwich complex is formed. After incubation, the unbound material is washed 
off and an anti-rabbit peroxidase conjugate is added for detection of the bound leptin. After 
addition of the substrate solution, the intensity of colour developed is proportional to the 
concentration of leptin in the sample. 
 
Sample collection and handling: 
Blood was collected by venepuncture into heparin containing tubes (BD 
Vacutainer® Plasma Tube, Becton Dickinson UK Limited) to prevent coagulation and 
stored at -80°C until analysis.  
 
Procedure: 
All samples and reagents were thawed and brought to room temperature before use. All 
standards and samples were analysed in duplicates as below- 
 
Wash solution was prepared by diluting 30 mls of concentrated wash solution with 1170 
mls distilled water to a final volume of 1200 mls. 
1. 15µl of each standard, control and samples were dispensed into microtitre wells 
with new disposable pipette tips. 
2. To this 100µl of assay buffer was added and thoroughly mixed for 10 seconds by 
placing on a plate shaker. 
3. The above plate was incubated for 120 minutes at room temperature and then 
washed thoroughly by briskly shaking out the contents of the wells. 300µl of Wash 
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Solution was added to each well and this was repeated 3 times. This was then 
tapped sharply on absorbent paper to remove residual droplets.  
4. 100µl of Antiserum was then added into each well and left to incubate at room 
temperature for 30 minutes. 
5. The plate was thoroughly washed as explained in point 3. 
6. To this, 100µl of Enzyme Complex was added into each well and left to incubate at 
room temperature for 30 minutes. 
7. The above solution was washed thoroughly as mentioned in point 3. 
8. 100µl of Substrate Solution was added to each well and left to incubate at room 
temperature for 15 minutes. 
9. To stop the enzymatic reaction, 50µl of Stop Solution was added to each well. 
10. Optical density was read at 450nm with a microtitre plate reader within 10 minutes 
after adding the Stop Solution. 
 
Calculation of results: 
Average absorbance values for each standards, controls and study samples were calculated. 
A standard curve was constructed by plotting mean absorbance obtained from each 
standard against its concentration with absorbance values on the Y-axis and concentration 
on the X-axis. Using the mean absorbance value for each sample the corresponding 
concentration was determined from the standard curve. This was performed using a four 
parameter logistic function as recommended in the package insert with the help of Softmax 
Pro version 4.0 (Microplate Data Acquisition and Analysis Software Molecular Devices, 
USA). 
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Appendix 21 - Detailed protocol for NEFA analysis 
 
Wako NEFA C test kit (Wako Chemicals GmbH, Germany) was used to measure NEFA 
concentration in plasma. This kit utilises an in vitro enzymatic colorimetric method for 
NEFA quantification.  
 
Preparation: 
• Colour reagent solution A: Dissolve contents of colour reagent A with 10ml of 
solvent A and mix well. 
• Colour reagent solution B: Dissolve contents of colour reagent B with 20ml of 
solvent B and mix well. 
 
Procedure: 
All samples and reagents were thawed and brought to room temperature before use. All 
standards and samples were analysed in duplicates as below- 
 
1. Pipette into vials 50μl of samples and control solution. To this, add 1000μl 
of colour reagent solution A and mix well. All samples and control 
solutions were analysed in duplicate. 
2. Incubate for 15 minutes at 25°C. 
3. To this add 2000μl of colour reagent solution B and mix well. 
4. Accurately incubate for 15 minutes at 25°C.  
5. Read absorbance at wavelength 550nm.  
 
Results: 
ILAB 600 (Instrumentation Laboratory, Werfen Group IVD, Spain) was used to analyse 
the samples along with control solutions. The analyser is controlled by an external PC 
running under Windows XP. The results were displayed onto the excel sheet and later 
tabulated manually.  
 
Precision: 
Within-run CV of 3 repeated assays (n = 20) was 2.7% or less (as reported in the package 
insert). In the current analysis, 3 control samples were used to maintain quality control. 
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Results of all 3 control solutions were within expected range and CV was 0.01% at  
513μmol/l; 0.01% at 617μmol/l; 0.005% at 1001μmol/l.  
  
ILAB 600, Analysed at the Hugh Sinclair 
Nutrition Research Group laboratory at the 
University of Reading. 
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Appendix 22 - Illustrations of equipment used for methods  
 
Squirrel data logger:  
 
 
 
 
 
 
 
 
 
HemoCue® Glucose 201 analyser:  
 
 
 
 
 
 
 
 
 
 
 
Accutrend GC monitor: 
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Deltatrac II: 
Miniphotometer LP20:  
Sphygmomanometer:  
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Appendix 23 - Skin folds measurement sites  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subscapular 
Supraspinale 
Biceps 
Triceps 
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Appendix 24 - Commendation by TOAST for obesity research 
